Endocrinology and Metabolism

Corrigendum

Miscellaneous
Corrigendum: Correction of Acknowledgments. Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma: Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2022;37(1):180. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2022.103; Corrects: Endocrinol Metab 2021;36(4):717

4,583 View
116 Download
1 Web of Science
1 Crossref

PDF PubReader ePub

Citations

Citations to this article as recorded by

Lateral Involvement in Different Sized Papillary Thyroid Carcinomas Patients with Central Lymph Node Metastasis: A Multi-Center Analysis
Yu Heng, Zheyu Yang, Pengyu Cao, Xi Cheng, Lei Tao
Journal of Clinical Medicine.2022; 11(17): 4975. CrossRef

Original Articles

Thyroid
Clinical Characteristics and Prognosis of Coexisting Thyroid Cancer in Patients with Graves’ Disease: A Retrospective Multicenter Study: Jee Hee Yoon, Meihua Jin, Mijin Kim, A Ram Hong, Hee Kyung Kim, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Ho-Cheol Kang; Endocrinol Metab. 2021;36(6):1268-1276. Published online November 26, 2021; DOI: https://doi.org/10.3803/EnM.2021.1227

9,112 View
226 Download
17 Web of Science
17 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The association between Graves’ disease (GD) and co-existing thyroid cancer is still controversial and most of the previously reported data have been based on surgically treated GD patients. This study investigated the clinicopathological findings and prognosis of concomitant thyroid cancer in GD patients in the era of widespread application of ultrasonography.
Methods
Data of GD patients who underwent thyroidectomy for thyroid cancer between 2010 and 2019 in three tertiary hospitals in South Korea (Asan Medical Center, Chonnam National University Hwasun Hospital, and Pusan National University Hospital) were collected and analyzed retrospectively. In the subgroup analysis, aggressiveness and clinical outcomes of thyroid cancer were compared nodular GD and non-nodular GD groups according to the presence or absence of the thyroid nodules other than thyroid cancer (index nodules).
Results
Of the 15,159 GD patients treated at the hospitals during the study period, 262 (1.7%) underwent thyroidectomy for coexisting thyroid cancer. Eleven patients (4.2%) were diagnosed with occult thyroid cancer and 182 patients (69.5%) had microcarcinomas. No differences in thyroid cancer aggressiveness, ultrasonographic findings, or prognosis were observed between the nodular GD and non-nodular GD groups except the cancer subtype. In the multivariate analysis, only lymph node (LN) metastasis was an independent prognostic factor for recurrent/persistent disease of thyroid cancer arising in GD (P=0.020).
Conclusion
The prevalence of concomitant thyroid cancer in GD patients was considerably lower than in previous reports. The clinical outcomes of thyroid cancer in GD patients were also excellent but, more cautious follow-up is necessary for patients with LN metastasis in the same way as for thyroid cancer in non-GD patients.

Citations

Citations to this article as recorded by

Incidental Thyroid Cancer in Patients With Graves’ Disease: Not as Rare as We Previously Believed
Shaidy Moronta, Lauren Slattery, Rongzhi Wang, Fiemu Nwariaku, Jessica Liu McMullin
Journal of Surgical Research.2025; 308: 122. CrossRef
Preoperative serum lipids as novel predictors for concomitant thyroid carcinoma in Graves’ disease
Xingxing Gao, Mi Liu, Yijun Wu
PeerJ.2025; 13: e19915. CrossRef
Clinicopathologic predictors of incidental thyroid cancer in Graves’ disease: a single-center retrospective cohort study
Wei Huang, Wei-Hsin Chen
Updates in Surgery.2025;[Epub] CrossRef
Comparison of Surgical Outcomes of Transoral Versus Open Thyroidectomy for Graves Disease
Suo-Hsien Wang, Wu-Po Chao, Ta-You Lo, Soh-Ching Ng, Yu-Hsien Chen
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 150. CrossRef
Characterization of Immune Infiltrate Along the Leading Edge of Differentiated Thyroid Cancer
Anupam Kotwal, Krysten Vance, Kemal Hajric, Ana Yuil-Valdes, Benjamin Swanson, Ernesto Martinez Duarte, Oleg Shats, Michael Hollingsworth, Hamid Band, Whitney Goldner
Thyroid®.2024; 34(8): 999. CrossRef
The Role of Risk Factors for the Progression of Patients with T1b-T2 Papillary Thyroid Carcinoma (PC) during Long-Term Follow-Up
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Antonio Mura, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
Journal of Clinical Medicine.2024; 13(18): 5373. CrossRef
Outcomes of Surgical Treatment for Graves’ Disease: A Single-Center Experience of 216 Cases
Hanxing Sun, Hui Tong, Xiaohui Shen, Haoji Gao, Jie Kuang, Xi Chen, Qinyu Li, Weihua Qiu, Zhuoran Liu, Jiqi Yan
Journal of Clinical Medicine.2023; 12(4): 1308. CrossRef
Cancer and Mortality Risks of Graves’ Disease in South Korea Based on National Data from 2010 to 2019
Young Ju Choi, Kyungdo Han, Won Kyoung Cho, Min Ho Jung, Byung-Kyu Suh
Clinical Epidemiology.2023; Volume 15: 535. CrossRef
Risk and Prognosis of Thyroid Cancer in Patients with Graves’ Disease: An Umbrella Review
Marco Palella, Francesca Maria Giustolisi, Adriana Modica Fiascaro, Martina Fichera, Antonella Palmieri, Rossella Cannarella, Aldo E. Calogero, Margherita Ferrante, Maria Fiore
Cancers.2023; 15(10): 2724. CrossRef
Characteristics, staging and outcomes of differentiated thyroid cancer in patients with and without Graves’ disease
Chaitra Gopinath, Hanna Crow, Sujata Panthi, Leonidas Bantis, Kenneth D. Burman, Chitra Choudhary
Journal of Clinical & Translational Endocrinology.2023; 33: 100321. CrossRef
Prevalence, Treatment Status, and Comorbidities of Hyperthyroidism in Korea from 2003 to 2018: A Nationwide Population Study
Hwa Young Ahn, Sun Wook Cho, Mi Young Lee, Young Joo Park, Bon Seok Koo, Hang-Seok Chang, Ka Hee Yi
Endocrinology and Metabolism.2023; 38(4): 436. CrossRef
Hashimoto’s Thyroiditis and Papillary Thyroid Carcinoma: A Follow-Up Study in Patients with Absence of Aggressive Risk Factors at the Surgery of the Primary Tumor
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Sonia Vargiu, Angela Spanu, Giuseppe Madeddu
Diagnostics.2023; 13(19): 3068. CrossRef
Table of Contents

Clinical Thyroidology.2022; 34(2): 48. CrossRef
Predisposition to and Prognosis of Thyroid Cancer May Not Be Affected by Graves’ Disease, But Some Questions Still Remain
Yanrui Huang, Haixia Guan
Clinical Thyroidology.2022; 34(2): 59. CrossRef
A Comparative Follow-Up Study of Patients with Papillary Thyroid Carcinoma Associated or Not with Graves’ Disease
Andrea Marongiu, Susanna Nuvoli, Andrea De Vito, Maria Rondini, Angela Spanu, Giuseppe Madeddu
Diagnostics.2022; 12(11): 2801. CrossRef
An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
Thyroid Research and Practice.2022; 19(1): 47. CrossRef
An unusual case of papillary thyroid carcinoma presenting as Graves’ disease
Pooja Tiwari, Uma Kaimal Saikia, Abhamoni Baro, Ashok Krishna Bhuyan
Thyroid Research and Practice.2021; 18(3): 129. CrossRef

Thyroid
Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea: Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim; Endocrinol Metab. 2021;36(5):1078-1085. Published online October 28, 2021; DOI: https://doi.org/10.3803/EnM.2021.1151

7,534 View
130 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Hürthle cell carcinoma (HCC), a type of thyroid carcinoma, is rare in South Korea, and few studies have investigated its prognosis.
Methods
This long-term multicenter retrospective cohort study evaluated the clinicopathological features and clinical outcomes in patients with HCC who underwent thyroid surgery between 1996 and 2009.
Results
The mean age of the 97 patients included in the study was 50.3 years, and 26.8% were male. The mean size of the primary tumor was 3.2±1.8 cm, and three (3.1%) patients had distant metastasis at initial diagnosis. Ultrasonographic findings were available for 73 patients; the number of nodules with low-, intermediate-, and high suspicion was 28 (38.4%), 27 (37.0%), and 18 (24.7%), respectively, based on the Korean-Thyroid Imaging Reporting and Data System. Preoperatively, follicular neoplasm (FN) or suspicion for FN accounted for 65.2% of the cases according to the Bethesda category, and 13% had malignancy or suspicious for malignancy. During a median follow-up of 8.5 years, eight (8.2%) patients had persistent/recurrent disease, and none died of HCC. Older age, gross extrathyroidal extension (ETE), and widely invasive types of tumors were significantly associated with distant metastasis (all P<0.01). Gross ETE (hazard ratio [HR], 27.7; 95% confidence interval [CI], 2.2 to 346.4; P=0.01) and widely invasive classification (HR, 6.5; 95% CI, 1.1 to 39.4; P=0.04) were independent risk factors for poor disease-free survival (DFS).
Conclusion
The long-term prognosis of HCC is relatively favorable in South Korea from this study, although this is not a nation-wide data, and gross ETE and widely invasive cancer are significant prognostic factors for DFS. The diagnosis of HCC by ultrasonography and cytopathology remains challenging.

Citations

Citations to this article as recorded by

Prognostic impact of fibrosclerotic changes in non-papillary, non-anaplastic, follicular cell-derived thyroid carcinomas
Giulia Orlando, Giulia Capella, Giulia Vocino Trucco, Elena Vissio, Jasna Metovic, Francesca Maletta, Marco Volante, Mauro Papotti
Virchows Archiv.2025; 487(3): 701. CrossRef
Differentiating oncocytic carcinoma from oncocytic adenoma: a comprehensive evaluation of preoperative characteristics and diagnostic approaches in a retrospective cohort study
Eunji Kim, Jun Hyun Park, Ji-Young Park, Sang-Woo Lee, Jin Hyang Jung
Annals of Surgical Treatment and Research.2025; 109(2): 105. CrossRef
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John
Thyroid®.2025; 35(8): 841. CrossRef
Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma
Lindsay A. Bischoff, Ian Ganly, Laura Fugazzola, Erin Buczek, William C. Faquin, Bryan R. Haugen, Bryan McIver, Caitlin P. McMullen, Kate Newbold, Daniel J. Rocke, Marika D. Russell, Mabel Ryder, Peter M. Sadow, Eric Sherman, Maisie Shindo, David C. Shonk
JAMA Otolaryngology–Head & Neck Surgery.2024; 150(3): 265. CrossRef
Oncocytic carcinoma of the thyroid: Conclusions from a 20‐year patient cohort
Nelson R. Gruszczynski, Shahzeb S. Hasan, Ana G. Brennan, Julian De La Chapa, Adithya S. Reddy, David N. Martin, Prem P. Batchala, Edward B. Stelow, Eric M. Dowling, Katherine L. Fedder, Jonathan C. Garneau, David C. Shonka
Head & Neck.2024; 46(8): 2042. CrossRef
Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report
Xiqian Wang, Yingao Liu, Lijie Chen, Jie Zhang, Ruoyu Jiang, Lei Zhang, Han Yan, Jie Zhang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Clinical Considerations of Oncocytic Thyroid Cancer: A Review
Soo Young Kim
Journal of Endocrine Surgery.2024; 24(3): 49. CrossRef
Mitochondrial Proteome Defined Molecular Pathological Characteristics of Oncocytic Thyroid Tumors
Lu Li, Likun Zhang, Wenhao Jiang, Zhiqiang Gui, Zhihong Wang, Hao Zhang, Yi He, Yi Zhu, Tiannan Guo, Haixia Guan, Zhiyan Liu, Yaoting Sun, Jianqing Gao
Endocrine Pathology.2024; 35(4): 442. CrossRef
Hurthle cell carcinoma: a rare variant of thyroid malignancy – a case report
Yuvraj Adhikari, Anupama Marasini, Nawaraj Adhikari, Laxman D. Paneru, Binit Upadhaya Regmi, Manita Raut
Annals of Medicine & Surgery.2023; 85(5): 1940. CrossRef
Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature
Costanza Chiapponi, Milan J.M. Hartmann, Matthias Schmidt, Michael Faust, Christiane J. Bruns, Anne M. Schultheis, Hakan Alakus
Frontiers in Endocrinology.2022;[Epub] CrossRef

Review Article

Thyroid
Active Surveillance as an Effective Management Option for Low-Risk Papillary Thyroid Microcarcinoma: Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2021;36(4):717-724. Published online August 11, 2021; DOI: https://doi.org/10.3803/EnM.2021.1042; Correction in: Endocrinol Metab 2022;37(1):180

8,126 View
203 Download
9 Web of Science
6 Crossref

Abstract PDF PubReader ePub

Active surveillance (AS) for low-risk papillary thyroid microcarcinoma (PTMC) has been accepted worldwide as safe and effective. Despite the growing acceptance of AS in the management of low-risk PTMCs, there are barriers to AS in real clinical settings, and it is important to understand and establish appropriate AS protocol from initial evaluation to follow-up. PTMC management strategies should be decided upon after careful consideration of patient and tumor characteristics by a multidisciplinary team of thyroid cancer specialists. Patients should understand the risks and benefits of AS, participate in decision-making and follow structured monitoring strategies. In this review, we discuss clinical outcomes of AS from previous studies, optimal indications and follow-up strategies for AS, and unresolved questions about AS.

Citations

Citations to this article as recorded by

Towards an Integrated Framework for Health Surveillance Systems: A Systematic Literature Review of Design Components and Implementation Challenges
Maryam Mollabagher, Alireza Hassanzadeh, Mohammad Mahdi Sepehri, Abbas Habibelahi, Abolghasem Sarabadani
Health Science Reports.2026;[Epub] CrossRef
Risk factors for lateral neck lymph node metastasis in papillary thyroid ultra micro carcinoma with implications for active surveillance
Hyeung Kyoo Kim, Ho Jung Jeong, Jin Seok Lee, Soo Young Kim, Yong Sang Lee, Hang-Seok Chang
Scientific Reports.2025;[Epub] CrossRef
Diagnostic Accuracy of Preoperative Radiologic Findings in Papillary Thyroid Microcarcinoma: Discrepancies with the Postoperative Pathologic Diagnosis and Implications for Clinical Outcomes
Ying Li, Seul Ki Kwon, Hoonsung Choi, Yoo Hyung Kim, Sunyoung Kang, Kyeong Cheon Jung, Jae-Kyung Won, Do Joon Park, Young Joo Park, Sun Wook Cho
Endocrinology and Metabolism.2024; 39(3): 450. CrossRef
Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Papillary Thyroid Microcarcinoma: Active Surveillance Against Surgery. Considerations of an Italian Working Group From a Systematic Review
Giuseppina Orlando, Gregorio Scerrino, Alessandro Corigliano, Irene Vitale, Roberta Tutino, Stefano Radellini, Francesco Cupido, Giuseppa Graceffa, Gianfranco Cocorullo, Giuseppe Salamone, Giuseppina Melfa
Frontiers in Oncology.2022;[Epub] CrossRef
Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2022; 29(12): 7835. CrossRef

Original Articles

Clinical Study
Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults: Eyun Song, Min Ji Jeon, Hye Jin Yoo, Sung Jin Bae, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Hong-Kyu Kim, Won Gu Kim; Endocrinol Metab. 2021;36(2):365-373. Published online April 7, 2021; DOI: https://doi.org/10.3803/EnM.2020.939

9,135 View
175 Download
6 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Serum calcitonin measurement contains various clinical and methodological aspects. Its reference level is wide and unclear despite sensitive calcitonin kits are available. This study aimed to identify the specific reference range in the healthy Korean adults.
Methods
Subjects were ≥20 years with available calcitonin (measured by a two-site immunoradiometric assay) data by a routine health checkup. Three groups were defined as all eligible subjects (group 1, n=10,566); subjects without self or family history of thyroid disease (group 2, n=5,152); and subjects without chronic kidney disease, autoimmune thyroid disease, medication of proton pump inhibitor/H2 blocker/steroid, or other malignancies (group 3, n=4,638).
Results
This study included 6,341 male and 4,225 female subjects. Males had higher mean calcitonin than females (2.3 pg/mL vs. 1.9 pg/mL, P<0.001) in group 1. This gender difference remained similar in groups 2 and 3. Calcitonin according to age or body mass index was not significant in both genders. Higher calcitonin in smoking than nonsmoking men was observed but not in women. Sixty-nine subjects had calcitonin higher than the upper reference limit (10 pg/mL) and 64 of them had factors associated with hypercalcitoninemia besides medullary thyroid cancer. Our study suggests the reference intervals for men who were non, ex-, current smokers, and women (irrespective of smoking status) as <5.7, <7.1, <7.9, and <3.6 pg/mL, respectively.
Conclusion
Specific calcitonin reference range should be provided considering for sex and smoking status. Taking account for several factors known to induce hypercalcitoninemia can help interpret the gray zone of moderately elevated calcitonin.

Citations

Citations to this article as recorded by

Circulating Biomarkers in Medullary Thyroid Carcinoma: Bridging Laboratory Complexities and Clinical Application Through Algorithm Design
Luca Giovanella, Federica D’Aurizio, Petra Petranović Ovčariček
Journal of Clinical Medicine.2025; 14(16): 5645. CrossRef
Determinants of circulating calcitonin value: analysis of thyroid features, demographic data, anthropometric characteristics, comorbidities, medications, and smoking habits in a population with histological full exclusion of medullary thyroid carcinoma
Pierpaolo Trimboli, Giuseppe Peloni, Dorotea Confalonieri, Elena Gamarra, Tommaso Piticchio, Francesco Frasca, Petra Makovac, Arnoldo Piccardo, Lorenzo Ruinelli
Frontiers in Oncology.2024;[Epub] CrossRef
Surgical treatment of solid variant of papillary thyroid carcinoma: Fifteen-year experience of a tertiary center
Katarina Tausanović, Marina Stojanović, Milan Jovanović, Boban Stepanović, Jovan Ilić, Sara Ivaniš, Vladan Živaljević
Medicinska istrazivanja.2024; 57(1): 121. CrossRef
Impact of dietary, lifestyle and sociodemographic factors on calcitonin levels in a healthy population
Ivana Gunjača, Mirjana Babić Leko, Nikolina Pleić, Ante Jurić, Dubravka Brdar, Vesela Torlak, Marko Vuletić, Ante Punda, Ozren Polašek, Caroline Hayward, Tatijana Zemunik
Bone.2024; 187: 117214. CrossRef
Some genetic differences in patients with rheumatoid arthritis
Hosam M. Ahmad, Zaki M. Zaki, Asmaa S. Mohamed, Amr E. Ahmed
BMC Research Notes.2023;[Epub] CrossRef
Presence or severity of Hashimoto’s thyroiditis does not influence basal calcitonin levels: observations from CROHT biobank
M. Cvek, A. Punda, M. Brekalo, M. Plosnić, A. Barić, D. Kaličanin, L. Brčić, M. Vuletić, I. Gunjača, V. Torlak Lovrić, V. Škrabić, V. Boraska Perica
Journal of Endocrinological Investigation.2022; 45(3): 597. CrossRef
Environmental Factors That Affect Parathyroid Hormone and Calcitonin Levels
Mirjana Babić Leko, Nikolina Pleić, Ivana Gunjača, Tatijana Zemunik
International Journal of Molecular Sciences.2021; 23(1): 44. CrossRef

Clinical Study
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis: Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim; Endocrinol Metab. 2020;35(4):830-837. Published online November 18, 2020; DOI: https://doi.org/10.3803/EnM.2020.747

7,403 View
149 Download
8 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC.
Methods
We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of >1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (≥90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM).
Results
Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM.
Conclusion
The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined >3 months after TT considering other prognostic factors.

Citations

Citations to this article as recorded by

Dynamic risk assessment in patients with differentiated thyroid cancer
Erika Abelleira, Fernando Jerkovich
Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79. CrossRef
Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis
Kathryn Graham, Fay Tough, Helena Belikova, Irene Wotherspoon, David Colville, Nicholas Reed
Endocrine Practice.2024; 30(4): 327. CrossRef
Radioiodine ablation after thyroidectomy could be safely abandoned or postponed in selected stage I papillary thyroid carcinoma patients of low-risk group: an observational prospective study
S.M. Cherenko, A.Yu. Glagolieva, D.E. Makhmudov
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(1): 7. CrossRef
Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study
Tao He, Ming Li, Zheng-lian Gao, Xiang-yu Li, Hai-rong Zhong, Cui-shuang Ding, Hua-wei Cai
Nuclear Medicine Communications.2024; 45(9): 779. CrossRef
Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma
Xin Dai, Xinyi Ren, Jinyu Zhang, Yuxin Zheng, Zhengjie Wang, Gang Cheng
Annals of Nuclear Medicine.2024; 38(9): 688. CrossRef
Comparative evaluation of low and high radioiodine doses in differentiated thyroid carcinoma management: A multicenter study
M.B. Al-Osaimi, E.M. Abdelrazek, Ehab M. Attalla, Hosam Salaheldin
Journal of Radiation Research and Applied Sciences.2024; 17(4): 101206. CrossRef
Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK
J. Wadsley, N. Armstrong, V. Bassett-Smith, M. Beasley, R. Chandler, L. Cluny, A.J. Craig, K. Farnell, K. Garcez, N. Garnham, K. Graham, A. Hallam, S. Hill, H. Hobrough, F. McKiddie, M.W.J. Strachan
Clinical Oncology.2023; 35(1): 42. CrossRef
Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta‐analysis
Fang Cheng, Juan Xiao, Fengyan Huang, Chunchun Shao, Shouluan Ding, Canhua Yun, Hongying Jia
Cancer Medicine.2022; 11(12): 2386. CrossRef
Delayed (>3 Months) Postoperative Radioactive Iodine Ablation Does Not Impact Clinical Response or Survival in Differentiated Thyroid Cancers
Tatiana Fedorova, Lilah F. Morris-Wiseman
Clinical Thyroidology.2022; 34(10): 456. CrossRef

Clinical Study
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study: Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim; Endocrinol Metab. 2020;35(3):618-627. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.742

8,757 View
134 Download
10 Web of Science
11 Crossref

Abstract PDF PubReader ePub

Background
The study aimed to compare the prognostic value of the 4th edition of World Health Organization classification (WHO-2017) with the previous WHO classification (WHO-2004) for follicular thyroid carcinoma (FTC).
Methods
This multicenter retrospective cohort study included 318 patients with FTC from five tertiary centers who underwent thyroid surgery between 1996 and 2009. We evaluated the prognosis of patients with minimally invasive (MI), encapsulated angioinvasive (EA), and widely invasive (WI) FTC according to WHO-2017. Further, we evaluated the proportion of variation explained (PVE) and Harrell’s C-index to compare the predictability of disease-free survival (DFS) and disease-specific survival (DSS).
Results
In total, 227, 58, and 33 patients had MI-, EA-, and WI-FTC, respectively. During a median follow-up of 10.6 years, 46 (14.5%) patients had disease recurrence and 20 (6.3%) patients died from FTC. The 10-year DFS rates of patients with MI-, EA-, and WI-FTC were 91.1%, 78.2%, and 54.9%, respectively (P<0.001, PVE=7.1%, C-index=0.649). The corresponding 10-year DSS rates were 95.9%, 93.5%, and 73.5%, respectively (P<0.001, PVE=2.6%, C-index=0.624). The PVE and C-index values were higher using WHO-2017 than using WHO-2004 for the prediction of DFS, but not for DSS. In multivariate analysis, older age (P=0.02), gross extrathyroidal extension (ETE) (P=0.003), and distant metastasis (P<0.001) were independent risk factors for DSS.
Conclusion
WHO-2017 improves the predictability of DFS, but not DSS, in patients with FTC. Distant metastasis, gross ETE and older age (≥55 years) were independent risk factors for DSS.

Citations

Citations to this article as recorded by

The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline
Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Jeongmin Lee, Dong-Jun Lim, Chan Kwon Jung, Young Joo Park
Endocrinology and Metabolism.2025; 40(3): 357. CrossRef
Association of Ultrasonography Features of Follicular Thyroid Carcinoma With Tumor Invasiveness and Prognosis Based on WHO Classification and TERT Promoter Mutation
Myoung Kyoung Kim, Hyunju Park, Young Lyun Oh, Jung Hee Shin, Tae Hyuk Kim, Soo Yeon Hahn
Korean Journal of Radiology.2024; 25(1): 103. CrossRef
Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC
Genpeng Li, Ziyang Ye, Tao Wei, Jingqiang Zhu, Zhihui Li, Jianyong Lei
The Journal of Clinical Endocrinology & Metabolism.2024; 109(9): 2294. CrossRef
Radioiodine whole body scan pitfalls in differentiated thyroid cancer
Cristina Basso, Alessandra Colapinto, Valentina Vicennati, Alessandra Gambineri, Carla Pelusi, Guido Di Dalmazi, Elisa Lodi Rizzini, Elena Tabacchi, Arber Golemi, Letizia Calderoni, Stefano Fanti, Uberto Pagotto, Andrea Repaci
Endocrine.2024; 85(2): 493. CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 5. Evaluation of Recurrence Risk Postoperatively and Initial Risk Stratification in Different
Eun Kyung Lee, Young Shin Song, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Shin Je Moon, Dong-Jun Lim, Kyong Yeun Jung, Yun Jae Chung, Chan Kwon Jung, Young Joo Park
International Journal of Thyroidology.2024; 17(1): 68. CrossRef
The Prognostic Impact of Extent of Vascular Invasion in Follicular Thyroid Carcinoma
David Leong, Anthony J. Gill, John Turchini, Michael Waller, Roderick Clifton‐Bligh, Anthony Glover, Mark Sywak, Stan Sidhu
World Journal of Surgery.2023; 47(2): 412. CrossRef
TERT Promoter Mutation as a Prognostic Marker in Encapsulated Angioinvasive and Widely Invasive Follicular Thyroid Carcinomas
Yasuhiro Ito, Takashi Akamizu
Clinical Thyroidology.2023; 35(5): 202. CrossRef
Risk factors for death of follicular thyroid carcinoma: a systematic review and meta-analysis
Ting Zhang, Liang He, Zhihong Wang, Wenwu Dong, Wei Sun, Ping Zhang, Hao Zhang
Endocrine.2023; 82(3): 457. CrossRef
Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations
Hyunju Park, Hyeong Chan Shin, Heera Yang, Jung Heo, Chang-Seok Ki, Hye Seung Kim, Jung-Han Kim, Soo Yeon Hahn, Yun Jae Chung, Sun Wook Kim, Jae Hoon Chung, Young Lyun Oh, Tae Hyuk Kim
Modern Pathology.2022; 35(2): 186. CrossRef
Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8
Johan O Paulsson, Nima Rafati, Sebastian DiLorenzo, Yi Chen, Felix Haglund, Jan Zedenius, C Christofer Juhlin
The Journal of Clinical Endocrinology & Metabolism.2021; 106(11): 3265. CrossRef
Clinicopathological Characteristics and Disease-Free Survival in Patients with Hürthle Cell Carcinoma: A Multicenter Cohort Study in South Korea
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Yea Eun Kang, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
Endocrinology and Metabolism.2021; 36(5): 1078. CrossRef

Clinical Study
Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy: Meihua Jin, Jonghwa Ahn, Yu-Mi Lee, Tae-Yon Sung, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon; Endocrinol Metab. 2020;35(3):602-609. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.741

8,794 View
136 Download
7 Web of Science
6 Crossref

Abstract PDF PubReader ePub

Background
The optimal dose of radioactive iodine (RAI) therapy for N1b papillary thyroid carcinoma (PTC) is controversial. We evaluated the clinical outcome of N1b PTC patients treated with either 100 or 150 mCi of RAI.
Methods
We retrospectively analyzed N1b PTC patients who underwent total thyroidectomy and postoperative RAI therapy at a tertiary referral center between 2012 and 2017. As the baseline characteristics differed between treatment groups, we performed exact matching for various pathological factors according to RAI dose. We evaluated the response to therapy and recurrence-free survival (RFS) in the matched patients. Structural recurrent/persistent disease was defined as new structural disease detected after initial therapy, which was confirmed by cytology or pathology.
Results
Of the total 436 patients, 37 (8.5%) received 100 mCi of RAI and 399 (91.5%) received 150 mCi of RAI. After an exact 1:3 matching, 34 patients in the 100 mCi group and 100 patients in the 150 mCi group remained. There was no significant difference in response to therapy between the groups in the matched population (P=0.63). An excellent response was achieved in 70.6% (n=24) of patients in the 100 mCi group and 76.0% (n=76) in the 150 mCi group. Two (5.9%) patients in the 100 mCi group and four (4.0%) in the 150 mCi group had recurrence and there was no significant difference in RFS between the groups in the matched population (P=0.351).
Conclusion
There were no differences in response to therapy and RFS in N1b PTC patients according to RAI dose.

Citations

Citations to this article as recorded by

Radioactive iodine therapy dose impact on recurrence and survival in N1 papillary thyroid cancer
Elizabeth E. Odil, Katelyn R. Ward, Ryan T. Davis, Jordan M. Reilly, Fionna Sun, Heba Elassar, Morta Lapkus, Jacquelyn Pastewski, Diane M. Studzinski, Rose E. Callahan, Peter F. Czako, Sapna Nagar
Nuclear Medicine Communications.2025; 46(2): 113. CrossRef
Efficacy of Adjuvant Radioactive Iodine Therapy in Histological Variants of DTC: A Scoping Review
Brian A. Keith, Evan S. Chernov, Shaun A. Nguyen, Jyotika K. Fernandes, William G. Albergotti
Head & Neck.2025; 47(8): 2324. CrossRef
Comparison of total thyroidectomy and lobectomy for intermediate-risk papillary thyroid carcinoma with lateral lymph node metastasis: a systematic review and meta-analysis
Xinhua Li, Zhiqiang Gui, Chun Xu, Jingzhe Xiang, Jie Ming, Tao Huang, Mingming Jiang, Hao Zhang, Zhihong Wang
International Journal of Surgery.2025; 111(9): 6343. CrossRef
Multicenter analysis of radioactive iodine therapy outcomes after total thyroidectomy for T1-T2 stage papillary thyroid carcinoma with cervical lymph node metastasis in China
Xinhua Li, Qingshu Wu, Jie Zhao, Zhiqiang Gui, Jingzhe Xiang, Jie Ming, Tao Huang, Mingming Jiang, Hao Zhang, Zhihong Wang
International Journal of Surgery.2025; 111(10): 6931. CrossRef
Controversies in the Management of Intermediate-Risk Differentiated Thyroid Cancer
David Toro-Tobon, Juan P. Brito
Endocrine Practice.2024; 30(9): 879. CrossRef
The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature
Daniël J. van de Berg, Pedro M. Rodriguez Schaap, Faridi S. Jamaludin, Hanneke M. van Santen, Sarah C. Clement, Menno R. Vriens, A. S Paul van Trotsenburg, Christiaan F. Mooij, Eveline Bruinstroop, Schelto Kruijff, Robin P. Peeters, Frederik A. Verburg, R
Thyroid®.2024; 34(11): 1324. CrossRef

Clinical Study
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience: Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim; Endocrinol Metab. 2020;35(3):587-594. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.687

9,276 View
173 Download
21 Web of Science
19 Crossref

Abstract PDF PubReader ePub

Background
Vandetanib is the most widely used tyrosine kinase inhibitor for the treatment of patients with advanced medullary thyroid cancer (MTC). However, only limited data regarding its use outside clinical trials are available. We aimed to evaluate the efficacy and safety of vandetanib in patients with advanced MTC in routine clinical practice.
Methods
In this multicenter retrospective study, 12 patients with locally advanced or metastatic MTC treated with vandetanib at four tertiary hospitals were included. The primary outcome was the objective response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors. The progression-free survival (PFS), overall survival (OS), and toxicities were also evaluated.
Results
Eleven patients (92%) had distant metastasis and 10 (83%) had disease progression at enrollment. Partial response was observed in five patients (ORR, 42%) and stable disease lasting ≥24 weeks was reported in an additional five patients (83%). During the median 31.7 months of follow-up, disease progression was seen in five patients (42%); of these, two died due to disease progression. The median PFS was 25.9 months, while the median OS was not reached. All patients experienced adverse events (AEs) which were generally consistent with the known safety profile of vandetanib. Vandetanib was discontinued in two patients due to skin toxicity.
Conclusion
Consistent with the phase III trial, this study confirmed the efficacy of vandetanib for advanced MTC in terms of both ORR and PFS in the real-world setting. Vandetanib was well tolerated in the majority of patients, and there were no fatal AEs.

Citations

Citations to this article as recorded by

Neuroendocrine Neoplasms of the Lungs, Thyroid, and Thymus
Barbara Buchalska, Małgorzata Solnik, Karol Maciejewski, Marta Fudalej, Andrzej Deptała, Anna Badowska-Kozakiewicz
Biomedicines.2025; 13(5): 1028. CrossRef
Systemic therapies for medullary thyroid carcinoma: state of the art
Alejandro Román-González, Ines Califano, Marcio Concepción-Zavaleta, Fabian Pitoia, Sarimar Agosto Salgado
Therapeutic Advances in Endocrinology and Metabolism.2025;[Epub] CrossRef
Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center
Yara Maria Machlah, Tim Brandenburg, Philipp Muchalla, Vera Tiedje, Sarah Theurer, Manuel Weber, Frank Weber, Henning Dralle, Harald Lahner, Dagmar Führer
The Journal of Clinical Endocrinology & Metabolism.2025; 111(1): 167. CrossRef
Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies
Petar Brlek, Vedrana Škaro, Nenad Hrvatin, Luka Bulić, Ana Petrović, Petar Projić, Martina Smolić, Parth Shah, Dragan Primorac
Cancers.2025; 17(21): 3500. CrossRef
Synthesis of 4-styrylquinazolines enabled by a hypervalent iodine-promoted oxidative amination cascade
Lipeng Long, Ziyi Yu, Ziwen Huang, Min Ye, Wenjun Luo, Xunjin Jiang, Zhengwang Chen, Zhong-Xia Wang
Tetrahedron Chem.2025; 16: 100151. CrossRef
Alternative and efficient one-pot three-component synthesis of substituted 2-aryl-4-styrylquinazolines/4-styrylquinazolines from synthetically available 1-(2-aminophenyl)-3-arylprop-2-en-1-ones: characterization and evaluation of their antiproliferative a
Diego Fernando Rodríguez, Kelly Johanna Lipez, Elena Stashenko, Iván Díaz, Justo Cobo, Alirio Palma
RSC Advances.2024; 14(29): 20951. CrossRef
Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
Marilda Mormando, Rosa Lauretta, Giulia Puliani, Marta Bianchini, Maria Elena Spoltore, Marialuisa Appetecchia
Biomedicines.2024; 12(12): 2923. CrossRef
Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance
Katerina Saltiki, George Simeakis, Olga Karapanou, Stavroula A. Paschou, Maria Alevizaki
Endocrine.2023; 80(3): 570. CrossRef
Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea
Han-Sang Baek, Jeonghoon Ha, Seunggyun Ha, Ja Seong Bae, Chan Kwon Jung, Dong-Jun Lim
Current Oncology.2023; 30(3): 3020. CrossRef
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
Nicolas Sahakian, Frédéric Castinetti, Pauline Romanet
Cancers.2023; 15(19): 4865. CrossRef
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei
Frontiers in Endocrinology.2022;[Epub] CrossRef
Targeted therapy and drug resistance in thyroid cancer
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei
European Journal of Medicinal Chemistry.2022; 238: 114500. CrossRef
Daily Management of Patients on Multikinase Inhibitors’ Treatment
Carla Colombo, Simone De Leo, Matteo Trevisan, Noemi Giancola, Anna Scaltrito, Laura Fugazzola
Frontiers in Oncology.2022;[Epub] CrossRef
The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview
Cătălina Ionescu, Bogdan Oprea, Georgeta Ciobanu, Milena Georgescu, Ramona Bică, Garofiţa-Olivia Mateescu, Fidan Huseynova, Veronique Barragan-Montero
Medicina.2022; 58(7): 903. CrossRef
Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy
Tobiloba C. Elebiyo, Damilare Rotimi, Ikponmwosa O. Evbuomwan, Rotdelmwa Filibus Maimako, Matthew Iyobhebhe, Oluwafemi Adeleke Ojo, Olarewaju M. Oluba, Oluyomi S. Adeyemi
Cancer Treatment and Research Communications.2022; 32: 100620. CrossRef
Current Guidelines for Management of Medullary Thyroid Carcinoma
Mijin Kim, Bo Hyun Kim
Endocrinology and Metabolism.2021; 36(3): 514. CrossRef
Recent advances in precision medicine for the treatment of medullary thyroid cancer
Jolanta Krajewska, Aleksandra Kukulska, Malgorzata Oczko-Wojciechowska, Barbara Jarzab
Expert Review of Precision Medicine and Drug Development.2021; 6(5): 307. CrossRef
Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro
Mingming Han, Xiaodan Zhang, Zhize Ye, Jing Wang, Jianchang Qian, Guoxin Hu, Jianping Cai
Chemico-Biological Interactions.2021; 350: 109700. CrossRef
Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update
Alice Nervo, Francesca Retta, Alberto Ragni, Alessandro Piovesan, Alberto Mella, Luigi Biancone, Marco Manganaro, Marco Gallo, Emanuela Arvat
Critical Reviews in Oncology/Hematology.2021; 168: 103533. CrossRef

Clinical Study
Modification of the Tumor-Node-Metastasis Staging System for Differentiated Thyroid Carcinoma by Considering Extra-Thyroidal Extension and Lateral Cervical Lymph Node Metastasis: Mijin Kim, Won Gu Kim, Min Ji Jeon, Hee Kyung Kim, Hyon-Seung Yi, Eun Sook Kim, Bo Hyun Kim, Won Bae Kim, Young Kee Shong, Ho-Cheol Kang, Tae Yong Kim; Endocrinol Metab. 2020;35(1):149-156. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.149

9,122 View
96 Download
8 Web of Science
6 Crossref

Abstract PDF PubReader ePub

Background

Concerns have arisen about the classification of extra-thyroidal extension (ETE) and lateral cervical lymph node metastasis (N1b) in the 8th edition of the tumor-node-metastasis staging system (TNM-8). This study evaluated the prognostic validity of a modified-TNM staging system, focusing on ETE and N1b, in differentiated thyroid carcinoma (DTC) patients.

Methods

This multicenter retrospective cohort study included 4,878 DTC patients from five tertiary hospitals. In the modified-TNM, T3b in TNM-8 was down-staged to T2, and stage II was subdivided into stages IIA and IIB. Older patients with N1b were reclassified as stage IIB.

Results

The modified-TNM resulted in staging migration in 540 patients (11%) classified as stage II according to the TNM-8, with 75 (14%), 381 (71%), and 84 patients (16%) classified as stages I, IIA, and IIB, respectively. The 10-year disease-specific survival (DSS) rates in patients classified as stages I, II, III, and IV by TNM-8 were 99.8%, 95.9%, 81.0%, and 41.6%, respectively. The DSS rates of patients classified as stages I, IIA, IIB, III, and IV according to the modified-TNM were 99.8%, 96.4%, 93.3%, 81.0%, and 41.6%, respectively. DSS curves between stages on TNM-8 (P<0.001) and modified-TNM (P<0.001) differed significantly, but the modified-TNM discriminated better than TNM-8. The proportions of variation explained values of TNM-8 and modified-TNM were 6.3% and 6.5%, respectively.

Conclusion

Modification of the TNM staging system focusing on ETE and N1b could improve the prediction of DSS in patients with DTC. Further researches are needed to validate the prognostic accuracy of this modified-TNM staging system.

Citations

Citations to this article as recorded by

Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy
Wen Liu, Beibei Jiang, Jingli Xue, Ruijing Liu, Yuqing Wei, Peifeng Li
Annals of Diagnostic Pathology.2024; 69: 152243. CrossRef
Prognostic significance of T3b in papillary thyroid carcinoma: Appropriateness of classifying T3bN0M0 in patients aged 55 years or older into stage II
Yasuhiro Ito, Akira Miyauchi, Makoto Kawakami, Minoru Kihara, Akihiro Miya
World Journal of Surgery.2024; 48(9): 2132. CrossRef
Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis
Ion Negura, Victor Ianole, Mihai Danciu, Cristina Preda, Diana Gabriela Iosep, Radu Dănilă, Alexandru Grigorovici, Delia Gabriela Ciobanu Apostol
Diagnostics.2023; 13(2): 285. CrossRef
Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC)
Nadia Bouzehouane, Pascal Roy, Myriam Decaussin-Petrucci, Mireille Bertholon-Grégoire, Chantal Bully, Agnès Perrin, Helene Lasolle, Jean-Christophe Lifante, Françoise Borson-Chazot, Claire Bournaud
Cancers.2022; 14(11): 2591. CrossRef
Impacts of the American Joint Committee on Cancer (AJCC) 8th edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients
Yotsapon Thewjitcharoen, Waralee Chatchomchuan, Krittadhee Karndumri, Sriurai Porramatikul, Sirinate Krittiyawong, Ekgaluck Wanothayaroj, Siriwan Butadej, Soontaree Nakasatien, Veekij Veerasomboonsin, Auchai Kanchanapituk, Rajata Rajatanavin, Thep Himatho
Heliyon.2021; 7(3): e06624. CrossRef

Review Article

Thyroid
Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer: Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong; Endocrinol Metab. 2020;35(1):14-25. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.14

10,819 View
163 Download
16 Web of Science
12 Crossref

Abstract PDF PubReader ePub

The increased incidence of thyroid cancer is a worldwide phenomenon; however, the issue of overdiagnosis has been most prominent in South Korea. The age-standardized mortality rate of thyroid cancer in Korea steeply increased from 1985 to 2004 (from 0.17 per 100,000 to 0.85 per 100,000), and then decreased until 2015 to 0.42 per 100,000, suggesting that early detection reduced mortality. However, early detection of thyroid cancer may be cost-ineffective, considering its very high prevalence and indolent course. Therefore, risk stratification and tailored management are vitally important, but many prognostic markers can only be evaluated postoperatively. Discovery of preoperative marker(s), especially for small cancers, is the most important unmet clinical need for thyroid cancer. Herein, we discuss some such factors that we recently discovered. Another unmet clinical need is better treatment of radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) and undifferentiated cancers. Although sorafenib and lenvatinib are available, better drugs are needed. We found that phosphoglycerate dehydrogenase, a critical enzyme for serine biosynthesis, could be a novel therapeutic target, and that the lymphocyte-to-monocyte ratio is a prognostic marker of survival in patients with anaplastic thyroid carcinoma or RAIR DTC. Deeper insights are needed into tumor-host interactions in thyroid cancer to improve treatment.

Citations

Citations to this article as recorded by

Macrophage-Induced Carboxypeptidase A4 Promotes the Progression of Anaplastic Thyroid Cancer
Yeon-Sook Choi, Min Ji Jeon, Woo Kyung Lee Doolittle, Dong Eun Song, Kyunggon Kim, Won Bae Kim, Won Gu Kim
Thyroid®.2024; 34(9): 1150. CrossRef
Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Mijin Kim, Meihua Jin, Min Ji Jeon, Eui Young Kim, Dong Yeob Shin, Dong Jun Lim, Bo Hyun Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Hee Kyung Kim, Won Gu Kim
Thyroid.2023; 33(1): 91. CrossRef
Serum thyroglobulin testing after thyroid lobectomy in patients with 1–4 cm papillary thyroid carcinoma
Ahreum Jang, Meihua Jin, Chae A Kim, Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Endocrine.2023; 81(2): 290. CrossRef
Integration of ultrasound-based radiomics with clinical features for predicting cervical lymph node metastasis in postoperative patients with differentiated thyroid carcinoma
Fengjing Fan, Fei Li, Yixuan Wang, Zhengjun Dai, Yuyang Lin, Lin Liao, Bei Wang, Hongjun Sun
Endocrine.2023; 84(3): 999. CrossRef
Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
Seung-Jin Park, Yea Eun Kang, Jeong-Hwan Kim, Jong-Lyul Park, Seon-Kyu Kim, Seung-Woo Baek, In Sun Chu, Shinae Yi, Seong Eun Lee, Young Joo Park, Eun-Jae Chung, Jin Man Kim, Hye Mi Ko, Je-Ryong Kim, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Bon Seok Koo
Clinical and Experimental Otorhinolaryngology.2022; 15(2): 183. CrossRef
Prognosis of Patients with 1–4 cm Papillary Thyroid Cancer Who Underwent Lobectomy: Focus on Gross Extrathyroidal Extension Invading Only the Strap Muscles
Ahreum Jang, Meihua Jin, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2022; 29(12): 7835. CrossRef
Carboxy terminus of HSP70‐interacting protein (CHIP) attenuates the stemness of thyroid cancer cells through decreasing OCT4 protein stability
Ying Xu, Gang Xu, Huimin Dang, Wei Qu, Dan Chang, Xin He, Minmin Li, Qian Wang
Environmental Toxicology.2021; 36(4): 686. CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
Clinical Endocrinology.2021; 95(6): 882. CrossRef
80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53
Kun Yu, Hongjiang Lu, Yanhong Chen, Ying Xin, Zhuo Tan, Qiong Yang
Frontiers in Bioscience-Landmark.2021;[Epub] CrossRef
CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma
Young Mun Jeong, Haejin Cho, Tae-Min Kim, Yourha Kim, Sora Jeon, Andrey Bychkov, Chan Kwon Jung
Cancers.2020; 12(10): 3042. CrossRef
The Role of Exosomes in Thyroid Cancer and Their Potential Clinical Application
Kaixiang Feng, Runsheng Ma, Lele Zhang, Hongqiang Li, Yifeng Tang, Gongbo Du, Dongpeng Niu, Detao Yin
Frontiers in Oncology.2020;[Epub] CrossRef

Original Articles

Clinical Study
Quality of Life in Patients with Papillary Thyroid Microcarcinoma According to Treatment: Total Thyroidectomy with or without Radioactive Iodine Ablation: Jonghwa Ahn, Min Ji Jeon, Eyun Song, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim; Endocrinol Metab. 2020;35(1):115-121. Published online March 19, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.1.115

8,587 View
128 Download
16 Web of Science
19 Crossref

Abstract PDF PubReader ePub

Background

Recently, there has been some controversy regarding the role of radioactive iodine (RAI) ablation in the treatment of low-risk differentiated thyroid carcinoma (DTC), especially papillary thyroid microcarcinoma (PTMC). This study aimed to compare quality of life (QoL) parameters between patients with PTMC who underwent total thyroidectomy (TT) alone and those who underwent TT with RAI ablation.

Methods

In this cross-sectional study, patients with PTMC who underwent TT with/without RAI remnant ablation were prospectively enrolled between June 2016 and October 2017. All patients completed three questionnaires: the 12-item short-form health survey (SF-12), thyroid cancer-specific quality of life (THYCA-QoL) questionnaire, and fear of progression (FoP) questionnaire.

Results

The TT and TT with RAI groups comprised 107 and 182 patients, respectively. The TT with RAI group had significantly lower serum thyrotropin (TSH) levels than the TT group. However, after matching for TSH levels between the groups (n=100 in both groups), there were no significant differences in baseline characteristics. According to the SF-12, the score for general health was significantly lower in the TT with RAI group than in the TT group (P=0.047). The THYCA-QoL also showed a significant difference in the “felt chilly” score between groups (P=0.023). No significant differences in FoP scores were observed between the groups.

Conclusion

Patients with PTMC who underwent TT with RAI ablation experienced more health-related problems than those managed with TT alone. These findings support the idea that RAI ablation should be carefully considered in patients with low-risk DTCs.

Citations

Citations to this article as recorded by

Patient‑reported outcome measures for assessing health‑related quality of life in patients with differentiated thyroid cancer: a systematic review
Lujing Xiong, Lei Liu, Yuqing Xiang, Chao Li, Wei Dai, Jinchuan Hu, Chunyan Shui, Yuqiu Zhou, Xu Wang, Yongcong Cai
International Journal of Surgery.2025; 111(1): 1311. CrossRef
A comprehensive analysis of health-related quality of life in thyroid cancer patients using the THYCA-24 questionnaire
Thi Huyen Dinh, Hoang-Bac Nguyen, Thi Bang-Suong Nguyen, Hong Tuan-Nam Pham, Lam Doan-Van, Trung-Thong Luu-Nguyen, Thi Hoe Nguyen, Hoang-Quan Pham, Thi Xuan-Thao Le, Kim-Hai Nguyen
Scientific Reports.2025;[Epub] CrossRef
Impact of Scar on Quality of Life in Well‐Differentiated Thyroid Carcinoma: A Systematic Review
Aníbal Ariza, Alvaro Sanabria
OTO Open.2025;[Epub] CrossRef
From screening to follow-up: a review of quality of life and psychological status across the clinical care continuum in patients with differentiated thyroid cancer
Zifeng Kuang, Hao Zhao, Chenjia Zhang, Xiaoyi Li
Frontiers in Psychology.2025;[Epub] CrossRef
Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma
Daniel W. Scholfield, Lillian A. Boe, Alana Eagan, Helena Levyn, Fergal Kavanagh, R. Michael Tuttle, Ashok R. Shaha, Jennifer R. Cracchiolo, Jatin P. Shah, Richard J. Wong, Snehal G. Patel, Ian Ganly
JAMA Otolaryngology–Head & Neck Surgery.2025;[Epub] CrossRef
Quality of life of patients with thyroid cancer in Colombia
Oscar Gómez, Alvaro Sanabria
Endocrinología, Diabetes y Nutrición.2024; 71(2): 61. CrossRef
Quality of life of patients with thyroid cancer in Colombia
Oscar Gómez, Alvaro Sanabria
Endocrinología, Diabetes y Nutrición (English ed.).2024; 71(2): 61. CrossRef
Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review
Jacob Hampton, Ahmad Alam, Nicholas Zdenkowski, Christopher Rowe, Elizabeth Fradgley, Christine J. O'Neill
Thyroid®.2024; 34(5): 541. CrossRef
Short‐Term Postoperative Depression and Anxiety in Patients with Differentiated Thyroid Carcinoma: Assessment of Potential Oncologic‐Psycho Relevance
Lin Chen, Ningning Ren, Qing Yang, Xingsong Tian, Henrik Falhammar
International Journal of Endocrinology.2024;[Epub] CrossRef
Perception of health and illness and quality of life after total thyroidectomy for differentiated thyroid carcinoma: the PERSAM study
Elena Groff, Beatrice Soccal, Fabiola Carrossa, Federica Vianello, Sara Talomo, Alessandra Feltrin, Giovanni Scarzello, Honoria Ocagli, Dario Gregori, Matteo Martinato
Frontiers in Endocrinology.2024;[Epub] CrossRef
Review: Improving quality of life in patients with differentiated thyroid cancer
Pia Pace-Asciak, Jonathon O. Russell, Ralph P. Tufano
Frontiers in Oncology.2023;[Epub] CrossRef
Health-Related Quality of Life and Thyroid Cancer-Specific Symptoms in Patients Treated for Differentiated Thyroid Cancer: A Single-Center Cross-Sectional Survey from Mainland China
Changlian Chen, Jiayan Cao, Yueyang Wang, Xuya Han, Yaju Zhang, Shumei Zhuang
Thyroid.2023; 33(4): 474. CrossRef
The "not so good" thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life
Kyle Alexander, Sum-Yu Christina Lee, Stelios Georgiades, Constantina Constantinou
Journal of Medicine and Life.2023; 16(3): 348. CrossRef
Comparison of health‐related quality of life and cosmetic outcome between traditional gasless trans‐axillary endoscopic thyroidectomy and modified gasless trans‐axillary endoscopic thyroidectomy for patients with papillary thyroid microcarcinoma
Deenraj Kush Dhoomun, HuiLan Cai, Ning Li, YanHuan Qiu, XingRui Li, XiaoPeng Hu, WenZhuang Shen
Cancer Medicine.2023; 12(15): 16604. CrossRef
Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis
Shinje Moon, Ka Hee Yi, Young Joo Park
Cancers.2022; 14(10): 2382. CrossRef
Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules
Elizabeth J de Koster, Olga Husson, Eveline W C M van Dam, G Sophie Mijnhout, Romana T Netea-Maier, Wim J G Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens, _ _
Endocrine Connections.2022;[Epub] CrossRef
Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment
Poliane A.L. Santos, Maria E.D.M. Flamini, Felipe A. Mourato, Fernando R.A. Lima, Joelan A.L. Santos, Fabiana F. Lima, Estelita T.B. Albuquerque, Alexandra C. De Freitas, Simone C.S. Brandão
Brazilian Journal of Radiation Sciences.2022; 10(4): 1. CrossRef
Health-related quality of life after transoral robotic thyroidectomy in papillary thyroid carcinoma
Chang Myeon Song, Hyang Sook Bang, Hyung Gu Kim, Hae Jin Park, Kyung Tae
Surgery.2021; 170(1): 99. CrossRef
Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
Endocrinology and Metabolism.2021; 36(2): 359. CrossRef

Clinical Features of Multiple Endocrine Neoplasia Type I in Koreans.: Chul Hee Kim, Ghi Su Kim, Hong Kyu Kim, Joong Yeol Park, Young Kee Shong, Ki Up Lee; J Korean Endocr Soc. 1996;11(2):163-174. Published online November 7, 2019

1,688 View
25 Download

Abstract PDF: Background
Multiple endocrine neoplasia type I(MEN I) is a rare, eomplex, and potentially lethal disease. In Korean, only five anecdotal cases were reported as yet. The authors rescently experienced four cases of MEN I, and analysed the clinieal characteristics of MEN I in Koreans. Methods: The authors evaluated nine cases of MEN I, retrospectively. Four cases were analysed by clinical records in patients admitted to Asan Medical Center and five cases were reviewed by previously reported Korean literature from 1986 to 1995. Results: The average age was 39 years(ranged from 33 to 59 years). Eight of the nine patients had hyperparathyroidism documented by elevated serum calcium and PTH level with or without evidence of parathyroid mass. Initial presenting manifestations were symptomatic urinary stone, hypoglycernia due to insulinoma, hypogonadism, acromegaly, or peptic ulcer. Eight of nine patients had pancreatic islet cell tumors, and three of them were be malignant by radiologic and/or pathologic findings. The pancreatic tumors produced various hormones, such as gastrin, insulin, glucagon, or combination of them. Six of the nine cases had pituitary lesion. The most cornmon pituitary tumor was prolactinoma and the remaining was GH or GH and TSH producing tumor. In addition to the major components of MEN I, four had adrenocortical hyperplasia or adenoma and two had carcinoid tumor. There was only one familial case. Conclusion: The clinical charateristics of MEN I in Korean are mostly not different from the previous reports except older age at diagnosis, more comrnon adrenal involvement(44%) and gastrointestinal carcinoid tumor(22%). Although only one case was familial, more cases could be found if careful screening were done for the family members of the MBN I patients. In addition, screening and close follow up for endocrine pancreatic tumors are required for MEN I patients without detectable pancreatic lesion becau~se the malignant potential of pancreatic tumors has beeome an increasing concem for the prognosis of MEN I.

Autoantigenic Role of Variant Thyroperoxidase.: Young Kee Shong, Dae Hyuk Moon, Ghi Su Kim; J Korean Endocr Soc. 1996;11(1):61-67. Published online November 7, 2019

1,538 View
18 Download

Abstract PDF: Background
Thyroperoxidase(TPO) is one of the most important autoantigens in autoimmune thyroid disorders and autoantibody to TPO is found in almost every patients with various autoimmune thyroid diseases. Human TPO was already cloned and the completed nucleotide sequences are well known. In human thyroid tissues, several variants mRNA's of TPO are found in addition to the wild type. Especially the variants lacking exon 10(TPOΔexon10) and exon 16(TPOΔ exon16) are found in very large amount in both normal and Graves thyroid tissues. The significance of these variants TPO mRNAs are largely unknown. The authors tried to investigate the autoantigenic role of these variant TPO. Methods : To produce variant TPO cDNAs, oligonucleotide directed mutagenesis was performed using cDNA for wild type human TPO as template. The produced variants cDNAs were transfected into Cos-7 cells and variants TPO proteins were tested against patients sera showing high titers of anti-TPO antibody. Results: Seven of 12 Graves sera reacted with TPOΔexon 10 and 8 Graves sera with TPOΔ exonl6. Eight of 15 Hashimoto sera reacted TPOΔexon16 and 9 with TPOΔexon16. The reactivity with variants TPO was not related to clinical findings. Conclusion: These two variant TPOs, that is TPOexon10 and TPOΔexon16, could act as an autoantigen if they were translated in vivo, and could play a role in autoimmune thyroid disease. Their exact role in the pathogenesis of autoimmune thyroid disorders are to be clarified.

Difference of Thyroid Stimulating Antidody Activities Measured in Chinese Hamster Ovary Cells Stably Transfected with Human TSH Receptor and in FRTL-5 Cells in Graves Disease and Its Clinical Correlations.: Young Kee Shong Young Kee Shong, Hye Young Park, Bo Youn Cho, Won Bae Kim, Hong Gyu Lee, Chang Soon Koh, Yeon Sang Oh; J Korean Endocr Soc. 1996;11(1):18-29. Published online November 7, 2019

1,603 View
22 Download

Abstract PDF: Background
: Thyroid stimulating antibodies result in the development of hyperthyroidism and goiter in Graves disease. However, thyroid stimulating antibody activities do not correlate with the clinical features in many patients with Graves disease. The purpose of this study is to address this discrepancy between thyroid stimulating antibody activities and clinical features of Graves patients. Methods: We measured thyroid stimulating antibody activities simultaneously using human TSH receptor transfected Chinese hamster(hTSHR-CHO) cells and rat thyroid(FRTL-5) cells in 57 untreated patients with Graves disease, and compared their activities with clinical features including thyroid hormone levels. Results : The detection rate of thyroid stimulating antibody measured by hTSHR-CHO cells was 90% in 57 untreated Graves patients and it was higher than that measured by FRTL-5 cells. Thyroid stimulating antibody activity by hTSHR-CHO cells was significantly correlated with that by FRTL-5 cells(r=0.5, p<0.001), however, 18 of 57(32%) patients showed marked discrepancy of thyroid stimulating antibody activity between in hTSHR-CHO and FRTL-5 systems. Thyroid stimulating antibody activity measured by hTSHR-CHO cells was significantly correlated with serum total T3, free T4 levels, and goiter size but not 99mTc-thyroid uptake. On the other hand, thyroid stimulating antibody activity measured by FRTL-5 cells was significantly correlated with goiter size and 99mTc-thyroid uptake but not thyroid hormone levels. The difference between function and goiter size with respect to thyroid stimulating antibody measurement in two cells system is, nevertheless, particularly evident in the free T4/goiter ratio in patients with high hTSHR-CHO and low FRTL-5 cell assay values. Conclusion: These findings suggest that thyroid stimulating antibodies in Graves disease are heterogeneous population in terms of responses to different origin of cells. Further, thyroid stimulating antibody activities measured by FRTL-5 cells tend to correlate better with goiter size and Tc-thyroid uptake, whereas thyroid stimulating antibody activities measured by hTSH-CHO cells correlate better with thyroid hormone levels.

Clinical Significance of Routine Measurement of Serum Calcitonin in Korean Patients with Thyroid Nodules as a Screening test of Sporadic Thyroid Medullary Carcinoma.: Young Kee Shong, Cheol Soo Choi, Hye Young Park, Bo Youn Cho; J Korean Endocr Soc. 1996;11(1):11-17. Published online November 7, 2019

1,571 View
27 Download

Abstract PDF: Background
: It is not easy to diagnose sporadic medullary thyroid carcinoma(MTC) before surgery and this might lead the patient reoperation and/or lowered chance of definite cure. Methods : The prevalence of sporadic MTC in Korean was studied in patients with thyroid nodules. A prospective study of 1048 consecutive patients with thyroid nodules was performed. In all patients, measurements of basal serum calcitonin, thyroid hormones, TSH, anti-thyroglobulin antibody and anti-thyroperoxidase antibody were undertaken along with technetium-99m thyroid scintigraphy and fine needle aspiration cytology. In patients with elevated basal calcitonin levels, calcium stimulated calcitonin level was determined. Results: Two patient had markedly elevated calcitonin levels(over 3,200 pg/mL and 1,763 pg/ mL) and another one slightly elevated calcitoni#n(71.9 pg/mL). Fine needle aspiration cytology was suggestive of MTC in one and nodular hyperplasia in the other two. They underwent surgery and histological examination revealed MTC in those two with markedly elevated calcitonin levels. The patient with slightly elevated calcitonin, who was on the maintenance hemodialysis due to chronic renal failure, had nodular hyperplasia. Conclusion: MTC was found in 0.19% of patients with thyroid nodules, which was not different with the previously reported prevalence in Europe. Routine measurements of serum calcitonin might be of value to detect sporadic MTC; however, the cost-effectiveness of routine measurement of serum calcitonin is not clear, considering the relatively low prevalence of MTC in Koreans.

Case Report

A Korean Pedigree of Paget Bone Disease.: Young Kee Shong, Joong Yeol Park, Ki Up Lee, Ghi Su Kim, Suhn Hee Kim, Jae Kun Cho, You Sook Cho, Hong Ja Kim, Myung Jin Shin; J Korean Endocr Soc. 1995;10(4):451-455. Published online November 7, 2019

1,590 View
22 Download

Abstract PDF: Paget bone disease(PBD) is usually focal, but can be wide spread disorder of the skeletal remodeling characterized by greatly increased osteoclast size and activity. It has extremely variable prevalence worldwide, being common in England and northern European countries and areas populated by their descendants, but strikingly uncommon in Asia, the middle east, Africa and Scandinavia. It's occurrence also shows familial clustering, some postulates autosomal dominant inheritance. Many studies have shown that paramyxoviruses may play a critical role in the etiology of this disorder. However, the precise etiology of PBD remains unknown.We describe a kindred with PBD in 3 successive generations. The propositus, a 55-year-old man, has panostotic PBD and giant cell reparative granuloma of pagets disease involving his head, mandible, abdomen and ileum, rare tumorous complication of Paget's disease. Bowed limbs were first noticed at age 25 years, and progressed for 20 years. Giant cell reparative granuloma began manifesting at age 45 years, and responded dramatically to high-dose dexamethasone therapy. His pretreatment biochemical finding were remarkable for elevated serum ALP, 765(normal 66-220 u/L) and osteocalcin, 154(normal 6.3-30.7 mg/ml), but normal serum calcium, phosphorous, 250HD and PTH. A nondecalcified iliac crest specimen demonstrated classic histopathologic 25OHD and PTH. A nondecalcified iliac crest specimen demonstrated classic histopathologic changes of PBD on light microscopy. His decreased father had a similar degree of bony deformities beginning at age 20 years, but had not been examined. His two asymptomatic daughters, 20 and 24-year-old, were both found to be affected with widespread PBD by bone scan, radiographic study, and their serum ALP levels, 939 and 435U/L, respectively. This is the first report of familial occurance of PBD and a case of giant cell reparative granuloma of Paget's disease in Korea, where PBD is very rare.

Original Article

Thyroid Stimulating Antibody Assay with Chinese Hamster Ovary Cells Expressing Human Thyroid Stimulating Hormone (TSH) Receptor; Optimization of Assay Condition.: Bo Youn Cho, Hong Kyu Lee, Young Kee Shong, Chang Soon Koh, Ka Hee Yi, Yeon Sahng Oh, Won Bae Kim; J Korean Endocr Soc. 1995;10(4):333-346. Published online November 7, 2019

1,541 View
20 Download

Abstract PDF: We investigated the optimal condition of thyroid stimulating antibody(TSAb) assay using Chinese hamster ovary cells transfected with cDNA of human TSH receptor(TSHr-CHO) stably expressing functional TSH receptors. The extracellular cAMP responses of TSHr-CHO cells to the stimulation of bTSH or Graves' IgG were observed in three different incubation media. Stimulation indices of extracellular cAMP were higher when sucrose containing NaCl-free isotonic Hank's balanced salt solution(HBSS)(media A)was used as incubation media than those of NaCl-free hypotonic HBSS(media B) or those of NaCl containing isotonic HBSS(media C). The incubation of TSHr-CHO cells in media B caused marked increase in the basal cAMP level without concomittant fold-increase in the stimulated cAMP level at various doses of bTSH and Graves' IgG. Decreasing the stimulation indices of extracellular cAMP, use of media B failed to detect TSAb activities in two TSAb-positive Graves' IgG tested. In case of media C, extracellular cAMP responses are poor at 0.001 and 0.1U/L of bTSH and at all doses of Graves' IgG tested(0.5, 1, 5g/L). The incubation of TSHr-CHO cells in media B caused significant increase in the number of trypan blue-stained, nonviable cells(5.7+-1.5, 7.6+-1.9 and 8.5+-1.6% at 1, 2 and 3h of incubation, respectively; p<0.01) comparing to those incubated in media A or media C(about 2-3% in both media). Those decrease in the viability of TSHr-CHO cells when incubated in hypotonic incubation media may explain the decrease in the stimulation index of extracellular cAMP with the use of media B in contrast to the case of FRTL-5 cells. TSAb assay of 87 consecutive fresh Graves' patients with TSHr-CHO cells using media A detected TSAb activities in 90%(78 patients) of them, and moreover TSAb activities showed significant positive correlation with the pre-treatment serum T_3 and free T_4 levels of those patients. We conclude that TSAb assay with TSHr-CHO cells is a sensitive and physiologically relevant assay system to measure TSAb activities merely through measurements of extracellular cAMP provided that the cells are incubated in NaCl-free isotonic incubation media.

Editorial

Measurement of Thyrotropin Receptor Antibody.: Young Kee Shong; J Korean Endocr Soc. 1995;10(4):329-332. Published online November 7, 2019

1,329 View
16 Download

Abstract PDF: No abstract available.

Original Article

Clinical Significance of Thyrotropin Measurement as a Screening Test in Ambulatory Patients.: Young Kee Shong, Hong Kyu Kim, Ghi Su Kim, Dae Hyuk Moon; J Korean Endocr Soc. 1994;10(3):191-199. Published online November 6, 2019

1,837 View
18 Download

Abstract PDF: The objective of this study is to determine the clinical significance of thyrotropin(TSH) measurement as a screening test in ambulatory patients. One hundred and nintynine patients with abnormal TSH levels detected at routine examinations were studied. The patients were examined and histories about the recent medications and nonthyroidal illness were taken. Additional thyroid tests were done including measuments of total T_3, free T_4, antithyroid autoantibodies, thyroid scan and radioiodine uptake. Of the total 199 patients, 107(54.7%) had thyroid diseases. 49 out of 101 patients with subnormal TSH had thyroid diseases, and the remainder had supressed TSH due to medications, associated nonthyroidal illness, and normal variations. 58 out of 99 patients with elevated TSH had thyroid diseases. Of those 47 patients whose TSH level was below 0.05 mIU/L, functional sensitivity of TSH assay in our laboratory, 37 had thyroid diseases. Of those 19 patients whose TSH level was above 7.0mIU/L, two times of upper normal limit, all had thyroid iseases.Simultaneous measurement of free T_4 disclosed 50(25.1%) out of total 199 patients with abnormal TSH levels had abnormal free T_4 values which is regarded as evidence of clinical thyroid dysfunction. In summary, a single measurement of TSH level alone seems to have high sensitivity but low specificity. Simultaneous measurement of free T_4 can reasonably compensate the low specificity of TSH measurement. In case of ambulatory patients without significant nonthyroidal illness, TSH values below functional sensitivity or above twice upper normal limit may predict thyroid disease and dysfunction with reasonable specificity.

Case Report

Nesidioblastosis in Adult with Hyperinsulinemic Hypoglycemia.: Young Kee Shong, Hong Kyu Kim, Young Joo Min, Joong Yeol Park, Sung Kwan Hong, Ki Up Lee, Duck Jong Han, Ho Jeong Lee, Gyung Yub Gong; J Korean Endocr Soc. 1994;10(2):168-169. Published online November 6, 2019

1,287 View
17 Download

Abstract PDF: No abstract available.

Editorial

Measurement of free T4.: Young Kee Shong; J Korean Endocr Soc. 1994;10(2):95-97. Published online November 6, 2019

1,184 View
16 Download

Abstract PDF: No abstract available.

Original Articles

Cushing's Disease Due to ACTH Producing Pituitary Carcinoma.: Young Kee Shong, Joong Yeol Park, Ghi Su Kim, Won Kyoung Cho, Jung Kyo Lee, Ghee Young Choe, Mun Ho Lee, Ki Up Lee; J Korean Endocr Soc. 1994;9(2):136-140. Published online November 6, 2019

1,562 View
20 Download

Abstract PDF: Primary carcinoma of the pituitary is only rarely reported. About half of the reported cases are nonfunctional. It is generally agreed that the presence of distant metastasis is required to clearly establish the diagnosis of pituitary carcinoma. We have experienced a case of ACTH-producing pituitary carcinoma causing Cushing's syndrome which could be diagnosed by histologic features only without evidence of distant metastasis. A 35-year-old female with Cushingoid appearance was diagnosed as Cushing's disease after biochemical and neuroradiological evaluation. Near total removal of the pituitary tumor was performed. By histopathologic examination, the tumor revealed evidences of histological malignancy such as prominent nuclear pleomorphism, frequent mitoses and extensive tumor necrosis. Pseudosarcomatous components were also noted. By immunohistochemical studies, the tumor cells expressed ACTH. However, there was no evidence of distant metastasis at the initial operation. She was diagnosed as having ACTH producing pituitary carcinoma by histologic feature only. One month later, she complained progressive nausea and vomiting, and follow-up brain MRI revealed regrowing pituitary mass. She was reoperated and near total tumor bulk was removed again followed by radiotherapy with 5580 rads. Four month after the second operation, she developed generalized tonic clonic seizure. Brain CT showed multiple enhancing nodules on left temporal and frontal lobes, and around falx cerebri. She refused further treatment and was managed only with anticonvalsants. About month after discharge she died at home.

Sporadic Nonfamilial Hypophosphatemic Osteomalacia.: Young Kee Shong, Joong Yeol Park, Ghi Su Kim, You Sook Cho, Goo Yeong Cho, Sang Wook Kim, Jung Sik Park, Ki Up Lee; J Korean Endocr Soc. 1994;9(1):25-31. Published online November 6, 2019

1,662 View
29 Download

Abstract PDF: Chronic hypophosphatemia caused by decreased intestinal absorption or increased renal clearance, may lead to rickets or osteomalacia independently of other predisposing abnormalities. The conditions commonly associated with increased renal clearance of phosphate are X-linked hypophosphatemic rickets, tumor associated rickets/osteomalacia, RTA and Fanconi syndrome. Recently we experienced 3 men with adult-onset, histologically proven osteomalacia associated with increased renal clearance of phosphate. None of them had a family history of bone disease, tumors or other tubular defects. All of these had remarkable biochemical and clinical improvement with medical treatment such as 1, 25-dihydroxyvitamin D and phosphate supplementation. Although we did not find tumors yet, we could not rule out the possibility of tumor-associated osteomalcia since it often takes several years to make a diagnosis because of small size, benign nature and unusual location of tumors. Thus, careful long-term follow up for tumor occurrence will be maintained in these patients with sporadic nonfamilial hypophosphatemic osteomalacia.

Case Report

A Case of Primary Thyroid Lymphoma Involving Bone Marrow (Stage IVE) Assoeiated with Hashimoto's Thyroiditis.: Young Kee Shong, Joong Yeol Park, Ghi Su Kim, Jae Kun Cho, Yun Ho Chu, Wan Sik Eom, Sang Hee Kim, Hyun Sook Chi, Gyung Yub Gong, Ki Up Lee; J Korean Endocr Soc. 1994;9(4):390-394. Published online November 6, 2019

1,616 View
19 Download

Abstract PDF: Primary lymphoma of the thyroid is a relatively rare malignant tumor of the thyroid. It is known to be frequently associated with Hashimoto's thyroiditis. In Korea, a few cases of primary lymphoma of the thyroid have been reported and most of these cases were in the stage I E or II E. Recently, we experienced a case of the primary thyroid lymphoma, stage IV E associated with Hashimoto's thyroiditis in a 70-year-old woman who presented with dysphagia and dyspnea due to rapidly enlarging neck mass.She was treated with combination chemotherapy(cyclophosphamide, adriamycin, vincristine and methylprednisolone) and local radiotherapy and achieved partial response with resolution of dysphagia and dyspnea.

Review Article

Thyroperoxidase in Autoimmune Thyroid Disorders.: Young Kee Shong; J Korean Endocr Soc. 1994;9(4):277-283. Published online November 6, 2019

1,411 View
16 Download

Abstract PDF: No abstract available.

Case Report

A Case of Nesidioblastosis in Adult with Hyperinsulinemic Hypoglycemia.: Young Kee Shong, Hong Kyu Kim, Young Joo Min, Joong Yeol Park, Sung Kwan Hong, Ki Up Lee, Duck Jong Han, Ho Jeong Lee, Ghi Su Kim, Gyung Yub Gong; J Korean Endocr Soc. 1994;10(3):273-277. Published online November 6, 2019

1,632 View
20 Download

Abstract PDF: Nesidioblastosis is a primarily childhood disease which is often associated with hyperinsulinemic hypoglycemia. It is very rarely found in adults. Only a few well documented cases are found in the world interature. The authors have recently experienced a case of nesidioblastosis in an adult. A 55-year-old man was admitted due to repeated episodes of reversible loss of consciousness. Hyperinsulinemic hypoglycemia was documented. Under the presumptive diagnosis of insulinoma, localization procedures were done but no definite tumor was found. Only suspicious gradient in insulin concentration was found around the head of pancreas by percutaneous transhepatic portal venous sampling. Exploratory laparotomy was performed and Whipple's operation was done. Seventy percent of proximal pancreas was removed. Histomorphometric study of the resected specimen revealed uneven graded hyperplasia of the islet cells with the most profuse hyperplasia in the head region and progressive decrease in the degree of hyperplasia to the body and tail. The patient remains euglycemia until 6 months after operation since immediate postoperative period and can tolerate 24 hour fasting without any medication.

Original Articles

Endocrine Research
Expression of NF2 Modulates the Progression of BRAF^V600E Mutated Thyroid Cancer Cells: Mi-Hyeon You, Min Ji Jeon, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim; Endocrinol Metab. 2019;34(2):203-212. Published online June 24, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.203

7,701 View
75 Download
7 Web of Science
5 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

We previously reported the frequent neurofibromatosis 2 (NF2) gene mutations in anaplastic thyroid cancers in association with the BRAF^V600E mutation. We aimed to investigate the role of NF2 in thyroid cancer with BRAF mutation.

Methods

To identify the function of NF2 in thyroid cancers, we investigated the changes in cell proliferation, colon formation, migration and invasion of thyroid cancer cells (8505C, BHT101, and KTC-1) with BRAF^V600E mutation after overexpression and knock-down of NF2. We also examined how cell proliferation changed when NF2 was mutagenized. Human NF2 expression in papillary thyroid carcinoma (PTC) was analyzed using the The Cancer Genome Atlas (TCGA) data.

Results

First, NF2 was overexpressed in 8505C and KTC-1 cells. Compared to control, NF2 overexpressed group of both thyroid cancer cells showed significant inhibition in cell proliferation and colony formation. These results were also confirmed by cell migration and invasion assay. After knock-down of NF2 in 8505C cells, there were no significant changes in cell proliferation and colony formation, compared with the control group. However, after mutagenized S288^* and Q470^* sites of NF2 gene, the cell proliferation increased compared to NF2 overexpression group. In the analysis of TCGA data, the mRNA expression of NF2 was significantly decreased in PTCs with lateral cervical lymph node (LN) metastasis compared with PTCs without LN metastasis.

Conclusion

Our study suggests that NF2 might play a role as a tumor suppressor in thyroid cancer with BRAF mutation. More studies are needed to elucidate the mechanism how NF2 acts in thyroid cancer with BRAF mutation.

Citations

Citations to this article as recorded by

Mechanistic Insights of Thyroid Cancer Progression
Luis Javier Leandro-García, Iñigo Landa
Endocrinology.2023;[Epub] CrossRef
Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?
Cesar Seigi Fuziwara, Diego Claro de Mello, Edna Teruko Kimura
Cancers.2022; 14(3): 844. CrossRef
Extracellular Vesicles as Signal Carriers in Malignant Thyroid Tumors?
Małgorzata Grzanka, Anna Stachurska-Skrodzka, Anna Adamiok-Ostrowska, Ewa Gajda, Barbara Czarnocka
International Journal of Molecular Sciences.2022; 23(6): 3262. CrossRef
Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression
Mi-Hyeon You, Min Ji Jeon, Seong ryeong Kim, Woo Kyung Lee, Sheue-yann Cheng, Goo Jang, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Scientific Reports.2021;[Epub] CrossRef
High Phosphoglycerate Dehydrogenase Expression Induces Stemness and Aggressiveness in Thyroid Cancer
Min Ji Jeon, Mi-Hyeon You, Ji Min Han, Soyoung Sim, Hyun Ju Yoo, Woo Kyung Lee, Tae Yong Kim, Dong Eun Song, Young Kee Shong, Won Gu Kim, Won Bae Kim
Thyroid.2020; 30(11): 1625. CrossRef

Thyroid
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age: Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2018;33(4):459-465. Published online November 30, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.4.459

8,457 View
70 Download
9 Web of Science
7 Crossref

Abstract PDF PubReader ePub

Background

Differentiated thyroid carcinoma (DTC) shows a very good prognosis, but older patients have a higher recurrence rate and those show poor prognosis than younger patients. The aim of this study was to determine the clinical outcomes of thyroid cancer patients who experienced recurrence in old age according to the treatment strategy used.

Methods

This retrospective observational cohort study was conducted at Asan Medical Center, Seoul, Korea. Among DTC patients with no evidence of disease after initial treatment, we enrolled 86 patients who experienced recurrence at an age >65 years from 1994 to 2012. Sixty-nine patients had local recurrence and 17 patients showed distant metastasis.

Results

The mean age of patients at recurrence was 72 years. Patients were followed up for a median of 4.1 years after recurrence. Sixty-three of the 69 patients with local recurrence received additional treatment, while the other six received conservative care. The cancer-specific mortality rate was 15.5% in the local recurrence group. Airway problems were the main cause of death in patients who did not receive further treatment for local recurrence. Among the 17 patients with distant metastasis, 10 underwent specific treatment for metastasis and seven received only supportive management. Seven of those 17 patients died, and the cancer-specific mortality rate was 35% in the distant metastasis group.

Conclusion

The overall cancer-specific mortality rate was 20% in DTC patients in whom recurrence was first detected at an age >65 years. Mortality due to uncontrolled local disease occurred frequently in patients who did not receive definitive management for recurrence.

Citations

Citations to this article as recorded by

Diagnostic performance of fluorine-18-fluorodeoxyglucose PET/MRI for detection of disease recurrence in differentiated thyroid cancer: a compartment-based analysis
Elgin Özkan, Sena Ünal, Pinar Akkuş, Elif Peker, Mine Araz, Ecenur Dursun, Cigdem Soydal, Nil Sezer Yilmazer Zorlu, Mustafa Kursat Gökcan, Murat Faik Erdoğan, Yasemin Yavuz, Nuriye Ozlem Küçük
Nuclear Medicine Communications.2025; 46(3): 230. CrossRef
Radiofrequency Ablation for Recurrent Thyroid Cancers: 2025 Korean Society of Thyroid Radiology Guideline
Eun Ju Ha, Min Kyoung Lee, Jung Hwan Baek, Hyun Kyung Lim, Hye Shin Ahn, Seon Mi Baek, Yoon Jung Choi, Sae Rom Chung, Ji-hoon Kim, Jae Ho Shin, Ji Ye Lee, Min Ji Hong, Hyun Jin Kim, Leehi Joo, Soo Yeon Hahn, So Lyung Jung, Chang Yoon Lee, Jeong Hyun Lee,
Korean Journal of Radiology.2025; 26(1): 10. CrossRef
125I seed implantation for lymph node metastasis from radioactive iodine-refractory differentiated thyroid carcinoma: a study on short-term efficacy and dosimetry
Wenwen Zhang, Shanhu Hao, Zhiguo Wang, Tingting Ding, Guoxu Zhang
Frontiers in Oncology.2024;[Epub] CrossRef
Identification of Circulating Tumor Cell Phenotype in Differentiated Thyroid Carcinoma
Huiling Wang, Mian Lv, Yonghong Huang, Xiaoming Pan, Changyuan Wei
Journal of Biomaterials and Tissue Engineering.2022; 12(4): 813. CrossRef
Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
Zhong-Ling Qiu, Chen-Tian Shen, Zhen-Kui Sun, Hong-Jun Song, Chuang Xi, Guo-Qiang Zhang, Yang Wang, Quan-Yong Luo
Frontiers in Endocrinology.2021;[Epub] CrossRef
Head-to-Head Comparison of Neck 18F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment
Yangmeihui Song, Fang Liu, Weiwei Ruan, Fan Hu, Muhsin H. Younis, Zairong Gao, Jie Ming, Tao Huang, Weibo Cai, Xiaoli Lan
Cancers.2021; 13(14): 3436. CrossRef
Highly sensitive electrochemical immunosensor using a protein-polyvinylidene fluoride nanocomposite for human thyroglobulin
Maria Oneide Silva de Moraes, João de Deus Pereira de Moraes Segundo, Marcos Marques da Silva Paula, Maria Goreti Ferreira Sales, Walter Ricardo Brito
Bioelectrochemistry.2021; 142: 107888. CrossRef

Thyroid
Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF^V600E Mutation in Thyroid Neoplasm: Hye-Seon Oh, Hyemi Kwon, Suyeon Park, Mijin Kim, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Jene Choi, Won Gu Kim, Dong Eun Song; Endocrinol Metab. 2018;33(1):62-69. Published online January 30, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.1.62

9,226 View
81 Download
20 Web of Science
22 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

The BRAF^V600E mutation is the most common genetic alteration identified in papillary thyroid carcinoma (PTC). Because of its costs effectiveness and sensitivity, direct Sanger sequencing has several limitations. The aim of this study was to evaluate the efficiency of immunohistochemistry (IHC) as an alternative method to detect the BRAF^V600E mutation in preoperative and postoperative tissue samples.

Methods

We evaluated 71 patients who underwent thyroid surgery with the result of direct sequencing of the BRAF^V600E mutation. IHC staining of the BRAF^V600E mutation was performed in 49 preoperative and 23 postoperative thyroid specimens.

Results

Sixty-two patients (87.3%) had PTC, and of these, BRAF^V600E was confirmed by direct sequencing in 57 patients (91.9%). In 23 postoperative tissue samples, the BRAF^V600E mutation was detected in 16 samples (70%) by direct sequencing and 18 samples (78%) by IHC. In 24 fine needle aspiration (FNA) samples, BRAF^V600E was detected in 18 samples (75%) by direct sequencing and 16 samples (67%) by IHC. In 25 core needle biopsy (CNB) samples, the BRAF^V600E mutation was detected in 15 samples (60%) by direct sequencing and 16 samples (64%) by IHC. The sensitivity and specificity of IHC for detecting the BRAF^V600E mutation were 77.8% and 66.7% in FNA samples and 99.3% and 80.0% in CNB samples.

Conclusion

IHC could be an alternative method to direct Sanger sequencing for BRAF^V600E mutation detection both in postoperative and preoperative samples. However, application of IHC to detect the BRAF^V600E mutation in FNA samples is of limited value compared with direct sequencing.

Citations

Citations to this article as recorded by

2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph Osborne, John
Thyroid®.2025; 35(8): 841. CrossRef
Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value
Somayeh Igder, Mozhdeh Zamani, Shima Fakher, Morvarid Siri, Hassan Ashktorab, Negar Azarpira, Pooneh Mokarram, Sowjanya Thatikonda
Disease Markers.2024; 2024: 1. CrossRef
Fluorescent primers amplification refractory mutation system qPCR (FP ARMS-qPCR) for MTHFR C677T SNP genotyping
Yongjun Han, Hong Wu
Molecular Biology Reports.2024;[Epub] CrossRef
Inter- and Intra-observer Reproducibility of Thyroid Fine Needle Aspiration Cytology: An investigation of Bethesda 2023 Using Immunohistochemical BRAFV600E Antibody
Erdogan Bahattin, Dündar Emine, Çetin Kısmet Çivi, Yılmaz Fatih
Journal of Cytology.2024; 41(4): 221. CrossRef
The Accurate Interpretation and Clinical Significance of Morphological Features of Fine Needle Aspiration Cells in Papillary Thyroid Carcinoma
Xue-Jiao Xiong, Ming-Ming Xiao, Yi-Xia Zhang, Dong-Ge Liu, Mu-Lan Jin, Jian Wang, Hong-Tao Xu, Qing-Chang Li, Guang-Ping Wu, Giovanni Tuccari
Analytical Cellular Pathology.2023;[Epub] CrossRef
An effective approach for BRAF V600E mutation analysis of routine thyroid fine needle aspirates
Tanupriya Agrawal, Liqiang Xi, Winnifred Navarro, Mark Raffeld, Snehal B. Patel, Mark J. Roth, Joanna Klubo‐Gwiezdzinska, Armando C. Filie
Cytopathology.2022; 33(3): 344. CrossRef
A dual identification strategy based on padlock ligation and CRISPR/Cas14a for highly specific detection of BRAF V600E mutation in clinical samples
Weicheng Shi, Yao Gong, Decai Zhang, Tiantian Yang, Ming Yi, Jingyi Tan, Shijia Ding, Wei Cheng
Analytical Methods.2022; 14(19): 1913. CrossRef
Research Progress of BRAF V600E Gene Mutation in Papillary Thyroid Carcinoma
延泽刘
Advances in Clinical Medicine.2022; 12(09): 8499. CrossRef
VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients
Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Sameer Aga
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
BRAF testing in a South African cohort of MLH1 deficient endometrial carcinomas: lessons learnt
Reubina Wadee, Wayne Grayson
Southern African Journal of Gynaecological Oncology.2021; 13(1): 1. CrossRef
Association between mutation profiles and clinicopathological features in Chinese patients with thyroid cancer
Changwen Jing, Haixia Cao, Rong Ma, Jianzhong Wu, Zhuo Wang
Precision Medical Sciences.2021; 10(3): 113. CrossRef
Development of a Molecular Assay for Detection and Quantification of theBRAFVariation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens
Guodong Fu, Ronald S. Chazen, Christina MacMillan, Ian J. Witterick
JAMA Network Open.2021; 4(10): e2127243. CrossRef
Variations in MAP kinase gladiators and risk of differentiated thyroid carcinoma
Faiza Rashid, Ghulam Bhat, Mosin Khan, Sobia Tabassum, Mohammad Bhat
Molecular and Clinical Oncology.2021;[Epub] CrossRef
Порівняльне імуногістохімічне дослідження BRAFV600E-позитивних і BRAFV600E-негативних радіогенних і спорадичних папілярних тиреоїдних карцином
L. Yu. Zurnadzhy, T.I. Rogounovitch, V.O. Saenko, M.Yu. Bolgov, S.V. Masiuk, S.V. Burko, T.L. Degtyaryova, S.V. Chernyshov, S.V. Gulevatyi, N. Mitsutake, M.D. Tronko, T.I. Bogdanova
Endokrynologia.2021; 26(2): 105. CrossRef
Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay
Tien Viet Tran, Kien Xuan Dang, Quynh Huong Pham, Ung Dinh Nguyen, Nhung Thi Trang Trinh, Luong Van Hoang, Son Anh Ho, Ba Van Nguyen, Duc Trong Nguyen, Dung Tuan Trinh, Dung Ngoc Tran, Arto Orpana, Ulf-Håkan Stenman, Jakob Stenman, Tho Huu Ho
BMC Cancer.2020;[Epub] CrossRef
VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
Sonam Choden, Somboon Keelawat, Chan Kwon Jung, Andrey Bychkov
Cancers.2020; 12(3): 596. CrossRef
Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis
Kyle G. Parker, Michael G. White, Nicole A. Cipriani
Head and Neck Pathology.2020; 14(4): 1067. CrossRef
Next generation sequencing based detection of 15 target genes mutations in papillary thyroid carcinoma
Zhuo Wang, Changwen Jing, Haixia Cao, SiWen Liu, Jianzhong Wu, Rong Ma
Precision Medical Sciences.2020; 9(2): 90. CrossRef
A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology
Ranjit Singarayer, Ozgur Mete, Laure Perrier, Lehana Thabane, Sylvia L. Asa, Stan Van Uum, Shereen Ezzat, David P. Goldstein, Anna M. Sawka
Endocrine Pathology.2019; 30(3): 201. CrossRef
Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAFV600E mutation in papillary thyroid carcinoma
Zhuo Wang, Kejing Sun, Changwen Jing, Haixia Cao, Rong Ma, Jianzhong Wu
Journal of Clinical Laboratory Analysis.2019;[Epub] CrossRef
Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection
Narittee Sukswai, Joseph D. Khoury
Current Hematologic Malignancy Reports.2019; 14(5): 368. CrossRef
Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma
Xiangyan Zhang, Lili Wang, Jigang Wang, Han Zhao, Jie Wu, Shuhong Liu, Lu Zhang, Yujun Li, Xiaoming Xing
Experimental and Molecular Pathology.2018; 105(1): 153. CrossRef

Review Article

Active Surveillance of Papillary Thyroid Microcarcinoma: A Mini-Review from Korea: Tae Yong Kim, Young Kee Shong; Endocrinol Metab. 2017;32(4):399-406. Published online December 14, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.4.399

8,367 View
75 Download
36 Web of Science
35 Crossref

Abstract PDF PubReader

In Korea, the incidence of thyroid cancer increased explosively in the early 2000s, and reached a plateau in the early 2010s. Most cases of newly diagnosed thyroid cancer are small indolent microcarcinoma and could be good candidates for active surveillance (AS) instead of immediate surgery. Many considerations must be taken into account for establishing selection criteria for candidates for AS of papillary thyroid microcarcinoma (PTMC), including the characteristics of the tumor, the patient, and the medical team. If possible, AS of PTMC should be a part of a prospective clinical trial to ensure long-term safety and to identify clinical and/or molecular markers of the progression of PTMC. In this review, we discuss lessons regarding surgical interventions for PTMC, and then describe the concept, application, caveats, unanswered questions, and future perspectives of AS of PTMC. For appropriately selected patients with PTMC, AS can be a good alternative to immediate surgery.

Citations

Citations to this article as recorded by

Incidental thyroid carcinoma in an endemic goiter area in Italy: histopathological features and predictors of a common finding
Eusebio Chiefari, Nadia Innaro, Rita Gervasi, Maria Mirabelli, Stefania Giuliano, Alessandra Donnici, Stefania Obiso, Francesco S. Brunetti, Daniela Patrizia Foti, Antonio Brunetti
Endocrine.2024; 84(2): 589. CrossRef
Advances in clinical research on ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma
Hua Xu, Jin-yan Yang, Xing Zhao, Zhe Ma
Frontiers in Oncology.2024;[Epub] CrossRef
Thyroid cancer-specific mortality during 2005–2018 in Korea, aftermath of the overdiagnosis issue: a nationwide population-based cohort study
Kyeong Jin Kim, Jimi Choi, Sue K. Park, Young Joo Park, Sin Gon Kim
International Journal of Surgery.2024; 110(9): 5489. CrossRef
Study on diagnosis of thyroid nodules based on convolutional neural network
AiTao Yin, YongPing Lu, Fei Xu, YiFan Zhao, Yue Sun, Miao Huang, XiangBi Li
Die Radiologie.2023; 63(S2): 64. CrossRef
Mortality rate and causes of death in papillary thyroid microcarcinoma
Jung Heo, Hyun Jin Ryu, Hyunju Park, Tae Hyuk Kim, Sun Wook Kim, Young Lyun Oh, Jae Hoon Chung
Endocrine.2023; 83(3): 671. CrossRef
Thyroid Papillary Microcarcinoma - Carcinoma with Clinically Benign Behaviour
Hitesh R Singhavi, Manish Mair, Burhanuddin Qayyumi, Arjun Singh, Pankaj Chaturvedi
Journal of Head & Neck Physicians and Surgeons.2023; 11(2): 95. CrossRef
Clinicopathological Findings Associated With Cervical Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Retrospective Study in China
Yimeng Shi, Zheyu Yang, Yu Heng, Huijun Ju, Yu Pan, Yifan Zhang
Cancer Control.2022;[Epub] CrossRef
Nomograms Based on Serum N-glycome for Diagnosis of Papillary Thyroid Microcarcinoma and Prediction of Lymph Node Metastasis
Zejian Zhang, Zhen Cao, Rui Liu, Zepeng Li, Jianqiang Wu, Xiaoli Liu, Mengwei Wu, Xiequn Xu, Ziwen Liu
Current Oncology.2022; 29(9): 6018. CrossRef
Meta-Analysis of the Application Effect of Different Modalities of Thermal Ablation and Surgical Treatment in Papillary Thyroid Microcarcinoma
Tao Li, Bin Lu, Yuanpeng Zhang, Yong Sun, Tian jiao Wang
Disease Markers.2022; 2022: 1. CrossRef
Impact of Molecular Testing on the Management of Indeterminate Thyroid Nodules Among Western and Asian Countries: a Systematic Review and Meta-analysis
Hanh Thi Tuyet Ngo, Truong Phan Xuan Nguyen, Trang Huyen Vu, Chan Kwon Jung, Lewis Hassell, Kennichi Kakudo, Huy Gia Vuong
Endocrine Pathology.2021; 32(2): 269. CrossRef
Unnecessary thyroid nodule biopsy rates under four ultrasound risk stratification systems: a systematic review and meta-analysis
Pyeong Hwa Kim, Chong Hyun Suh, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee
European Radiology.2021; 31(5): 2877. CrossRef
Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review
Michael Y. Guo, Jacob J. Wiseman, Sam M. Wiseman
Expert Review of Anticancer Therapy.2021; 21(2): 205. CrossRef
Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Microcarcinoma: A Multicenter Cohort Study in Korea
Meihua Jin, Hye In Kim, Jeonghoon Ha, Min Ji Jeon, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Jae Hoon Chung, Young Kee Shong, Tae Hyuk Kim, Won Bae Kim
Thyroid.2021; 31(10): 1494. CrossRef
Long-Term Efficacy of Ultrasound-Guided Laser Ablation for Papillary Thyroid Microcarcinoma: Results of a 10-Year Retrospective Study
Ho Jin Kim, Seung Min Chung, Hanbyul Kim, Ju Young Jang, Jae Hong Yang, Jun Sung Moon, Gitak Son, Jong-Ryool Oh, Jong Yup Bae, Hyundae Yoon
Thyroid.2021; 31(11): 1723. CrossRef
Cost-Effectiveness Analysis of Active Surveillance Compared to Early Surgery in Small Papillary Thyroid Cancer: A Systemic Review
Han-sang Baek, Chai-ho Jeong, Jeonghoon Ha, Ja-Seong Bae, Jeong-soo Kim, Dong-Jun Lim, Chul-Min Kim
Cancer Management and Research.2021; Volume 13: 6721. CrossRef
More Aggressive Cancer Behaviour in Thyroid Cancer Patients in the Post-COVID-19 Pandemic Era: A Retrospective Study
Hanqing Liu, Ling Zhan, Liantao Guo, Xizi Yu, Lingrui Li, Hongfang Feng, Dan Yang, Zhiliang Xu, Yi Tu, Chuang Chen, Shengrong Sun
International Journal of General Medicine.2021; Volume 14: 7197. CrossRef
Completion Thyroidectomy
Yongil Cheon, Sung-Chan Shin, Byung-Joo Lee
International Journal of Thyroidology.2021; 14(2): 87. CrossRef
Deep Learning based Classification of Thyroid Cancer using Different Medical Imaging Modalities : A Systematic Review
Maheen Ilyas, Hassaan Malik, Muhammad Adnan, Umair Bashir, Wajahat Anwaar Bukhari, Muhammad Imran Ali Khan, Adnan Ahmad
VFAST Transactions on Software Engineering.2021; 9(4): 1. CrossRef
Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?
Dessislava I. Stefanova, Arpita Bose, Timothy M. Ullmann, Jessica N. Limberg, Brendan M. Finnerty, Rasa Zarnegar, Thomas J. Fahey, Toni Beninato
World Journal of Surgery.2020; 44(2): 452. CrossRef
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim
Endocrinology and Metabolism.2020; 35(4): 830. CrossRef
Impact of the new guidelines of the American Thyroid Association on the treatment of the differentiated thyroid tumor in an Italian center with medium-high volume thyroid surgery
Aldo Bove, Paolo Panaccio, Gino Palone, Ludovica Esposito, Lucia Marino, Giuseppe Bongarzoni
BMC Surgery.2019;[Epub] CrossRef
Malignancy risk of initially benign thyroid nodules: validation with various Thyroid Imaging Reporting and Data System guidelines
Su Min Ha, Jung Hwan Baek, Young Jun Choi, Sae Rom Chung, Tae Yon Sung, Tae Yong Kim, Jeong Hyun Lee
European Radiology.2019; 29(1): 133. CrossRef
Proteomic analysis of the papillary thyroid microcarcinoma
Shan Jin, Wuyuntu Bao, Yun-Tian Yang, Quan Fu, Yinbao Bai, Yousheng Liu
Annales d'Endocrinologie.2019; 80(5-6): 293. CrossRef
Quality of Life in Patients with Papillary Thyroid Microcarcinoma Managed by Active Surveillance or Lobectomy: A Cross-Sectional Study
Min Ji Jeon, Yu-Mi Lee, Tae-Yon Sung, Minkyu Han, Yong-Wook Shin, Won Gu Kim, Tae Yong Kim, Ki-Wook Chung, Young Kee Shong, Won Bae Kim
Thyroid.2019; 29(7): 956. CrossRef
Papillary Thyroid Micro Carcinoma: The Incidence of High-Risk Features and Its Prognostic Implications
Rui Gao, Xi Jia, Yiqian Liang, Kun Fan, Xiaoxiao Wang, Yuanbo Wang, Lulu Yang, Aimin Yang, Guangjian Zhang
Frontiers in Endocrinology.2019;[Epub] CrossRef
Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma
Hye-Seon Oh, Hyemi Kwon, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jeong Hyun Lee, Won Bae Kim, Young Kee Shong, Ki-Wook Chung, Jung Hwan Baek, Won Gu Kim
Thyroid.2019; 29(5): 642. CrossRef
Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples
Peng Lin, Zhina Yao, Yu Sun, Wenjuan Li, Yan Liu, Kai Liang, Yuan Liu, Jun Qin, Xinguo Hou, Li Chen
Journal of Proteomics.2019; 204: 103414. CrossRef
Diagnostic performance of CT in detection of metastatic cervical lymph nodes in patients with thyroid cancer: a systematic review and meta-analysis
Se Jin Cho, Chong Hyun Suh, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee
European Radiology.2019; 29(9): 4635. CrossRef
Diagnostic Performance of Practice Guidelines for Thyroid Nodules: Thyroid Nodule Size versus Biopsy Rates
Su Min Ha, Jung Hwan Baek, Dong Gyu Na, Chong Hyun Suh, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee
Radiology.2019; 291(1): 92. CrossRef
Update on thyroid ultrasound
Xiao-Wen Liang, Yong-Yi Cai, Jin-Sui Yu, Jian-Yi Liao, Zhi-Yi Chen
Chinese Medical Journal.2019; 132(16): 1974. CrossRef
Primary versus Tertiary Care Follow-Up of Low-Risk Differentiated Thyroid Cancer: Real-World Comparison of Outcomes and Costs for Patients and Health Care Systems
Syed Ali Imran, Karen Chu, Murali Rajaraman, Drew Rajaraman, Sunita Ghosh, Sarah De Brabandere, Stephanie M. Kaiser, Stan Van Uum
European Thyroid Journal.2019; 8(4): 208. CrossRef
Active Surveillance of Papillary Thyroid Microcarcinoma: A Mini-Review from Korea (Endocrinol Metab2017;32:399-406, Tae Yong Kim et al.)
Hui Sun, Gianlorenzo Dionigi
Endocrinology and Metabolism.2018; 33(1): 135. CrossRef
Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea
Hye-Seon Oh, Jeonghoon Ha, Hye In Kim, Tae Hyuk Kim, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Young Kee Shong, Jae Hoon Chung, Jung Hwan Baek
Thyroid.2018; 28(12): 1587. CrossRef
Ultrasound-guided percutaneous microwave ablation versus surgery for papillary thyroid microcarcinoma
Jianming Li, Yujiang Liu, Jibin Liu, Linxue Qian
International Journal of Hyperthermia.2018; 34(5): 653. CrossRef
Diagnosis and treatment of low-risk papillary thyroid microcarcinoma
Jae Hoon Moon, Young Joo Park
Journal of the Korean Medical Association.2018; 61(4): 232. CrossRef

Original Article

Clinical Study
Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study: Min Ji Jeon, Won Gu Kim, Tae Hyuk Kim, Hee Kyung Kim, Bo Hyun Kim, Hyon-Seung Yi, Eun Sook Kim, Hosu Kim, Young Nam Kim, Eun Heui Kim, Tae Yong Kim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2017;32(4):434-441. Published online November 22, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.4.434

9,562 View
66 Download
30 Web of Science
29 Crossref

Abstract PDF Supplementary Material PubReader

Background

Little is known regarding disease-specific mortality of differentiated thyroid cancer (DTC) patients and its risk factors in Korea.

Methods

We retrospectively reviewed a large multi-center cohort of thyroid cancer from six Korean hospitals and included 8,058 DTC patients who underwent initial surgery between 1996 and 2005.

Results

Mean age of patients at diagnosis was 46.2±12.3 years; 87% were females. Most patients had papillary thyroid cancer (PTC; 97%) and underwent total thyroidectomy (85%). Mean size of the primary tumor was 1.6±1.0 cm. Approximately 40% of patients had cervical lymph node (LN) metastases and 1.3% had synchronous distant metastases. During 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred; the 10-year disease-specific survival (DSS) rate was 98%. According to the year of diagnosis, the number of disease-specific mortality was not different. However, the rate of disease-specific mortality decreased during the study period (from 7.7% to 0.7%). Older age (≥45 years) at diagnosis, male, follicular thyroid cancer (FTC) versus PTC, larger tumor size (>2 cm), presence of extrathyroidal extension (ETE), lateral cervical LN metastasis, distant metastasis and tumor node metastasis (TNM) stage were independent risk factors of disease-specific mortality of DTC patients.

Conclusion

The rate of disease-specific mortality of Korean DTC patients was 1.9%; the 10-year DSS rate was 98% during 1996 to 2005. Older age at diagnosis, male, FTC, larger tumor size, presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stages were significant risk factors of disease-specific mortality of Korean DTC patients.

Citations

Citations to this article as recorded by

Rectum, Penile, Brain and Bladder, Consecutive Rare Distant Metastasis in Two Patients With Papillary Thyroid Carcinoma: Case Reports
Douk Kwon, Won Woong Kim, Byung-Chang Kim, Yu-mi Lee, Ki-Wook Chung, Tae-Yon Sung
Journal of Endocrine Surgery.2025; 25(3): 109. CrossRef
Laterocervical Lymph Node Metastases in Papillary Thyroid Carcinoma: Predictive Factors for Recurrence and Oncological Outcome
Andrea Migliorelli, Marianna Manuelli, Agnese Maria Tringali, Claudio Moretti, Virginia Corazzi, Matteo Geminiani, Andrea Ciorba, Francesco Stomeo, Stefano Pelucchi, Chiara Bianchini
Journal of Personalized Medicine.2025; 15(10): 496. CrossRef
Impact of Tumor Size on Prognosis in Differentiated Thyroid Cancer with Gross Extrathyroidal Extension to Strap Muscles: Redefining T3b
Joonseon Park, Solji An, Ja Seong Bae, Kwangsoon Kim, Jeong Soo Kim
Cancers.2024; 16(14): 2577. CrossRef
Log odds of negative lymph nodes/T stage ratio (LONT): A new prognostic tool for differentiated thyroid cancer without metastases in patients aged 55 and older
Xuezhen Wang, Yufan Wu, Xiaoxia Li, Jinsheng Hong, Mingwei Zhang
Frontiers in Endocrinology.2023;[Epub] CrossRef
The association between vitamin D supplementation and the long-term prognosis of differentiated thyroid cancer patients: a retrospective observational cohort study with propensity score matching
Jong-hyuk Ahn, Hoonsung Choi, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Do Joon Park, Young Joo Park
Frontiers in Endocrinology.2023;[Epub] CrossRef
Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer
Kyeong Jin Kim, Kyoung Jin Kim, Jimi Choi, Nam Hoon Kim, Sin Gon Kim
JNCI: Journal of the National Cancer Institute.2023; 115(6): 695. CrossRef
Outcomes of Advanced Medullary Thyroid Carcinoma in the Era of Targeted Therapy
Nicholas L. Kesby, Alexander J. Papachristos, Matti Gild, Ahmad Aniss, Mark S. Sywak, Roderick Clifton-Bligh, Stan B. Sidhu, Anthony R. Glover
Annals of Surgical Oncology.2022; 29(1): 64. CrossRef
Clinical Implication of Mutifocality for Risk of Recurrence in Patients With Papillary Thyroid Carcinoma
Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim
Journal of Endocrine Surgery.2022; 22(1): 10. CrossRef
Clinical Factors Predictive of Lymph Node Metastasis in Thyroid Cancer Patients: A Multivariate Analysis
Hui Zheng, Victoria Lai, Jana Lu, Jin K Kang, Jiling Chou, Kenneth D Burman, Leonard Wartofsky, Jennifer E Rosen
Journal of the American College of Surgeons.2022; 234(4): 691. CrossRef
Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients
Ra-Yeong Song, Hee Sung Kim, Kyung Ho Kang
World Journal of Surgical Oncology.2022;[Epub] CrossRef
Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma
Il Ku Kang, Kwangsoon Kim, Joonseon Park, Ja Seong Bae, Jeong Soo Kim
Cancers.2022; 14(15): 3677. CrossRef
Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma
Pengfei Gu, Yu Zeng, Weike Ma, Wei Zhang, Yu Liu, Fengli Guo, Xianhui Ruan, Jiadong Chi, Xiangqian Zheng, Ming Gao
Frontiers in Endocrinology.2022;[Epub] CrossRef
MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer
Jong-Lyul Park, Seon-Kyu Kim, Sora Jeon, Chan-Kwon Jung, Yong-Sung Kim
Cancers.2021; 13(4): 632. CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer: a propensity score-matching study
Joonseon Park, Kwangsoon Kim, Dong-Jun Lim, Ja Seong Bae, Jeong Soo Kim
Scientific Reports.2021;[Epub] CrossRef
A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
International Journal of Thyroidology.2021; 14(2): 175. CrossRef
Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma
Eyun Song, Jonghwa Ahn, Dong Eun Song, Won Woong Kim, Min Ji Jeon, Tae‐Yon Sung, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Yu‐Mi Lee, Won Gu Kim
Clinical Endocrinology.2020; 92(4): 358. CrossRef
Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases
Omnia Mohamed Talaat, Ismail Mohamed Ali, Sherif Maher Abolyazid, Bader Abdelmaksoud, Ibrahim Mansour Nasr
Nuclear Medicine Communications.2020; 41(4): 327. CrossRef
Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
Sue Youn Kim, Taeeun Kim, Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, Chan Kwon Jung
Journal of Pathology and Translational Medicine.2020; 54(4): 310. CrossRef
Clinical Implication of World Health Organization Classification in Patients with Follicular Thyroid Carcinoma in South Korea: A Multicenter Cohort Study
Meihua Jin, Eun Sook Kim, Bo Hyun Kim, Hee Kyung Kim, Hyon-Seung Yi, Min Ji Jeon, Tae Yong Kim, Ho-Cheol Kang, Won Bae Kim, Young Kee Shong, Mijin Kim, Won Gu Kim
Endocrinology and Metabolism.2020; 35(3): 618. CrossRef
The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice
Krzysztof Kaliszewski, Dorota Diakowska, Łukasz Nowak, Beata Wojtczak, Jerzy Rudnicki
BMC Cancer.2020;[Epub] CrossRef
Lobectomy Is Feasible for 1–4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence
Eyun Song, Minkyu Han, Hye-Seon Oh, Won Woong Kim, Min Ji Jeon, Yu-Mi Lee, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Tae-Yon Sung, Won Gu Kim
Thyroid.2019; 29(1): 64. CrossRef
The binary presence or absence of lymph node metastasis or extrathyroidal extension is not associated with survival in papillary thyroid cancers: Implications for staging systems
Hyun-Soo Zhang, Eun-Kyung Lee, Yuh-Seog Jung, Byung-Ho Nam, Boyoung Park
Cancer Epidemiology.2019; 63: 101589. CrossRef
Risk of Adverse Obstetric Outcomes and the Abnormal Growth of Offspring in Women with a History of Thyroid Cancer
Geum Joon Cho, So-youn Kim, Hoi Chang Lee, Kyu-Min Lee, Sung Won Han, Min-Jeong Oh, Teresa K. Woodruff
Thyroid.2019; 29(6): 879. CrossRef
Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer
Suyeon Park, Min Ji Jeon, Hye-Seon Oh, Yu-Mi Lee, Tae-Yon Sung, Minkyu Han, Ji Min Han, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2018; 28(8): 997. CrossRef
Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
Ji Min Han, Ji Cheol Bae, Hye In Kim, Sam Kwon, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2018; 33(4): 459. CrossRef
Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea
Hosu Kim, Hye In Kim, Sun Wook Kim, Jaehoon Jung, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Hee Kyung Kim, Ho-Cheol Kang, Ji Min Han, Yoon Young Cho, Tae Hyuk Kim, Jae Hoon Chung
Endocrinology and Metabolism.2018; 33(2): 287. CrossRef
Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study
Min Ji Jeon, Hee Kyung Kim, Eun Heui Kim, Eun Sook Kim, Hyon-Seung Yi, Tae Yong Kim, Ho-Cheol Kang, Young Kee Shong, Won Bae Kim, Bo Hyun Kim, Won Gu Kim
Thyroid.2018; 28(9): 1121. CrossRef
Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma: A Multi-Center Cohort Study in Korea
Hye-Seon Oh, Jeonghoon Ha, Hye In Kim, Tae Hyuk Kim, Won Gu Kim, Dong-Jun Lim, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Young Kee Shong, Jae Hoon Chung, Jung Hwan Baek
Thyroid.2018; 28(12): 1587. CrossRef

Special Article

Clinical Guidelines for the Management of Adrenal Incidentaloma: Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang Wan Kim, Soo-Kyung Kim, Hae Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo; Endocrinol Metab. 2017;32(2):200-218. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.200

28,443 View
895 Download
105 Web of Science
110 Crossref

Abstract PDF PubReader

An adrenal incidentaloma is an adrenal mass found in an imaging study performed for other reasons unrelated to adrenal disease and often accompanied by obesity, diabetes, or hypertension. The prevalence and incidence of adrenal incidentaloma increase with age and are also expected to rise due to the rapid development of imaging technology and frequent imaging studies. The Korean Endocrine Society is promoting an appropriate practice guideline to meet the rising incidence of adrenal incidentaloma, in cooperation with the Korean Adrenal Gland and Endocrine Hypertension Study Group. In this paper, we discuss important core issues in managing the patients with adrenal incidentaloma. After evaluating core proposition, we propose the most critical 20 recommendations from the initially organized 47 recommendations by Delphi technique.

Citations

Citations to this article as recorded by

Surgical and functional outcomes of adrenalectomy by urologists: A 17-year cohort review
Keshav Agarwal, Mehul Gupta, Rashmi Ramachandran, Nikhil Tandon, Rajeev Kumar
Indian Journal of Urology.2026; 42(1): 24. CrossRef
The Relationship Between Bone Health Status of Post-Menopausal Women with Non-Functional Adrenal Tumours/Mild Autonomous Cortisol Secretion and Their Baseline Morning Adrenocorticotropic Level
Alexandra-Ioana Trandafir, Oana-Claudia Sima, Nina Ionovici, Dana Manda, Mihai Costachescu, Mara Carsote
Diagnostics.2026; 16(2): 180. CrossRef
Clinical and Radiological Features of Atypical Adrenal Masses—A Multicenter Retrospective Study
Vania Balderrama-Brondani, Ruaa Al-Ward, Katja Kiseljak-Vassiliades, Lauren Fishbein, Danielle Dawes, Oksana Hamidi, Reza Pishdad, Juan Pablo Perdomo Rodriguez, Mohamad Anas Sukkari, Joseph R Grajo, Hans Kumar Ghayee, Sara Bedrose, Roland L Bassett, Amir
The Journal of Clinical Endocrinology & Metabolism.2025; 110(7): e2183. CrossRef
Outcomes after adrenalectomy in elderly patients; a propensity score matched analysis
Charlotte L. Viëtor, Inge S. van Egmond, Gaston J. H. Franssen, Cornelis Verhoef, Richard A. Feelders, Tessa M. van Ginhoven
Updates in Surgery.2025; 77(1): 183. CrossRef
Digital Phenotyping of Rare Endocrine Diseases Across International Data Networks and the Effect of Granularity of Original Vocabulary
Seunghyun Lee, Namki Hong, Gyu Seop Kim, Jing Li, Xiaoyu Lin, Sarah Seager, Sungjae Shin, Kyoung Jin Kim, Jae Hyun Bae, Seng Chan You, Yumie Rhee, Sin Gon Kim
Yonsei Medical Journal.2025; 66(3): 187. CrossRef
Use of natural language processing to retrospectively identify and improve follow-up of adrenal incidentalomas based on patient and nodule characteristics
Lillie Grace Veazey, Christopher Wu, Zhixing Song, Haleigh Negrete, Srini Tridandapani, Herbert Chen, Andrea Gillis, Jessica Fazendin, John D. Osborne, Brenessa Lindeman
The American Journal of Surgery.2025; 242: 116199. CrossRef
Two-Stage Deep Learning Model for Adrenal Nodule Detection on CT Images: A Retrospective Study
Chang Ho Ahn, Taewoo Kim, Kyungmin Jo, Seung Shin Park, Min Joo Kim, Ji Won Yoon, Taek Min Kim, Sang Youn Kim, Jung Hee Kim, Jaegul Choo
Radiology.2025;[Epub] CrossRef
Evaluation of the Adrenal Mass in Urologic Practice
Jackson Schmidt, Marshall Strother
Urologic Clinics of North America.2025; 52(2): 181. CrossRef
The impact of mild autonomous cortisol secretion and proposed interventions
María Bernarda Iriarte-Durán, Sara Donato, Aura Herrera, Arturo Vega, José María Jiménez Casinello, Mónica Marazuela, Marta Araujo-Castro
Expert Review of Endocrinology & Metabolism.2025; 20(4): 251. CrossRef
Imaging of Adrenal Incidentalomas: What Actually Happens in Everyday Clinical Practice?
Brian Ngo, Tracy Liu, Eddie Lau
Journal of Medical Imaging and Radiation Oncology.2025; 69(3): 328. CrossRef
Adrenal incidentaloma: Prevalence and evaluation. Experiences from a single health network
Mitchell Munnings, Shaun Koh, Christopher Gilfillan
Endocrine and Metabolic Science.2025; 18: 100238. CrossRef
The Landmark Series: Evaluation and Management of Adrenal Incidentalomas
Lily Owei, Heather Wachtel
Annals of Surgical Oncology.2025; 32(7): 4712. CrossRef
Our Surgical Treatment Results for Suprarenal Masses: Single-Center Study
İbrahim Halil Öcal, Ömer Başol, Hüseyin Bilge
Medical Records.2025; 7(2): 361. CrossRef
Imaging of Adrenal Masses
Francis T. Delaney, Ryan Chung, Michael A. Blake, Ann T. Sweeney
Endocrine Practice.2025; 31(7): 965. CrossRef
Washed up: the end of an era for adrenal incidentaloma CT
James H. Seow, Damien L. Stella, Christopher J. Welman, Arjuna J. Somasundaram, Jan F. Gerstenmaier
Insights into Imaging.2025;[Epub] CrossRef
The differential diagnosis of adrenal incidentalomas with non-benign appearence on unenhanced computed tomography: a retrospective study
Irena A. Ilovayskaya, Anna Y. Lugovskaya, Alexey A. Glazkov, Timur A. Britvin, Larisa E. Gurevich, Valentina E. Shikina
Almanac of Clinical Medicine.2025; 53(2): 71. CrossRef
Efficiency of Microwave Ablation for Cortisol-Producing Adrenal Adenomas: Case Series and a Literature Review
Alicija Krasavceva, Juozas Jarašūnas, Donatas Jocius, Romena Laukienė, Žydrūnė Visockienė, Virgilijus Beiša
Acta medica Lituanica.2025; 32(2): 5. CrossRef
Imaging of Adrenal Tumors
Patrick J. Navin, Michael T. Corwin, Michael Campbell, Khaled M. Elsayes
Magnetic Resonance Imaging Clinics of North America.2025; 33(4): 681. CrossRef
Adrenal Incidentaloma
Wendy Tu, Michael T. Corwin
Magnetic Resonance Imaging Clinics of North America.2025; 33(4): 667. CrossRef
Adrenal adenomas: an overview
Mohammed Abdel-Magid, Faisal Hasan
Medicine.2025; 53(10): 709. CrossRef
Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge
Alexandra Mirica, Dana-Mihaela Tilici, Diana Loreta Paun, Ana Maria Arnautu, Victor Nimigean, Sorin Paun
Biomedicines.2025; 13(9): 2298. CrossRef
The role of adrenal-sparing surgery in the management of aldosterone-producing adenoma: a systematic review and meta-analysis
Alberto Artiles Medina, Victoria Gómez Dos Santos, César Mínguez Ojeda, Alfonso Sanjuanbenito, Joaquín Gómez-Ramírez, Enrique Mercader, Felicia A Hanzu, Leire Zarain, Óscar Vidal, Alfonso Muriel, Marta Araujo-Castro
European Journal of Endocrinology.2025; 193(3): S36. CrossRef
The importance of using the oral glucose tolerance test when assessing the glycemic profile in patients with adrenal incidentaloma
Julia Magarão Costa, João Felipe Dickson Rebelo, Andrea Faria Dutra Fragoso Perozo, Fernanda Damasceno Junqueira, Ana Beatriz Alcantara Bérenger Samarcos De Almeida, Juliana Saldanha Milaresco, Michele dos Santos Souza, Aline Barbosa Moraes, Joana Rodrigu
Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
The Effect of Radiological Imaging Reports in Clinical Decision-Making in the Management of Adrenal Incidentaloma
Puren Gökbulut, Cagatay Emir Onder, Serife Mehlika Kuskonmaz
Experimental and Clinical Endocrinology & Diabetes.2025; 133(09): 453. CrossRef
Case of adrenocortical cancer eleven years after diagnosis of adrenocortical adenoma
Aleksandr A. Lisitsyn, Vyacheslav P. Zemlianoy, Vadim I. Mazurov, Ludmila I. Velikanova, Irina A. Bekhtereva
Kazan medical journal.2025; 106(6): 1023. CrossRef
Diagnosis and management of adrenal incidentaloma: use of clinical judgment and evidence in dialog with the patient
Yusaku Yoshida, Kiyomi Horiuchi, Michio Otsuki, Takahiro Okamoto
Surgery Today.2024; 54(12): 1417. CrossRef
The improvement of postoperative blood pressure and associated factors in patients with hormone‐negative adrenal adenoma and hypertension
Jiaxing Sun, Yingchun Dong, Hanbo Wang, Xudong Guo, Ning Suo, Shangjian Li, Xiangbin Ren, Shaobo Jiang
Journal of Surgical Oncology.2024; 129(6): 1073. CrossRef
Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study
Xiaojiang Zhu, Saisai Liu, Yimin Yuan, Nannan Gu, Jintong Sha, Yunfei Guo, Yongji Deng
BMC Pediatrics.2024;[Epub] CrossRef
Mineral metabolism assays and osteoporotic fracture risk evaluation in menopausal population diagnosed with adrenal incidentalomas: a sub-analysis of PRECES study
Alexandra-Ioana Trandafir, Mihaela Stanciu, Ana Valea, Oana-Claudia Sima, Claudiu Nistor, Mădălina Gabriela Iliescu, Ileana Ciobanu, Florina Ligia Popa, Mara Carsote
Balneo and PRM Research Journal.2024; 15(Vol.15, no): 692. CrossRef
Assessment of the diagnostic efficacy of radiological and functional evaluation of primary adrenal mass and its’ surgical outcomes
Yash Manharlal Tilala, Sabyasachi Panda, Abhilekh Tripathi, Sachin Sharma, Amiya Shankar Paul, Sanjay Choudhuri, Samir Swain
Urologia Journal.2024; 91(4): 674. CrossRef
Demographic and Clinical Characteristics of Patients with Adrenal Incidentaloma from a Single Center in South India: A Retrospective Study
Abhijeet B Jawanjal, Siddarth Sadananda, Nikitha Sriramaneni, Y. P. Ganavi, Pramila Kalra, Chitra Selvan, P. R. Manjunath, Praneethi K. Shetty
Annals of African Medicine.2024; 23(4): 567. CrossRef
Quantitative imaging biomarkers in the assessment of adrenal nodules
Mariana Yalon, Patrick J. Navin
Abdominal Radiology.2024; 50(5): 2169. CrossRef
A Case of Adrenal Incidentaloma Treated with Hand-assisted Laparoscopic Surgery
Yuki YAMANASHI, Tomoyoshi NAKAI, Juro YANAGIDA, Yusaku YOSHIDA, Yoko OMI, Kiyomi HORIUCHI, Naoko ITOU, Youji NAGASHIMA
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2024; 85(11): 1596. CrossRef
Characterizing incidental mass lesions in abdominal dual-energy CT compared to conventional contrast-enhanced CT
Jack Junchi Xu, Peter Sommer Ulriksen, Camilla Wium Bjerrum, Michael Patrick Achiam, Timothy Andrew Resch, Lars Lönn, Kristoffer Lindskov Hansen
Acta Radiologica.2023; 64(3): 945. CrossRef
Metastatic Adrenal PEComa: Case Report and Short Review of the Literature
Enrico Battistella, Luca Pomba, Marica Mirabella, Michele Gregianin, Antonio Scapinello, Marco Volante, Antonio Toniato
Medicina.2023; 59(1): 149. CrossRef
Surgical management and outcomes of spinal metastasis of malignant adrenal tumor: A retrospective study of six cases and literature review
Xiangzhi Ni, Jing Wang, Jiashi Cao, Kun Zhang, Shuming Hou, Xing Huang, Yuanjin Song, Xin Gao, Jianru Xiao, Tielong Liu
Frontiers in Oncology.2023;[Epub] CrossRef
An adrenal incidentaloma that had appeared to produce dehydroepiandrosterone-sulfate in excess before immunohistochemical study of the tumor
Toshihide Yamamoto, Takuma Kimura, Yuki Kubo, Shin-ichi Nakatsuka, Hiromasa Harada, Takashi Suzuki, Hironobu Sasano
Endocrine Journal.2023; 70(1): 43. CrossRef
Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study
Albin Kjellbom, Ola Lindgren, Malin Danielsson, Henrik Olsen, Magnus Löndahl
The Journal of Clinical Endocrinology & Metabolism.2023; 108(8): e536. CrossRef
Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study
Mingzhen Li, Xiaoying Duan, Di You, Linlin Liu
Frontiers in Medicine.2023;[Epub] CrossRef
Primary Aldosteronism Prevalence – An Unfolding Story
Suranut Charoensri, Adina F. Turcu
Experimental and Clinical Endocrinology & Diabetes.2023; 131(07/08): 394. CrossRef
Management of Adrenal Cortical Adenomas: Assessment of Bone Status in Patients with (Non-Functioning) Adrenal Incidentalomas
Alexandra-Ioana Trandafir, Mihaela Stanciu, Simona Elena Albu, Vasile Razvan Stoian, Irina Ciofu, Cristian Persu, Claudiu Nistor, Mara Carsote
Journal of Clinical Medicine.2023; 12(13): 4244. CrossRef
Clinical manifestations of functionally autonomous cortisol secretion in patients with adrenal masse
T. R. Chzhen, T. P. Kiseleva
Ural Medical Journal.2023; 22(3): 13. CrossRef
Tumor enlargement in adrenal incidentaloma is related to glaucoma: a new prognostic feature?
M. Caputo, T. Daffara, A. Ferrero, M. Romanisio, E. Monti, C. Mele, M. Zavattaro, S. Tricca, A. Siani, A. Clemente, C. Palumbo, S. De Cillà, A. Carriero, A. Volpe, P. Marzullo, G. Aimaretti, F. Prodam
Journal of Endocrinological Investigation.2023; 47(2): 377. CrossRef
Adrenal ganglioneuroma: Features and outcomes of cases series
Pei Li, Rongchang Zhang, Guang Wang, Jiongming Li
Asian Journal of Surgery.2023; 46(11): 5272. CrossRef
Recent Updates on the Management of Adrenal Incidentalomas
Seung Shin Park, Jung Hee Kim
Endocrinology and Metabolism.2023; 38(4): 373. CrossRef
Adrenal malakoplakia a rare lesion that mimics a neoplasm
Orión Erenhú Rodríguez González, Jesus Eduardo Osorio, Edgar Iván Bravo Castro
Urology Case Reports.2023; 51: 102568. CrossRef
LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines
Jongsung Noh, Chaelin Lee, Jung Hee Kim, Seung Woon Myung, Man Ho Choi
Journal of Lipid Research.2023; 64(11): 100453. CrossRef
Incidentaloma adrenal. Del hallazgo casual al diagnóstico definitivo
Mercedes Retamal Ortíz, Ana Belén Vicario Parada, Elena Vázquez Jarén
Actualización en Medicina de Familia.2023;[Epub] CrossRef
Can MDCT Enhancement Patterns Be Helpful in Differentiating Secretory from Non-Functional Adrenal Adenoma?
Svetlana Kocic, Vladimir Vukomanovic, Aleksandar Djukic, Jovica Saponjski, Dusan Saponjski, Vuk Aleksic, Vesna Ignjatovic, Katarina Vuleta Nedic, Vladan Markovic, Radisa Vojinovic
Medicina.2023; 60(1): 72. CrossRef
Diagnosis, Management, and Follow-Up of the Incidentally Discovered Adrenal Mass: CUA Guideline Endorsed by the AUA
Neal E. Rowe, Ravi Kumar, Nicola Schieda, Ferhan Siddiqi, Thomas McGregor, Kristen McAlpine, Philippe Violette, Varun Bathini, Michael Eng, Jason Izard
Journal of Urology.2023; 210(4): 590. CrossRef
Computer-assisted Reporting and Decision Support Increases Compliance with Follow-up Imaging and Hormonal Screening of Adrenal Incidentalomas
Renata R. Almeida, Bernardo C. Bizzo, Ramandeep Singh, Katherine P. Andriole, Tarik K. Alkasab
Academic Radiology.2022; 29(2): 236. CrossRef
Incidental Adrenal Masses: Adherence to Guidelines and Methods to Improve Initial Follow-Up: A Systematic Review
Timothy Feeney, Andrea Madiedo, Philip E. Knapp, Avneesh Gupta, David McAneny, Frederick Thurston Drake
Journal of Surgical Research.2022; 269: 18. CrossRef
Incidental Adrenal Lesions May Not Always Require Further Imaging Work-up
Deborah A. Baumgarten
Radiology.2022; 302(1): 138. CrossRef
Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy
Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee
Radiology.2022; 302(1): 129. CrossRef
Management of incidental adrenal nodules: a survey of abdominal radiologists conducted by the Society of Abdominal Radiology Disease-Focused Panel on Adrenal Neoplasms
Michael T. Corwin, Nicola Schieda, Erick M. Remer, Elaine M. Caoili
Abdominal Radiology.2022; 47(4): 1360. CrossRef
Primary hyperaldosteronism: indications for screening
Novella M. Chikhladze
Terapevticheskii arkhiv.2022; 94(1): 107. CrossRef
Pathophysiological Link between Insulin Resistance and Adrenal Incidentalomas
Jordan A. Higgs, Alyssa P. Quinn, Kevin D. Seely, Zeke Richards, Shad P. Mortensen, Cody S. Crandall, Amanda E. Brooks
International Journal of Molecular Sciences.2022; 23(8): 4340. CrossRef
Can Radiomics Provide Additional Diagnostic Value for Identifying Adrenal Lipid-Poor Adenomas From Non-Adenomas on Unenhanced CT?
Binhao Zhang, Huangqi Zhang, Xin Li, Shengze Jin, Jiawen Yang, Wenting Pan, Xue Dong, Jin Chen, Wenbin Ji
Frontiers in Oncology.2022;[Epub] CrossRef
Adrenal Surgery in the Era of Multidisciplinary Endocrine Tumor Boards
Costanza Chiapponi, Daniel Pinto Dos Santos, Milan Janis Michael Hartmann, Matthias Schmidt, Michael Faust, Roger Wahba, Christiane Josephine Bruns, Anne Maria Schultheis, Hakan Alakus
Hormone and Metabolic Research.2022; 54(05): 294. CrossRef
Optimal and novel imaging of the adrenal glands
Patrick J. Navin, Michael R. Moynagh
Current Opinion in Endocrinology, Diabetes & Obesity.2022; 29(3): 253. CrossRef
Adrenal Tumors in Young Adults: Case Reports and Literature Review
Małgorzata Zdrojewska, Emilia Mech-Siebieszuk, Renata Świątkowska-Stodulska, Bartosz Regent, Michał Kunc, Łukasz Zdrojewski, Krzysztof Sworczak
Medicina.2022; 58(6): 746. CrossRef
Incidence of malignancy in adrenal nodules detected on staging CTs of patients with potentially resectable colorectal cancer
Hae Young Kim, Yoon Jin Lee, Won Chang, Ji Hoon Park, Jungheum Cho, Hyeon Jeong Oh, Young Hoon Kim, Kyoung Ho Lee
European Radiology.2022; 32(12): 8560. CrossRef
Appendiceal Incidentalomas: Prevalence, Radiographic Characteristics, Management, and Outcomes
Adam Kelly, Stacy O’Connor, Diana Kane, Chiang-Ching Huang, Harveshp Mogal
Annals of Surgical Oncology.2022; 29(13): 8265. CrossRef
Laparoscopic large adrenal mass resection: why we should be more careful?
Mohsen Varyani, Mahmood Parvin, Hamidreza Akbari Gilani
African Journal of Urology.2022;[Epub] CrossRef
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
Nadia Sawicka-Gutaj, Hanna Komarowska, Dawid Gruszczyński, Aleksandra Derwich, Anna Klimont, Marek Ruchała
Journal of Clinical Medicine.2022; 11(19): 5563. CrossRef
Application of radiomics in adrenal incidentaloma: a literature review
Cheng Li, Yan Fu, Xiaoping Yi, Xiao Guan, Longfei Liu, Bihong T. Chen
Discover Oncology.2022;[Epub] CrossRef
Hormone-inactive adrenal tumors in clinician’s practice
T. R. Chzhen, T. P. Kiseleva
Perm Medical Journal.2022; 39(5): 48. CrossRef
The diagnostic value of salivary cortisol and salivary cortisone in patients with suspected hypercortisolism
Vendela Berndt, Per Dahlqvist, Jennie de Verdier, Henrik Ryberg, Oskar Ragnarsson
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Role of Intraoperative Indocyanine Green (ICG) and Preoperative 3-Dimensional (3D) Reconstruction in Laparoscopic Adrenalectomy: A Propensity Score-matched Analysis
Giuseppe Palomba, Vincenza Paola Dinuzzi, Francesca Pegoraro, Roberto Ivan Troisi, Roberto Montalti, Giovanni Domenico De Palma, Giovanni Aprea
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2022; 32(6): 643. CrossRef
The Etiological Profile of Adrenal Incidentalomas
Fatima-Zahra Lahmamssi, Loubna Saadaoui, Hayat Aynaou, Houda Salhi, Hanan El Ouahabi
Cureus.2022;[Epub] CrossRef
Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek
Endocrinology and Metabolism.2022; 37(6): 851. CrossRef
Conduite à tenir face à un fortuitome surrénalien chez le chien ou le chat
Diane Pichard, Ghita Benckekroun
Le Nouveau Praticien Vétérinaire canine & féline.2022; 19(82): 40. CrossRef
Laparoscopic transperitoneal adrenalectomy: a comparative study of different techniques for vessel sealing
Luca Cardinali, Edlira Skrami, Elisa Catani, Flavia Carle, Monica Ortenzi, Andrea Balla, Mario Guerrieri
Surgical Endoscopy.2021; 35(2): 673. CrossRef
Epidemiology and Comorbidity of Adrenal Cushing Syndrome: A Nationwide Cohort Study
Chang Ho Ahn, Jung Hee Kim, Man Young Park, Sang Wan Kim
The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1362. CrossRef
Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review
Marta Araujo-Castro, Pablo Valderrábano, Héctor F. Escobar-Morreale, Felicia A. Hanzu, Gregori Casals
Endocrine.2021; 72(1): 40. CrossRef
A Rare Neoplasm: Primary Adrenal Leiomyosarcoma
Jack T. Barnett, Christine W. Liaw, Reza Mehrazin
Urology.2021; 148: e11. CrossRef
Adrenal Ganglioneuroma Presenting as an Incidentaloma in an Adolescent Patient
Sonia G. Sharma, Steven N. Levine, Xin Gu
AACE Clinical Case Reports.2021; 7(1): 61. CrossRef
Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series
Jeongmin Lee, Jeonghoon Ha, Sang-Kuon Lee, Hye Lim Park, Sung-Hoon Kim, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Moo Il Kang, Min-Hee Kim
International Journal of General Medicine.2021; Volume 14: 673. CrossRef
Best Achievements in Pituitary and Adrenal Diseases in 2020
Chang Ho Ahn, Jung Hee Kim
Endocrinology and Metabolism.2021; 36(1): 51. CrossRef
Adrenal surgery: Review of 35 years experience in a single centre
Enrico Battistella, Stefania Ferrari, Luca Pomba, Antonio Toniato
Surgical Oncology.2021; 37: 101554. CrossRef
Adrenocortical Carcinoma: A Case of Missed Diagnosis
Yusef Hazimeh, Carlie Sigel, Carsello Carie, Mathew Leinung, Zaynab Khalaf
Cureus.2021;[Epub] CrossRef
Imagerie fonctionnelle en endocrinologie : nouveaux paradigmes à l’horizon 2020
E. Marchal
Médecine Nucléaire.2021; 45(3): 158. CrossRef
Adrenal Incidentaloma
Caren G. Solomon, Electron Kebebew
New England Journal of Medicine.2021; 384(16): 1542. CrossRef
Can Hematological Parameters Play a Role in the Differential Diagnosis of Adrenal Tumors?
Mehmet Gürkan Arıkan, Göktan Altuğ Öz, Nur Gülce İşkan, Necdet Süt, İlkan Yüksel, Ersan Arda
Uro.2021; 1(2): 39. CrossRef
Incidental Adrenal Nodules
Daniel I. Glazer, Michael T. Corwin, William W. Mayo-Smith
Radiologic Clinics of North America.2021; 59(4): 591. CrossRef
Antioxidant Barrier and Oxidative Damage to Proteins, Lipids, and DNA/RNA in Adrenal Tumor Patients
Barbara Choromańska, Piotr Myśliwiec, Tomasz Kozłowski, Magdalena Łuba, Piotr Wojskowicz, Jacek Dadan, Hanna Myśliwiec, Katarzyna Choromańska, Anna Gibała, Anna Starzyńska, Małgorzata Żendzian-Piotrowska, Anna Zalewska, Mateusz Maciejczyk, Jos L. Quiles
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef
Laparoscopic Retroperitoneoscopic Removal of an Adrenal Hemangioma: a Case Report
Kristin McCoy, Katherine Howe, Daniel Tershak
Journal of Endocrine Surgery.2021; 21(3): 70. CrossRef
Metabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Eu Jeong Ku, Chaelin Lee, Jaeyoon Shim, Sihoon Lee, Kyoung-Ah Kim, Sang Wan Kim, Yumie Rhee, Hyo-Jeong Kim, Jung Soo Lim, Choon Hee Chung, Sung Wan Chun, Soon-Jib Yoo, Ohk-Hyun Ryu, Ho Chan Cho, A Ram Hong, Chang Ho Ahn, Jung Hee Kim, Man Ho Choi
Endocrinology and Metabolism.2021; 36(5): 1131. CrossRef
Cross-Talk Between Nitrosative Stress, Inflammation and Hypoxia-Inducible Factor in Patients with Adrenal Masses
Barbara Choromańska, Piotr Myśliwiec, Tomasz Kozłowski, Magdalena Łuba, Piotr Wojskowicz, Jacek Dadan, Hanna Myśliwiec, Katarzyna Choromańska, Katarzyna Makarewicz, Anna Zalewska, Mateusz Maciejczyk
Journal of Inflammation Research.2021; Volume 14: 6317. CrossRef
Cirugía laparoscópica en incidentaloma suprarrenal para el cirujano general: serie de casos
Martín Adrián Bolívar-Rodríguez, Marcel Antonio Cázarez-Aguilar, Pedro Alejandro Magaña-Zavala, Francisco Magaña-Olivas, José Martín Niebla-Moreno
Revista Mexicana de Cirugía Endoscópica.2021; 22(1): 8. CrossRef
Adrenal adenomas: what to do with them? Review 2
S. Rybakov
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(3): 241. CrossRef
Laparoscopic adrenalectomy for giant adrenal tumours
Alessio Giordano, Giovanni Alemanno, Carlo Bergamini, Andrea Valeri, Paolo Prosperi
Journal of Minimal Access Surgery.2021; 17(1): 76. CrossRef
Is Follow-up of Adrenal Incidentalomas Always Mandatory?
Giuseppe Reimondo, Alessandra Muller, Elisa Ingargiola, Soraya Puglisi, Massimo Terzolo
Endocrinology and Metabolism.2020; 35(1): 26. CrossRef
Imaging Findings of Primary Adrenal Leiomyosarcoma: A Case Report
Hye Ran Yoon, Dong Hee Park
Journal of the Korean Society of Radiology.2020; 81(2): 459. CrossRef
WFUMB position paper on the management incidental findings: adrenal incidentaloma
Christoph F. Dietrich, Jean Michel Correas, Yi Dong, Christian Nolsoe, Susan Campbell Westerway, Christian Jenssen
Ultrasonography.2020; 39(1): 11. CrossRef
A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features
Takamasa Ichijo, Hajime Ueshiba, Hajime Nawata, Toshihiko Yanase
Endocrine Journal.2020; 67(2): 141. CrossRef
Mimics, pitfalls, and misdiagnoses of adrenal masses on CT and MRI
Khaled M. Elsayes, Mohab M. Elmohr, Sanaz Javadi, Christine O. Menias, Erick M. Remer, Ajaykumar C. Morani, Akram M. Shaaban
Abdominal Radiology.2020; 45(4): 982. CrossRef
Adrenal Incidentaloma
Mark Sherlock, Andrew Scarsbrook, Afroze Abbas, Sheila Fraser, Padiporn Limumpornpetch, Rosemary Dineen, Paul M Stewart
Endocrine Reviews.2020; 41(6): 775. CrossRef
A Web Application for Adrenal Incidentaloma Identification, Tracking, and Management Using Machine Learning
Wasif Bala, Jackson Steinkamp, Timothy Feeney, Avneesh Gupta, Abhinav Sharma, Jake Kantrowitz, Nicholas Cordella, James Moses, Frederick Thurston Drake
Applied Clinical Informatics.2020; 11(04): 606. CrossRef
Presentation and outcome of patients with an adrenal mass: A retrospective observational study
Nadeema Rafiq, Tauseef Nabi, SajadAhmad Dar, Shahnawaz Rasool
Clinical Cancer Investigation Journal.2020; 9(5): 198. CrossRef
Evaluation of Functionality and Growth Rates in Adrenal Incidentalomas: Single Center Experience
Suna AVCI, Yüksel Aslı OZTURKMEN, Sayid ZUHUR, Gulkan OZKAN, Elif GUVEN, Nazan DEMİR, Yuksel ALTUNTAS
Phoenix Medical Journal.2020; 2(3): 125. CrossRef
Percutaneous Adrenal Radiofrequency Ablation: A Short Review for Endocrinologists
Byung Kwan Park
Endocrinology and Metabolism.2020; 35(4): 750. CrossRef
Autonomous cortisol secretion in adrenal incidentalomas
Marta Araujo-Castro, Miguel Antonio Sampedro Núñez, Mónica Marazuela
Endocrine.2019; 64(1): 1. CrossRef
Primary adrenal schwannoma: a series of 31 cases emphasizing their clinicopathologic features and favorable prognosis
Jun Zhou, Dandan Zhang, Wencai Li, Luting Zhou, Haimin Xu, Saifang Zheng, Chaofu Wang
Endocrine.2019; 65(3): 662. CrossRef
Challenging risk factors for right and left laparoscopic adrenalectomy: A single centre experience with 272 cases
Kadir Omur Gunseren, Mehmet Cagatay Cicek, Hakan Vuruskan, Yakup Kordan, Ismet Yavascaoglu
International braz j urol.2019; 45(4): 747. CrossRef
A case report on 111In chloride bone marrow scintigraphy in management of adrenal myelolipoma
Tatsuya Yamamoto, Mitsuru Koizumi, Atsushi Kohno, Noboru Numao, Kentaro Inamura
Medicine.2019; 98(8): e14625. CrossRef
PRACTICAL ASPECTS OF LAPAROSCOPIC ADRENALECTOMY IN CHILDREN WITH BENIGN ADRENAL TUMORS
I. V. Poddubny, R. S. Oganesyan, K. N. Tolstov, M. A. Kareva
Russian Journal of Pediatric Surgery.2019; 23(5): 248. CrossRef
Incidental neuroblastoma with bilateral retinoblastoma: what are the chances?
Kelsey Roelofs, Furqan Shaikh, William Astle, Brenda L. Gallie, Sameh E. Soliman
Ophthalmic Genetics.2018; 39(3): 410. CrossRef
Surgical Considerations in Subclinical Cushing’s Syndrome. When is it Time to Operate?
Alexander M. Nixon, C Aggeli, C Tserkezis, GN Zografos
Hellenic Journal of Surgery.2018; 90(1): 27. CrossRef
Adrenal incidentaloma – diagnostic and treating problem – own experience
Ryszard Pogorzelski, Krzysztof Celejewski, Sadegh Toutounchi, Ewa Krajewska, Tomasz Wołoszko, Małgorzata Szostek, Wawrzyniec Jakuczun, Patryk Fiszer, Małgorzata Legocka, Zbigniew Gałązka
Open Medicine.2018; 13(1): 281. CrossRef

Original Articles

Clinical Study
Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules: Hyemi Kwon, Won Gu Kim, Markus Eszlinger, Ralf Paschke, Dong Eun Song, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(4):586-591. Published online November 4, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.4.586

7,277 View
59 Download
11 Web of Science
12 Crossref

Abstract PDF PubReader

Background

Molecular analysis for common somatic mutations in thyroid cancer can improve diagnostic accuracy of fine-needle aspiration cytology (FNAC) in the nondiagnostic or indeterminate category of thyroid nodules. In this study, we evaluated the feasibility of molecular diagnosis from residual liquid-based cytology (LBC) material after cytological diagnosis.

Methods

This prospective study enrolled 53 patients with thyroid nodules diagnosed as nondiagnostic, atypia of undetermined significance (AUS), or follicular lesion of undetermined significance (FLUS) after FNAC. DNAs and RNAs were isolated from residual LBC materials. BRAF^V600E and RAS point mutations, PAX8/peroxisome proliferator-activated receptor γ (PPARγ), RET/PTC1, and RET/PTC3 rearrangements were evaluated by real-time polymerase chain reaction and pyrosequencing.

Results

All DNAs from 53 residual LBC samples could be analysed and point mutations were detected in 10 samples (19%). In 17 AUS nodules, seven samples (41%) had point mutations including BRAF (n=4), NRAS (n=2), and KRAS (n=1). In 20 FLUS nodules, three samples (15%) had NRAS point mutations. RNA from only one FLUS nodule could be analysed for rearrangements and there was no abnormality.

Conclusion

Molecular analysis for BRAF and RAS mutations was feasible in residual LBC materials and might be useful for diagnosis of indeterminate thyroid nodules.

Citations

Citations to this article as recorded by

Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer
Masahiro Itonaga, Reiko Ashida, Shin-Ichi Murata, Yasunobu Yamashita, Keiichi Hatamaru, Takashi Tamura, Yuki Kawaji, Yuudai Kayama, Tomoya Emori, Manabu Kawai, Hiroki Yamaue, Ibu Matsuzaki, Hirokazu Nagai, Yuichi Kinoshita, Ke Wan, Toshio Shimokawa, Masay
Cancers.2022; 14(3): 551. CrossRef
From Traditional Histology to Next-Generation Pathology: A Review of The Workflow for the Characterisation and Molecular Profiling of Non-Small Cell Lung Cancer Samples

EMJ Oncology.2020;[Epub] CrossRef
Preanalytic variables in quality and quantity of nucleic acids extracted from FNA specimens of thyroid gland nodules collected in CytoLyt: Cellularity and storage time
Jonas J. Heymann, Lorene M. Yoxtheimer, Hyeon Jin Park, Evan M. Fernandez, Kirk E. Facey, Susan A. Alperstein, Hung V. Tran, Inji Baek, Theresa Scognamiglio, Hanna Rennert, Momin T. Siddiqui, Wei Song
Cancer Cytopathology.2020; 128(9): 656. CrossRef
Diagnostic accuracy of molecular testing with three molecular markers on thyroid fine‐needle aspiration cytology with abnormal category
Hatice Seneldir, Gozde Kir, Tuce Soylemez, Rabia B. Girgin, Nurver Ozbay, Filiz Ozen, Handan Ankarali, Gurhan Bas, Orhan Alimoglu
Diagnostic Cytopathology.2020; 48(6): 507. CrossRef
Small but powerful: the promising role of small specimens for biomarker testing
Qiong Gan, Sinchita Roy-Chowdhuri
Journal of the American Society of Cytopathology.2020; 9(5): 450. CrossRef
Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next‐generation sequencing of thyroid nodules
Wenrui Ye, Brette Hannigan, Stephanie Zalles, Meenakshi Mehrotra, Bedia A. Barkoh, Michelle D. Williams, Maria E. Cabanillas, Beth Edeiken‐Monroe, Peter Hu, Dzifa Duose, Ignacio I. Wistuba, L. Jeffrey Medeiros, John Stewart, Rajyalakshmi Luthra, Sinchita
Cancer Cytopathology.2019; 127(3): 146. CrossRef
Molecular testing of residual cytology samples: Rethink, reclaim, repurpose
Sinchita Roy‐Chowdhuri
Cancer Cytopathology.2019; 127(1): 15. CrossRef
K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma
Yoko Sekita-Hatakeyama, Takeshi Nishikawa, Mao Takeuchi, Kouhei Morita, Maiko Takeda, Kinta Hatakeyama, Tokiko Nakai, Tomoko Uchiyama, Hiroe Itami, Tomomi Fujii, Akira Mitoro, Masayuki Sho, Chiho Ohbayashi, Giancarlo Troncone
PLOS ONE.2018; 13(3): e0193692. CrossRef
Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of theBRAFV600EMutation in Thyroid Neoplasm
Hye-Seon Oh, Hyemi Kwon, Suyeon Park, Mijin Kim, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Jene Choi, Won Gu Kim, Dong Eun Song
Endocrinology and Metabolism.2018; 33(1): 62. CrossRef
Next-Generation Sequencing Identifies Gene Mutations That Are Predictive of Malignancy in Residual Needle Rinses Collected From Fine-Needle Aspirations of Thyroid Nodules
Maren Y. Fuller, Dina Mody, April Hull, Kristi Pepper, Heather Hendrickson, Randall Olsen
Archives of Pathology & Laboratory Medicine.2018; 142(2): 178. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Loss of c-KIT expression in thyroid cancer cells
Sara Franceschi, Francesca Lessi, Federica Panebianco, Elena Tantillo, Marco La Ferla, Michele Menicagli, Paolo Aretini, Alessandro Apollo, Antonio Giuseppe Naccarato, Ivo Marchetti, Chiara Maria Mazzanti, Aamir Ahmad
PLOS ONE.2017; 12(3): e0173913. CrossRef

Endocrine Research
Comparison of Thyroglobulin Measurements Using Three Different Immunoassay Kits: A BRAMHS Tg-Plus RIA Kit, a BRAMHS hTg Sensitive Kryptor Kit, and a Beckman Coulter ACCESS Immunoassay Kit: Mijin Kim, Min Ji Jeon, Won Gu Kim, Jong Jin Lee, Jin-Sook Ryu, Eun-Jung Cho, Dae-Hyun Ko, Woochang Lee, Sail Chun, Won-Ki Min, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(3):462-468. Published online August 2, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.3.462

7,878 View
59 Download
10 Web of Science
9 Crossref

Abstract PDF PubReader

Background

Second-generation thyroglobulin immunometric assays (Tg-IMAs) have been developed with improved sensitivity. Our aim was to compare the diagnostic value of Tg-IMA measurements using a Kryptor (BRAHMS AG) kit (Tg-K) and an ACCESS (Beckman Coulter) kit (Tg-A) with that of the first-generation Tg measurement using a Tg-plus (BRAHMS AG) kit (Tg+).

Methods

We enrolled 82 differentiated thyroid cancer patients who underwent total thyroidectomy with radioactive iodine remnant ablation and who underwent diagnostic whole body scan using recombinant human thyroid stimulating hormone (rhTSH). The Tg+, Tg-K, and Tg-A were measured before rhTSH administration during levothyroxine treatment (suppressed Tg) from the same sample. Serum Tg+ was measured after rhTSH stimulation (stimulated Tg).

Results

Suppressed Tg+ was more significantly correlated with suppressed Tg-K (R²=0.919, P<0.001) than with suppressed Tg-A (R²=0.536, P<0.001). The optimal cut-off values of suppressed Tg+, Tg-K, and Tg-A for predicting stimulated Tg+ of 1 ng/mL were 0.3, 0.2, and 0.2 ng/mL, respectively. The sensitivity, specificity, and accuracy of suppressed Tg+ were 67%, 100%, and 90%, respectively; those of suppressed Tg-K were 83%, 90%, and 88%; those of suppressed Tg-A were 96%, 82%, and 87%, respectively. The positive predictive and negative predictive values of Tg+ were 100% and 87%, respectively; those of Tg-K were 79% and 92%; and those of Tg-A were 73% and 98%.

Conclusion

We could not clearly demonstrate which kit had better diagnostic performance after comparison of first-generation Tg measurements with Tg-IMA measurements. Also, there were kit-to-kit variations between Tg-IMA kits. Suppressed Tg measured by Tg-IMA was insufficient to completely substitute for a stimulated Tg measurement.

Citations

Citations to this article as recorded by

A deep dive into four thyroglobulin immunoassays from analytical perspective
Tuba Saadet Deveci Bulut, Muhittin Abdulkadir Serdar, Mehmet Muhittin Yalçın, Meriç Coşkun, Aylar Poyraz, Seda Gökgöz Acar, Gizem Yaz Aydın, Özlem Gülbahar
Scandinavian Journal of Clinical and Laboratory Investigation.2025; 85(2): 148. CrossRef
Revisiting Thyroglobulin Measurement: Current Methods and Future Perspectives Using Dried Blood Spot Sampling for Enhanced Clinical Practice
Nicole Monza, Claudia Fumagalli, Lisa Pagani, Natalia Shelly Porto, Felisia Di Nicoli, Clizia Chinello, Simone Serrao, Eleonora Bossi, Marta Nobile, Fabio Pagni, Fulvio Magni, Vanna Denti
Metabolites.2025; 15(12): 769. CrossRef
Comparison of the diagnostic performances of US-guided fine needle aspiration cytology and thyroglobulin measurement for lymph node metastases in patients with differentiated thyroid carcinoma: a meta-analysis
Rong-Bin Liu, Da-Lei Zhou, Bo-Heng Xu, Xin-Hua Yang, Qing Liu, Xiao Zhang, Tao Tang, Zu-Lu Ye, Yue Li
European Radiology.2021; 31(5): 2903. CrossRef
Preoperative Serum Thyroglobulin and Its Correlation with the Burden and Extent of Differentiated Thyroid Cancer
Hosu Kim, So Young Park, Jun-Ho Choe, Jee Soo Kim, Soo Yeon Hahn, Sun Wook Kim, Jae Hoon Chung, Jaehoon Jung, Tae Hyuk Kim
Cancers.2020; 12(3): 625. CrossRef
Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Eyun Song, Jonghwa Ahn, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Jung Hwan Baek, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2020; 30(3): 418. CrossRef
Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Clinical Endocrinology.2019; 91(3): 449. CrossRef
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
Mijin Kim, Tae Hyuk Kim, Dong Yeob Shin, Dong Jun Lim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Bo Hyun Kim, Won Gu Kim
Thyroid.2018; 28(3): 340. CrossRef
A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better
Min Ji Jeon, Mijin Kim, Suyeon Park, Hye-Seon Oh, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Won Gu Kim
Thyroid.2018; 28(2): 187. CrossRef
Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer
Hosu Kim, Young Nam Kim, Hye In Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jae Hoon Chung, Tae Hyuk Kim, Sun Wook Kim
Scientific Reports.2017;[Epub] CrossRef

Clinical Study
Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease: Hyemi Kwon, Won Gu Kim, Eun Kyung Jang, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(2):300-310. Published online April 25, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.300

9,067 View
117 Download
29 Web of Science
30 Crossref

Abstract PDF PubReader

Background

Hyperthyroidism relapse in Graves disease after antithyroid drug (ATD) withdrawal is common; however, measuring the thyrotropin receptor antibody (TRAb) at ATD withdrawal in order to predict outcomes is controversial. This study compared measurement of thyroid stimulatory antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) at ATD withdrawal to predict relapse.

Methods

This retrospective study enrolled patients with Graves disease who were treated with ATDs and whose serum thyroid-stimulating hormone levels were normal after receiving low-dose ATDs. ATD therapy was stopped irrespective of TRAb positivity after an additional 6 months of receiving the minimum dose of ATD therapy. Patients were followed using thyroid function tests and TSAb (TSAb group; n=35) or TBII (TBII group; n=39) every 3 to 6 months for 2 years after ATD withdrawal.

Results

Twenty-eight patients (38%) relapsed for a median follow-up of 21 months, and there were no differences in baseline clinical characteristics between groups. In the TSAb group, relapse was more common in patients with positive TSAb at ATD withdrawal (67%) than patients with negative TSAb (17%; P=0.007). Relapse-free survival was shorter in TSAb-positive patients. In the TBII group, there were no differences in the relapse rate and relapse-free survivals according to TBII positivity. For predicting Graves disease relapse, the sensitivity and specificity of TSAb were 63% and 83%, respectively, whereas those of TBII were 28% and 65%.

Conclusion

TSAb at ATD withdrawal can predict the relapse of Graves hyperthyroidism, but TBII cannot. Measuring TSAb at ATD withdrawal can assist with clinical decisions making for patients with Graves disease.

Citations

Citations to this article as recorded by

US-based, Prospective, Blinded Study of Thyrotropin Receptor Antibody in Autoimmune Thyroid Disease
Mark A Lupo, Paul D Olivo, Maximilian Luffy, Jan Wolf, George J Kahaly
The Journal of Clinical Endocrinology & Metabolism.2025; 110(5): e1619. CrossRef
Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease
Rongguang Peng, Pu Xie, Zhou Jin, Wenzhong Zhou, Yanqiu Wang, Xinxin Chen, Qinglei Yin, Liyun Shen, Lingyang Meng, Lei Ye, Yulin Zhou, Shu Wang
The Journal of Clinical Endocrinology & Metabolism.2025; 110(9): e3002. CrossRef
Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves’ orbitopathy: a systematic review and meta-analysis
Abdulelah G. Abumohssin, Rayan A. Alshareef, Saja Aljohani, Abdulrahman Alqutub, Abdulsalam Alqutub
Eye.2025; 39(10): 1901. CrossRef
Analysis of Influencing Factors of Radioactive Iodine Therapy for Graves’ Disease
绍欣李
Journal of Clinical Personalized Medicine.2025; 04(03): 235. CrossRef
Thyrotropin (TSH)-Binding Inhibiting Immunoglobulin-Negative, Thyroid-Stimulating Antibody-Positive Amiodarone-Induced Thyrotoxicosis
Yasufumi Seki, Kei Inai, Koichiro Kaneko, Atsuhiro Ichihara
AACE Endocrinology and Diabetes.2025; 12(3): 190. CrossRef
Low-dose Methimazole in the Long-term Management of Graves' Disease: Small Doses, Big Benefits
Danilo Villagelin, David S Cooper
The Journal of Clinical Endocrinology & Metabolism.2025;[Epub] CrossRef
Thyroid-stimulating immunoglobulin levels during low-dose antithyroid therapy predict Graves’ disease relapse
Phong Vu Nhat Nguyen, Khue Thy Nguyen
Frontiers in Endocrinology.2025;[Epub] CrossRef
Thyroid stimulating receptor autoantibodies
Yumeng Gao, Ling Qiu, Songlin Yu, Xinqi Cheng
Clinica Chimica Acta.2024; 559: 119700. CrossRef
Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration
Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim
Endocrinology and Metabolism.2024; 39(4): 579. CrossRef
Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the diagnosis and management of Graves’ disease
Peiwei Yao, Yunliang Xie, Yunlin Wang, Chunyan Liang, Bingwen Huang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Analysis of Related Factors in Refractory Graves’ Disease
鑫王
Advances in Clinical Medicine.2023; 13(08): 13439. CrossRef
Interpretation of Thyroid Autoantibodies in Hyperthyroidism
Han-Sang Baek, Dong-Jun Lim
The Korean Journal of Medicine.2023; 98(3): 132. CrossRef
The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim
Endocrinology and Metabolism.2023; 38(3): 338. CrossRef
Prediction of the recurrence risk of Graves' disease after antithyroid drug therapy
Qiang Zhang, Ying Fu
Environmental Disease.2023; 8(1): 7. CrossRef
Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse
Tiago Da Silva Santos, José Carlos Oliveira, Cláudia Freitas, André Couto de Carvalho
Cureus.2022;[Epub] CrossRef
The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
Han-Sang Baek, Jaejun Lee, Chai-Ho Jeong, Jeongmin Lee, Jeonghoon Ha, Kwanhoon Jo, Min-Hee Kim, Jae Hyoung Cho, Moo Il Kang, Dong-Jun Lim
Journal of the Endocrine Society.2022;[Epub] CrossRef
Identification of patients with Graves’ disease who benefit from high-dose radioactive iodine therapy
Shiro Watanabe, Shozo Okamoto, Kazumasa Akikawa, Noriyuki Miyamoto, Miyuki Okamura-Kawasaki, Yuko Uchiyama, Junki Takenaka, Takuya Toyonaga, Kenji Hirata, Kohsuke Kudo
Annals of Nuclear Medicine.2022; 36(11): 923. CrossRef
The relationship between atherosclerotic disease and relapse during ATD treatment
Xinxin Zhu, Yaguang Zhang, Xiaoyu Zhao, Xiaona Zhang, Zixuan Ru, Yanmeizhi Wu, Xu Yang, Boyu Hou, Hong Qiao
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinology and Metabolism.2021; 36(3): 491. CrossRef
The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
Yulin Zhou, Mengxi Zhou, Yicheng Qi, Weiqing Wang, Xinxin Chen, Shu Wang
Therapeutic Advances in Endocrinology and Metabolism.2021;[Epub] CrossRef
Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
Yun Mi Choi, Mi Kyung Kwak, Sang Mo Hong, Eun-Gyoung Hong
Endocrinology and Metabolism.2019; 34(3): 268. CrossRef
Graves' Disease: Can It Be Cured?
Wilmar M. Wiersinga
Endocrinology and Metabolism.2019; 34(1): 29. CrossRef
Medical Treatment of Graves' Disease
Hyun-Kyung Chung
International Journal of Thyroidology.2019; 12(2): 79. CrossRef
When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves’ disease be discontinued?
Suyeon Park, Eyun Song, Hye-Seon Oh, Mijin Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Doo Man Kim, Won Bae Kim
Endocrine.2019; 65(2): 348. CrossRef
Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse
Jianhui Li, Xiaohua Sun, Danzhen Yao, Jinying Xia
International Journal of Endocrinology.2018; 2018: 1. CrossRef
Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917. CrossRef
Free Thyroxine, Anti-Thyroid Stimulating Hormone Receptor Antibody Titers, and Absence of Goiter Were Associated with Responsiveness to Methimazole in Patients with New Onset Graves' Disease
Hoon Sung Choi, Won Sang Yoo
Endocrinology and Metabolism.2017; 32(2): 281. CrossRef
The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study
Ye An Kim, Sun Wook Cho, Hoon Sung Choi, Shinje Moon, Jae Hoon Moon, Kyung Won Kim, Do Joon Park, Ka Hee Yi, Young Joo Park, Bo Youn Cho
Thyroid.2017; 27(4): 491. CrossRef
The Recurrence Rate of Graves' Disease among Patients with Subclinical Thyrotoxicosis after Initial Remission with Antithyroid Agents
Myoung Sook Shim, Soo Min Nam, Jin Sae Yoo, Hae Kyung Kim, Sang Jun Lee, Mi Young Lee
International Journal of Thyroidology.2017; 10(2): 77. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef

Clinical Study
Thyrotoxic Periodic Paralysis and Polymorphisms of the ADRB2, AR, and GABRA3 Genes in Men with Graves Disease: Suyeon Park, Tae Yong Kim, Soyoung Sim, Seonhee Lim, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(1):142-146. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.142

5,829 View
40 Download
5 Web of Science
5 Crossref

Abstract PDF PubReader

Background

Thyrotoxic periodic paralysis (TPP) is a rare complication of thyrotoxicosis characterized by acute attacks of muscle weakness and hypokalemia. Recently, variation in several genes was suggested to be associated with TPP. This study evaluated the genetic predisposition to TPP in terms of the β2-adrenergic receptor (ADRB2), androgen receptor (AR), and γ-aminobutyric acid receptor α3 subunit (GABRA3) genes.

Methods

This study enrolled 48 men with Graves disease (GD) and TPP, and 48 GD patients without TPP. We compared the frequencies of candidate polymorphisms between the two groups.

Results

The frequency of the Gly16/Gly16 genotype in ADRB2 was not significantly associated with TPP (P=0.32). More CAG repeats (≥26) in the AR gene were not correlated with TPP (odds ratio [OR], 2.46; 95% confidence interval [CI], 0.81 to 8.09; P=0.08). The allele frequency of the TT genotype in the GABRA3 gene was not associated with TPP (OR, 1.83; 95% CI, 0.54 to 6.74; P=0.41).

Conclusion

The polymorphisms in the ADRB2, AR, and GABRA3 genes could not explain the genetic susceptibility to TPP in Korean men with GD.

Citations

Citations to this article as recorded by

Rebound Hyperkalemia in Hypokalemic Thyrotoxic Periodic Paralysis
Thomas J. Pisano, Brandon Merical, Zehui Wang, Joshua M. Levine
The Neurohospitalist.2026; 16(1): 78. CrossRef
RNASET2,GPR174, and PTPN22 gene polymorphisms are related to the risk of liver damage associated with the hyperthyroidism in patients with Graves’ disease
Qing Zhang, Shaozheng Liu, Yanxing Guan, Qingjie Chen, Qing Zhang, Xiang Min
Journal of Clinical Laboratory Analysis.2018;[Epub] CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Periodic Paralysis and Encephalopathy as Initial Manifestations of Graves’ Disease
Theocharis Tsironis, Athanasios Tychalas, Dimitrios Kiourtidis, Jannis Kountouras, Georgia Xiromerisiou, Jobst Rudolf, Georgia Deretzi
The Neurologist.2017; 22(4): 134. CrossRef
Thyrotoxic periodic paralysis
Zdeněk Doležel, Dana Novotná, Helena Schneiderová, Jan Papež, Martin Jouza
Pediatrie pro praxi.2016; 17(6): 379. CrossRef

Clinical Study
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma: Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(1):100-104. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.100

6,835 View
37 Download
16 Web of Science
15 Crossref

Abstract PDF PubReader

Background

Transcriptional activating mutations of telomerase reverse transcriptase (TERT) are associated with more aggressive thyroid cancer. We evaluated the significance of TERT promoter mutations in Korean patients with classic papillary thyroid cancer (PTC).

Methods

Genomic DNA was isolated from four thyroid cancer cell lines and 35 fresh-frozen PTC tissues. TERT promoter mutations (C228T and C250T) and the BRAF V600E mutation were evaluated by polymerase chain reaction amplification and direct sequencing.

Results

The CC228229TT mutation in the TERT promoter was detected in BCPAP cells and the C250T mutation was found in 8505C cells. No TERT promoter mutation was observed in Cal-62 or ML-1 cells. The C228T mutation was found in only 1 of 35 (2.8%) PTCs and no C250T mutations were detected in any of the study subjects. The BRAF V600E mutation was found in 20 of 35 (57.1%) PTCs. One patient with the C228T TERT mutation also harbored the BRAF V600E mutation and developed a recurrence.

Conclusion

The prevalence of somatic TERT promoter mutations was low in Korean patients with classic PTC. Therefore, the prognostic role of TERT promoter mutations might be limited in this patient cohort.

Citations

Citations to this article as recorded by

Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review
Jingxin Mao, Xingliang Huang, Mohammad K. Okla, Mostafa A. Abdel-Maksoud, Ayman Mubarak, Zahid Hameed, Razia Noreen, Aqsa Chaudhary, Shakira Ghazanfar, Yixuan Liao, Yasir Hameed, Chen Li, Min Tang
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population
Abdul K. Siraj, Rong Bu, Kaleem Iqbal, Sandeep Kumar Parvathareddy, Nabil Siraj, Sarah Siraj, Mark Ranier F. Diaz, Dionne Rae Rala, Allianah D. Benito, Maria Angelita Sabido, Maha Al-Rasheed, Khadija A.S. Al-Obaisi, Wael Al-Haqawi, Ingrid G. Victoria, Waf
Genomics.2020; 112(2): 1746. CrossRef
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
Jing Yang, Yanping Gong, Shuping Yan, Hui Chen, Siqin Qin, Rixiang Gong
Endocrine.2020; 67(1): 44. CrossRef
The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer
Jose R. W. Martínez, Sergio Vargas-Salas, Soledad Urra Gamboa, Estefanía Muñoz, José Miguel Domínguez, Augusto León, Nicolás Droppelmann, Antonieta Solar, Mark Zafereo, F. Christopher Holsinger, Hernán E. González
Hormones and Cancer.2019; 10(2-3): 97. CrossRef
Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma
Jiangqiao Geng, Yuanhu Liu, Yongli Guo, Huanmin Wang, Jun Tai, Yaqiong Jin, Jie Zhang, Yongbo Yu, Shengcai Wang, Yingluan Song, Xin Ni
Science China Life Sciences.2019; 62(12): 1563. CrossRef
Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells
Valentina Maggisano, Marilena Celano, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Valeria Pecce, Antonella Verrienti, Federica Baldan, Catia Mio, Lorenzo Allegri, Marianna Maranghi, Rosa Falcone, Giuseppe Damante, Diego Russo, Stef
Endocrine.2019; 63(3): 545. CrossRef
BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea
Mijin Kim, Min Ji Jeon, Hye-Seon Oh, Suyeon Park, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Kyunggon Kim, Won Gu Kim, Dong Eun Song
Thyroid.2018; 28(4): 504. CrossRef
The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer
Anqi Jin, Jianhao Xu, Yan Wang
Medicine.2018; 97(29): e11548. CrossRef
Telomere Maintenance Mechanisms in Cancer
Tiago Bordeira Gaspar, Ana Sá, José Manuel Lopes, Manuel Sobrinho-Simões, Paula Soares, João Vinagre
Genes.2018; 9(5): 241. CrossRef
Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft
Giovanni E. Lombardo, Valentina Maggisano, Marilena Celano, Donato Cosco, Chiara Mignogna, Federica Baldan, Saverio M. Lepore, Lorenzo Allegri, Sonia Moretti, Cosimo Durante, Giuseppe Damante, Massimo Fresta, Diego Russo, Stefania Bulotta, Efisio Puxeddu
Molecular Cancer Therapeutics.2018; 17(6): 1187. CrossRef
Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells
Valentina Maggisano, Marilena Celano, Giovanni Enrico Lombardo, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Antonella Verrienti, Federica Baldan, Efisio Puxeddu, Cosimo Durante, Sebastiano Filetti, Giuseppe Damante, Diego Russo, St
Molecular and Cellular Endocrinology.2017; 448: 34. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Telomerase: The Devil Inside
Mukesh Kumar, Andre Lechel, Çagatay Güneş
Genes.2016; 7(8): 43. CrossRef
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications
Tiantian Liu, Xiaotian Yuan, Dawei Xu
Genes.2016; 7(7): 38. CrossRef
Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene
Muhammad Ramlee, Jing Wang, Wei Toh, Shang Li
Genes.2016; 7(8): 50. CrossRef

Clinical Study
Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea: Hee Kyung Kim, Jee Hee Yoon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Min Jin Lee, Bo Hyun Kim, In Joo Kim, Ji Young Joung, Sun Wook Kim, Jae Hoon Chung, Ho-Cheol Kang; Endocrinol Metab. 2015;30(4):475-480. Published online December 31, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.4.475

7,354 View
69 Download
16 Web of Science
16 Crossref

Abstract PDF PubReader

Background

Antithyroid drugs (ATDs) can lead to the development of agranulocytosis, which is the most serious adverse effect. Characteristics of ATD-induced agranulocytosis (AIA) have seldom been reported due to the rarity. In this study, we characterized the clinical features for AIA in Korean patients.

Methods

We retrospectively reviewed data from patients with AIA diagnosed between 1997 and 2014 at four tertiary hospitals. Agranulocytosis was defined as an absolute neutrophil count (ANC) below 500/mm³.

Results

The mean age of the patients (11 males, 43 females) was 38.2±14.9 years. Forty-eight patients (88.9%) with AIA had fever and sore throat on initial presentation, 20.4% of patients developed AIA during the second course of treatment, and 75.9% of patients suffered AIA within 3 months after initiation of ATD. The patients taking methimazole (n=39) showed lower levels of ANC and more frequent use of granulocyte-macrophage colony-stimulating factor than propylthiouracil (n=15) users. The median duration of agranulocytosis was 5.5 days (range, 1 to 20). No differences were observed between the long (≥6 days) and short recovery time (≤5 days) groups in terms of age, gender, ATDs, duration of ATDs, or initial ANC levels. Four patients (7.4%) who were taking ATDs for less than 2 months died of sepsis on the first or second day of hospitalization.

Conclusion

The majority of AIA incidents occur in the early treatment period. Considering the high fatality rate of AIA, an early aggressive therapeutic approach is critical and patients should be well informed regarding the warning symptoms of the disease.

Citations

Citations to this article as recorded by

Novel Association of KLRC4-KLRK1 Gene Polymorphisms with Susceptibility and Progression of Antithyroid Drug-Induced Agranulocytosis
Yayi He, Pan Ma, Yuanlin Luo, Xiaojuan Gong, Jiayang Gao, Yuxin Sun, Pu Chen, Suliang Zhang, Yuxin Tian, Bingyin Shi, Bao Zhang
Experimental and Clinical Endocrinology & Diabetes.2024; 132(01): 17. CrossRef
A Disproportionality Analysis of the Adverse Effect Profiles of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Using the Japanese Adverse Drug Event Report Database
Masanori Arai, Takahiro Tsuno, Hiromi Konishi, Kuniyuki Nishiyama, Yasuo Terauchi, Ryota Inoue, Jun Shirakawa
Thyroid®.2023; 33(7): 804. CrossRef
The Current Status of Hyperthyroidism in Korea
Hyemi Kwon
Endocrinology and Metabolism.2023; 38(4): 392. CrossRef
Clinical characteristics of neutropenic patients under antithyroid drug: Twelve-year experience in a medical center
Chih-Hsueh Tseng, Chi-Lung Tseng, Harn-Shen Chen, Pei-Lung Chen, Chun-Jui Huang
Journal of the Chinese Medical Association.2023; 86(9): 826. CrossRef
Association of MICA gene polymorphisms with thionamide-induced agranulocytosis
P. Ma, P. Chen, J. Gao, H. Guo, S. Li, J. Yang, J. Lai, X. Yang, B. Zhang, Y. He
Journal of Endocrinological Investigation.2021; 44(2): 363. CrossRef
Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease
Hyun Gyung Lee, Eun Mi Yang, Chan Jong Kim
Annals of Pediatric Endocrinology & Metabolism.2021; 26(3): 199. CrossRef
MICA polymorphisms associated with antithyroid drug‐induced agranulocytosis in the Chinese Han population
Xiaojuan Gong, Pu Chen, Pan Ma, Jiayang Gao, Jingsi Yang, Hui Guo, Chunxia Yan, Bao Zhang, Yayi He
Immunity, Inflammation and Disease.2020; 8(4): 695. CrossRef
The Management of Thyroid Disease in COVID-19 Pandemic
Won Sang Yoo, Hyun-Kyung Chung
International Journal of Thyroidology.2020; 13(2): 65. CrossRef
Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study
Michal Gershinsky, Walid Saliba, Idit Lavi, Chen Shapira, Naomi Gronich
Thyroid.2019; 29(2): 193. CrossRef
A Case of Acute Supraglottitis Following Anti-Thyroid Drug-Induced Agranulocytosis
Jung Jun Lee, Dong Young Kim, Jeon Yeob Jang
Journal of The Korean Society of Laryngology, Phoniatrics and Logopedics.2019; 30(2): 128. CrossRef
Association of HLA-B∗38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients
Mai Phuong Thao, Pham Vo Anh Tuan, Le Gia Hoang Linh, Lam Van Hoang, Phan Huu Hen, Le Tuyet Hoa, Hoang Anh Vu, Do Duc Minh
International Journal of Endocrinology.2018; 2018: 1. CrossRef
Severe Gingival Ulceration and Necrosis Caused by an Antithyroid Drug: One Case Report and Proposed Clinical Approach
Ying‐Ying Chang, Chih‐Wen Tseng, Kuo Yuan
Clinical Advances in Periodontics.2018; 8(1): 11. CrossRef
Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16 years at one Chinese center
Y. He, J. Li, J. Zheng, Z. Khan, W. Qiang, F. Gao, Y. Zhao, B. Shi
Journal of Endocrinological Investigation.2017; 40(7): 733. CrossRef
Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China
Yayi He, Jie Zheng, Qian Zhang, Peng Hou, Feng Zhu, Jian Yang, Wenhao Li, Pu Chen, Shu Liu, Bao Zhang, Bingyin Shi
Scientific Reports.2017;[Epub] CrossRef
Use of granulocyte colony‐stimulating factor in the treatment of methimazole‐induced agranulocytosis: a case report
Asha Birmingham, Carissa Mancuso, Craig Williams
Clinical Case Reports.2017; 5(10): 1701. CrossRef
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
Douglas S. Ross, Henry B. Burch, David S. Cooper, M. Carol Greenlee, Peter Laurberg, Ana Luiza Maia, Scott A. Rivkees, Mary Samuels, Julie Ann Sosa, Marius N. Stan, Martin A. Walter
Thyroid.2016; 26(10): 1343. CrossRef

Erratum

Thyroid
Erratum: Figure Correction: Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010: Yun Mi Choi, Tae Yong Kim, Eun Kyung Jang, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2015;30(1):116. Published online March 27, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.1.116

3,850 View
32 Download

PDF PubReader

Case Report

Thyroid
Solitary Skin Metastasis of Papillary Thyroid Carcinoma: Hyemi Kwon, Hyojung Kim, Sojung Park, Dong Eun Song, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2014;29(4):579-583. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.579

7,194 View
61 Download
8 Web of Science
11 Crossref

Abstract PDF PubReader

A solitary skin metastasis is a rare manifestation of papillary thyroid carcinoma (PTC). A 55-year-old woman presented with a movable subcutaneous nodule in her anterior neck for several months. Three years ago, she underwent total thyroidectomy and remnant ablation for classical PTC (pT3N0M0) and was under thyroxine suppression therapy without any evidence of recurrent disease. The subcutaneous nodule was 0.4 cm in size, firm, and movable without any change in the overlying skin. Recurrent PTC was confirmed after excision biopsy. Eight months after, she got a new nodule along the previous excision site. After punch biopsy, metastatic PTC was confirmed in the deep dermis and was re-excised with a clear resection margin. This is the first report of a case of solitary skin metastasis of PTC in Korea. Although solitary skin metastasis of PTC is rare, it should be considered in patients with a skin nodule.

Citations

Citations to this article as recorded by

Isolated Skin Metastasis From Papillary Thyroid Carcinoma: A Rare Presentation
Naseem Eisa
JCEM Case Reports.2025;[Epub] CrossRef
Cutaneous Manifestation of Metastatic Papillary Thyroid Carcinoma
Joseph H. Kelly, Elise V. H. Meide, Brian J. Tjarks
The American Journal of Dermatopathology.2025;[Epub] CrossRef
Skin metastasis of papillary thyroid carcinoma: A case report and literature review
Haidi Chu, Dong Wang, Yanqing Qu
Oncology Letters.2024;[Epub] CrossRef
Skin Metastasis Occurring 30 Years After Thyroidectomy for Papillary Thyroid Carcinoma
Mohammed S Alwhaid, Olaa Mhish, Mutahir A Tunio, Salman AlMalki, Mushabbab Al Asiri, Khalid Al-Qahtani
Cureus.2022;[Epub] CrossRef
Solitary Nasopharyngeal Metastasis From Papillary Thyroid Carcinoma Shown on FDG PET/CT
Anqi Xu, Xiao Jie, Yan Xiu, Hongcheng Shi
Clinical Nuclear Medicine.2022; 47(5): e425. CrossRef
PD-L1-positive Anaplastic Transformation in a BRAF V600E Expressing Papillary Thyroid Carcinoma with Cutaneous Metastasis: An Unusual Case Report
Pooja Ramakant, Anand Mishra, Chanchal Rana, Kulranjan Singh
Indian Journal of Endocrine Surgery and Research.2022; 17(1): 21. CrossRef
Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review
Eleonora Farina, Fabio Monari, Giovanni Tallini, Andrea Repaci, Renzo Mazzarotto, Francesca Giunchi, Riccardo Panzacchi, Silvia Cammelli, Gilbert D. A. Padula, Francesco Deodato, Renato Pasquali, Stefano Fanti, Michelangelo Fiorentino, Alessio G. Morganti
Endocrine Pathology.2016; 27(1): 55. CrossRef
Skin manifestations of endocrine and neuroendocrine tumors
Jonathan S. Leventhal, Irwin M. Braverman
Seminars in Oncology.2016; 43(3): 335. CrossRef
Isolated Metastasis in Male Breast from Differentiated Thyroid Carcinoma – Oncological Curiosity. A Case Report and Review of Literature
Lakshminarasimman Parasuraman, Shubhada V. Kane, Prathamesh S. Pai, Kintan Shanghvi
Indian Journal of Surgical Oncology.2016; 7(1): 91. CrossRef
A Closer Look at Papillary Thyroid Carcinoma
Won Bae Kim
Endocrinology and Metabolism.2015; 30(1): 1. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef

Original Articles

Thyroid
Standardized Thyroid Cancer Mortality in Korea between 1985 and 2010: Yun Mi Choi, Tae Yong Kim, Eun Kyung Jang, Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2014;29(4):530-535. Published online December 29, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.4.530

7,154 View
41 Download
23 Web of Science
36 Crossref

Abstract PDF PubReader

Background

The prevalence of thyroid cancer has increased very rapidly in Korea. However, there is no published report focusing on thyroid cancer mortality in Korea. In this study, we aimed to evaluate standardized thyroid cancer mortality using data from Statistics Korea (the Statistical Office of Korea).

Methods

Population and mortality data from 1985 to 2010 were obtained from Statistics Korea. Age-standardized rates of thyroid cancer mortality were calculated according to the standard population of Korea, as well as World Health Organization (WHO) standard population and International Cancer Survival Standard (ICSS) population weights.

Results

The crude thyroid cancer mortality rate increased from 0.1 to 0.7 per 100,000 between 1985 and 2010. The pattern was the same for both sexes. The age-standardized mortality rate (ASMR) for thyroid cancer for Korean resident registration population increased from 0.19 to 0.67 between 1985 and 2000. However, it decreased slightly, from 0.67 to 0.55, between 2000 and 2010. When mortality was adjusted using the WHO standard population and ICSS population weights, the ASMR similarly increased until 2000, and then decreased between 2000 and 2010.

Conclusion

Thyroid cancer mortality increased until 2000 in Korea. It started to decrease from 2000.

Citations

Citations to this article as recorded by

Trends in incidence and overdiagnosis of thyroid cancer in China, Japan, and South Korea
Yongtian Lin, Yu Wu
Cancer Science.2023; 114(10): 4052. CrossRef
Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis
Shinje Moon, Ka Hee Yi, Young Joo Park
Cancers.2022; 14(10): 2382. CrossRef
Asymptomatic Patients and Rising Incidence of Thyroid Cancer—Reply
Mirabelle Sajisevi, Louise Davies
JAMA Otolaryngology–Head & Neck Surgery.2022; 148(12): 1186. CrossRef
Asymptomatic Patients and Rising Incidence of Thyroid Cancer
Shijie Yang, Xiequn Xu
JAMA Otolaryngology–Head & Neck Surgery.2022; 148(12): 1185. CrossRef
Does the radioactive iodine dose affect smell, taste sensation and nose function?
B Tutar, T Özülker, G Berkiten, S Karaketir, M E Ekincioğlu, Z Saltürk, Ö Onaran, B Gürpınar, Ş Karaketir, T L Kumral, Y Uyar
The Journal of Laryngology & Otology.2021; 135(1): 50. CrossRef
Disparities in Cancer-Related Avoidable Mortality by the Level of Area Deprivation in South Korea
Woorim Kim, Seongkyeong Jang, Gangeun Lee, Yoon Jung Chang
International Journal of Environmental Research and Public Health.2021; 18(15): 7856. CrossRef
Thyroid cancer: incidence and mortality trends in China, 2005–2015
Junyi Wang, Fangfang Yu, Yanna Shang, Zhiguang Ping, Li Liu
Endocrine.2020; 68(1): 163. CrossRef
A miRNA-clinicopathological nomogram for the prediction of central lymph node metastasis in papillary thyroid carcinoma-analysis from TCGA database
Mingjun Wang, Rongjing Li, Xiuhe Zou, Tao Wei, Rixiang Gong, Jingqiang Zhu, Zhihui Li
Medicine.2020; 99(35): e21996. CrossRef
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea
Hwa Young Ahn, Jae Eun Chae, Hyemi Moon, Junghyun Noh, Young Joo Park, Sin Gon Kim
Endocrinology and Metabolism.2020; 35(4): 811. CrossRef
Optimal Thyrotropin Suppression Therapy in Low-Risk Thyroid Cancer Patients after Lobectomy
Yu-Mi Lee, Min Ji Jeon, Won Woong Kim, Tae-Yon Sung, Ki-Wook Chung, Young Kee Shong, Suck Joon Hong
Journal of Clinical Medicine.2019; 8(9): 1279. CrossRef
Improved survival after early detection of asymptomatic distant metastasis in patients with thyroid cancer
Hosu Kim, So Young Park, Jaehoon Jung, Jung-Han Kim, Soo Yeon Hahn, Jung Hee Shin, Young Lyun Oh, Man Ki Chung, Hye In Kim, Sun Wook Kim, Jae Hoon Chung, Tae Hyuk Kim
Scientific Reports.2019;[Epub] CrossRef
Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Eyun Song, Min Ji Jeon, Hye-Seon Oh, Minkyu Han, Yu-Mi Lee, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Dong Eun Song, Won Gu Kim
European Journal of Endocrinology.2018; 179(3): 135. CrossRef
Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro)
Jae Hoon Moon, Ji-hoon Kim, Eun Kyung Lee, Kyu Eun Lee, Sung Hye Kong, Yeo Koon Kim, Woo-jin Jung, Chang Yoon Lee, Roh-Eul Yoo, Yul Hwangbo, Young Shin Song, Min Joo Kim, Sun Wook Cho, Su-jin Kim, Eun Jae Jung, June Young Choi, Chang Hwan Ryu, You Jin Lee
Endocrinology and Metabolism.2018; 33(2): 278. CrossRef
Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis
H I Kim, T H Kim, J-H Choe, J-H Kim, J S Kim, Y N Kim, H Kim, S W Kim, J H Chung
British Journal of Surgery.2018; 105(3): 270. CrossRef
Ultrasound requested by general practitioners or for symptoms unrelated to the thyroid gland may explain higher prevalence of thyroid nodules in females
Ana Germano, Willian Schmitt, Pedro Almeida, Rui Mateus-Marques, Valeriano Leite
Clinical Imaging.2018; 50: 289. CrossRef
Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies
Shinje Moon, Hye Soo Chung, Jae Myung Yu, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Young Joo Park
Endocrinology and Metabolism.2018; 33(4): 473. CrossRef
Refining the eighth edition AJCC TNM classification and prognostic groups for papillary thyroid cancer with lateral nodal metastasis
Hye In Kim, Kyunga Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hyeon Seon Ahn, Sun Wook Kim, Tae Hyuk Kim, Jae Hoon Chung
Oral Oncology.2018; 78: 80. CrossRef
Decreasing Disease-Specific Mortality of Differentiated Thyroid Cancer in Korea: A Multicenter Cohort Study
Min Ji Jeon, Hee Kyung Kim, Eun Heui Kim, Eun Sook Kim, Hyon-Seung Yi, Tae Yong Kim, Ho-Cheol Kang, Young Kee Shong, Won Bae Kim, Bo Hyun Kim, Won Gu Kim
Thyroid.2018; 28(9): 1121. CrossRef
Are pregnancy, parity, menstruation and breastfeeding risk factors for thyroid cancer? Results from the Korea National Health and Nutrition Examination Survey, 2010‐2015
Hosu Kim, Kyong Young Kim, Jong Ha Baek, Jaehoon Jung
Clinical Endocrinology.2018; 89(2): 233. CrossRef
Case–Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea
Joon‐Hyop Lee, Ra‐Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su‐jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K. Park
World Journal of Surgery.2018; 42(5): 1424. CrossRef
Patterns of Initial Recurrence in Completely Resected Papillary Thyroid Carcinoma
Hosu Kim, Tae Hyuk Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Sang ah Chi, Sin-Ho Jung, Young Nam Kim, Hye In Kim, Sun Wook Kim, Jae Hoon Chung
Thyroid.2017; 27(7): 908. CrossRef
Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data
Yun Mi Choi, Won Gu Kim, Hyemi Kwon, Min Ji Jeon, Minkyu Han, Tae Yong Kim, Young Kee Shong, Sang Mo Hong, Eun‐Gyoung Hong, Won Bae Kim
Cancer.2017; 123(24): 4808. CrossRef
Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score–Matched Cohort Study
Suyeon Park, Won Gu Kim, Minkyu Han, Min Ji Jeon, Hyemi Kwon, Mijin Kim, Tae-Yon Sung, Tae Yong Kim, Won Bae Kim, Suck Joon Hong, Young Kee Shong
Thyroid.2017; 27(9): 1164. CrossRef
Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer
Hosu Kim, Young Nam Kim, Hye In Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Jae Hoon Chung, Tae Hyuk Kim, Sun Wook Kim
Scientific Reports.2017;[Epub] CrossRef
Young Age and Male Sex Are Predictors of Large-Volume Central Neck Lymph Node Metastasis in Clinical N0 Papillary Thyroid Microcarcinomas
Hye-Seon Oh, Suyeon Park, Mijin Kim, Hyemi Kwon, Eyun Song, Tae-Yon Sung, Yu-Mi Lee, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Min Ji Jeon
Thyroid.2017; 27(10): 1285. CrossRef
Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size
Hye In Kim, Tae Hyuk Kim, Jun‐Ho Choe, Jung‐Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hye Won Jang, Young Nam Kim, Hosu Kim, Hyeon Seon Ahn, Kyunga Kim, Sun Wook Kim, Jae Hoon Chung
Cancer Medicine.2017; 6(10): 2244. CrossRef
Risk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma
Eun Young Kim, Kee Hoon Hyun, Yong Lai Park, Chan Heun Park, Ji-Sup Yun
Annals of Surgical Treatment and Research.2017; 92(1): 1. CrossRef
Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study
Min Ji Jeon, Won Gu Kim, Tae Hyuk Kim, Hee Kyung Kim, Bo Hyun Kim, Hyon-Seung Yi, Eun Sook Kim, Hosu Kim, Young Nam Kim, Eun Heui Kim, Tae Yong Kim, Sun Wook Kim, Ho-Cheol Kang, Jae Hoon Chung, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2017; 32(4): 434. CrossRef
Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis
Min Ji Jeon, Mi Sun Chung, Hyemi Kwon, Mijin Kim, Suyeon Park, Jung Hwan Baek, Dong Eun Song, Tae‐Yon Sung, Suck Joon Hong, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jeong Hyun Lee, Won Gu Kim
Clinical Endocrinology.2017; 86(6): 845. CrossRef
Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy
Suyeon Park, Won Gu Kim, Eyun Song, Hye-Seon Oh, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(4): 524. CrossRef
Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer
Ju Hye Jeong, Eun Jung Kong, Shin Young Jeong, Sang-Woo Lee, Ihn Ho Cho, Kyung Ah Chun, Jaetae Lee, Byeong-Cheol Ahn
Nuclear Medicine Communications.2017; 38(3): 228. CrossRef
Single-Incision, Gasless, Endoscopic Trans-Axillary Total Thyroidectomy: A Feasible and Oncologic Safe Surgery in Patients with Papillary Thyroid Carcinoma
Eun Young Kim, Kwan Ho Lee, Yong Lai Park, Chan Heun Park, Cho Rok Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Ji-Sup Yun
Journal of Laparoendoscopic & Advanced Surgical Techniques.2017; 27(11): 1158. CrossRef
Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma
Tae Hyuk Kim, Young Nam Kim, Hye In Kim, So Young Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Kyunga Kim, Jong Gill Jeong, Sun Wook Kim, Jae Hoon Chung
Oral Oncology.2017; 71: 81. CrossRef
Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Journal of Surgical Oncology.2016; 113(2): 152. CrossRef
Thyroid lobectomy with minimal incision approach
Tsuyoshi Kojima, Kazuhiko Shoji, Ryusuke Hori, Yusuke Okanoue, Shintaro Fujimura, Hideaki Okuyama, Masayuki Kitano
JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY.2016; 26(2): 283. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef

Thyroid
Lack of Associations between Body Mass Index and Clinical Outcomes in Patients with Papillary Thyroid Carcinoma: Hyemi Kwon, Mijin Kim, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Suck Joon Hong, Won Bae Kim; Endocrinol Metab. 2015;30(3):305-311. Published online November 26, 2014; DOI: https://doi.org/10.3803/EnM.2015.30.3.305

6,993 View
44 Download
15 Web of Science
16 Crossref

Abstract PDF PubReader

Background

Obesity is associated with aggressive pathological features and poor clinical outcomes in breast and prostate cancers. In papillary thyroid carcinoma (PTC), these relationships remain still controversial. This study aimed to evaluate the associations between body mass index (BMI) and the clinical outcomes of patients with PTC.

Methods

This retrospective study included 1,189 patients who underwent total thyroidectomy for PTCs equal to or larger than 1 cm in size. Clinical outcomes were evaluated and compared based on the BMI quartiles.

Results

There were no significant associations between BMI quartiles and primary tumor size, extrathyroidal invasion, cervical lymph node metastasis, or distant metastasis. However, an increase in mean age was associated with an increased BMI (P for trend <0.001). Multifocality and advanced tumor-node-metastasis (TNM) stage (stage III or IV) were significantly associated with increases of BMI (P for trend 0.02 and <0.001, respectively). However, these associations of multifocality and advanced TNM stage with BMI were not significant in multivariate analyses adjusted for age and gender. Moreover, there were no differences in recurrence-free survivals according to BMI quartiles (P=0.26).

Conclusion

In the present study, BMI was not associated with the aggressive clinicopathological features or recurrence-free survivals in patients with PTC.

Citations

Citations to this article as recorded by

Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series
Alessandro Prete, Carla Gambale, Valeria Bottici, Virginia Cappagli, Giacomo Aringhieri, Marco Puccini, Stefano Landi, Liborio Torregrossa, Ferruccio Santini, Antonio Matrone, Rossella Elisei
Cancers.2025; 17(6): 950. CrossRef
The Role of Body Mass Index (BMI) in Differentiated Thyroid Cancer: A Potential Prognostic Factor?
Chiara Mele, Lucrezia De Marchi, Giulia Marsan, Marco Zavattaro, Maria Grazia Mauri, Paolo Aluffi Valletti, Gianluca Aimaretti, Paolo Marzullo
Biomedicines.2024; 12(9): 1962. CrossRef
A Data-Driven Approach to Refine Predictions of Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study
Giorgio Grani, Michele Gentili, Federico Siciliano, Domenico Albano, Valentina Zilioli, Silvia Morelli, Efisio Puxeddu, Maria Chiara Zatelli, Irene Gagliardi, Alessandro Piovesan, Alice Nervo, Umberto Crocetti, Michela Massa, Maria Teresa Samà, Chiara Mel
The Journal of Clinical Endocrinology & Metabolism.2023; 108(8): 1921. CrossRef
Potential impact of obesity on the aggressiveness of low- to intermediate-risk papillary thyroid carcinoma: results from a MASTER cohort study
Mijin Kim, Yae Eun Kang, Young Joo Park, Bon Seok Koo, Eu Jeong Ku, June Young Choi, Eun Kyung Lee, Bo Hyun Kim
Endocrine.2023; 82(1): 134. CrossRef
Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy
Jingjia Cao, Xiaolu Zhu, Yaru Sun, Xiao Li, Canhua Yun, Wei Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Nutritional status and follicular-derived thyroid cancer: An update
Luigi Barrea, Marco Gallo, Rosaria Maddalena Ruggeri, Paola Di Giacinto, Franz Sesti, Natalie Prinzi, Valerio Adinolfi, Viola Barucca, Valerio Renzelli, Giovanna Muscogiuri, Annamaria Colao, Roberto Baldelli
Critical Reviews in Food Science and Nutrition.2021; 61(1): 25. CrossRef
Effects of concomitant obesity and diabetes on the aggressiveness and outcomes of differentiated thyroid cancer patients
Onur Elbasan, Dilek Gogas Yavuz
Archives of Endocrinology and Metabolism.2021;[Epub] CrossRef
Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta‐Analysis
R. J. O'Neill, S. Abd Elwahab, M. J. Kerin, A. J. Lowery
World Journal of Surgery.2021; 45(9): 2805. CrossRef
Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis
Aliki Economides, Konstantinos Giannakou, Ioannis Mamais, Panayiotis A. Economides, Panagiotis Papageorgis
Frontiers in Endocrinology.2021;[Epub] CrossRef
Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer
Antonio Matrone, Giovanni Ceccarini, Marianna Beghini, Federica Ferrari, Carla Gambale, Mariaida D’Aqui, Paolo Piaggi, Liborio Torregrossa, Eleonora Molinaro, Fulvio Basolo, Paolo Vitti, Ferruccio Santini, Rossella Elisei
The Journal of Clinical Endocrinology & Metabolism.2020; 105(4): e1124. CrossRef
Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study
Huijuan Wang, Pingping Wang, Yu Wu, Xiukun Hou, Zechun Peng, Weiwei Yang, Lizhao Guan, Linfei Hu, Jingtai Zhi, Ming Gao, Xiangqian Zheng
PeerJ.2020; 8: e9675. CrossRef
Lack of association between obesity and aggressiveness of differentiated thyroid cancer
G. Grani, L. Lamartina, T. Montesano, G. Ronga, V. Maggisano, R. Falcone, V. Ramundo, L. Giacomelli, C. Durante, D. Russo, M. Maranghi
Journal of Endocrinological Investigation.2019; 42(1): 85. CrossRef
Mitochondrial DNA haplogroup K as a contributor to protection against thyroid cancer in a population from southeast Europe
Relu Cocoş, Sorina Schipor, Corin Badiu, Florina Raicu
Mitochondrion.2018; 39: 43. CrossRef
The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer
Danuta Gąsior-Perczak, Iwona Pałyga, Monika Szymonek, Artur Kowalik, Agnieszka Walczyk, Janusz Kopczyński, Katarzyna Lizis-Kolus, Tomasz Trybek, Estera Mikina, Dorota Szyska-Skrobot, Klaudia Gadawska-Juszczyk, Stefan Hurej, Artur Szczodry, Anna Słuszniak,
PLOS ONE.2018; 13(10): e0204668. CrossRef
Pretreatment BMI Is Associated with Aggressive Clinicopathological Features of Papillary Thyroid Carcinoma: A Multicenter Study
Shi-tong Yu, Wanzhi Chen, Qian Cai, Faya Liang, Debin Xu, Ping Han, Jichun Yu, Xiaoming Huang
International Journal of Endocrinology.2017; 2017: 1. CrossRef
Associations between body mass index and lymph node metastases of patients with papillary thyroid cancer
Changhua Wu, Liang Wang, Wanjun Chen, Shujuan Zou, Aiju Yang
Medicine.2017; 96(9): e6202. CrossRef

Review Article

Thyroid
Current Status and Future Perspectives in Differentiated Thyroid Cancer: Tae Yong Kim, Won Gu Kim, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2014;29(3):217-225. Published online September 25, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.3.217

8,246 View
44 Download
79 Web of Science
66 Crossref

Abstract PDF PubReader

Thyroid cancer is increasing all over the world. The exact cause of this increase is still debated and there are conflicting reports. Sophisticated molecular studies suggest that environmental chemicals may have effects of thyroid carcinogenesis. The development of powerful molecular biology techniques has enabled targeted next-generation sequencing for detection of mutations in thyroid cancer, and this technique can make a specific diagnosis of thyroid cancer in cytologically indeterminate cases. The initial treatment of well-differentiated thyroid cancer (DTC) is surgery followed by radioiodine remnant ablation. However, further studies are needed to determine the optimal dosage of radioactive iodine for DTC patients with lateral neck metastasis. DTC is an indolent tumor and may cause death even decades later. Thus, long-term follow-up is mandatory. Recently, dynamic risk stratification (DRS) has begun to use stimulated thyroglobulin level at 1 year after the initial treatment and restratified the risk in accordance with the response to the initial treatment. This DRS strategy accurately predicts disease free survival and can be widely used in daily clinical settings. For the iodine refractory metastatic disease, redifferentiation therapy and targeted therapy are two promising alternative treatments. Sorafenib is the first approved agent for the treatment of progressive iodine refractory advanced thyroid cancer in Korea and may be very helpful for radioactive-refractory locally advanced or metastatic DTC. Selumetinib may be an effective redifferentiating agent and could be used within several years.

Citations

Citations to this article as recorded by

Locoregional Recurrence after Biochemical Incomplete Response in Differentiated Thyroid Cancer Patients: Insights into Influencing Clinicopathological Factors and the Potential Role of 18F-FDG PET/CT
Mai Amr Elahmadawy, Ismail Mohamed Ali, Ibrahim Mansour Nasr, Omnia Talaat
World Journal of Nuclear Medicine.2025;[Epub] CrossRef
Association between metabolic dysfunction-associated steatotic liver disease and the risk of thyroid cancer: a nationwide cohort study
Jeongmin Lee, Jeongeun Kwak, Min-Hee Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Hun-Sung Kim
The Korean Journal of Internal Medicine.2025; 40(5): 813. CrossRef
Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea
Hyemi Kwon, Kyung-Do Han, Sun Joon Moon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1095. CrossRef
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
Hélène Lasolle, Andrea Schiavo, Adrien Tourneur, Pierre Gillotay, Bárbara de Faria da Fonseca, Lucieli Ceolin, Olivier Monestier, Benilda Aganahi, Laura Chomette, Marina Malta Letro Kizys, Lieven Haenebalcke, Tim Pieters, Steven Goossens, Jody Haigh, Vinc
Oncogene.2024; 43(3): 155. CrossRef
Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation
Jing-Yang Su
American Journal of Cancer Research.2024; 14(2): 407. CrossRef
F-18 FDG PET/CT Versus RAI-WBS and Neck USG in Early Diagnosis of Recurrent Differentiated Thyroid Cancer
Jaimanti Bakshi, Naresh K. Panda, Atul Kumar Goyal, Jyoti Saini, Sovit Jung Baral, Bhagwant Rai Mittal, Anupam Lal
Journal of Pharmaceutical and BioSciences.2024; 12(3): 9. CrossRef
Study on Impact of Interpolation Methods on Performance of Super-Resolution ResNet Model in Nuclear Medicine Thyroid Phantom Imaging
Minha Kim, Chanrok Park
Journal of Radiological Science and Technology.2024; 47(6): 433. CrossRef
Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer
Tairong Liang, Xiuqian Wu, Lan Wang, Zhengzhong Ni, Ying Fan, Peishan Wu, Hongzhi Wang, Yongdong Niu, Haihua Huang
Pathology - Research and Practice.2023; 245: 154431. CrossRef
Thyroidkeeper: a healthcare management system for patients with thyroid diseases
Jing Zhang, Jianhua Li, Yi Zhu, Yu Fu, Lixia Chen
Health Information Science and Systems.2023;[Epub] CrossRef
Repeated Low High-Density Lipoprotein Cholesterol and the Risk of Thyroid Cancer: A Nationwide Population- Based Study in Korea
Jinyoung Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Kyungdo Han, Hyuk-Sang Kwon
Endocrinology and Metabolism.2022; 37(2): 303. CrossRef
Comparison of the prognostic value of AJCC cancer staging system 7th and 8th editions for differentiated thyroid cancer
Y. J. Morosán Allo, L. Bosio, A. Morejón, C. Parisi, M. C. Faingold, V. Ilera, A. Gauna, G. Brenta
BMC Endocrine Disorders.2022;[Epub] CrossRef
Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry
Jonghwa Ahn, Meihua Jin, Eyun Song, Yeon-mi Ryu, Dong Eun Song, Sang-Yeob Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
Thyroid.2021; 31(1): 61. CrossRef
A double mutation of BRAF L597Q and V600E in situ and solitary brain metastasis of occult papillary thyroid carcinoma
Ling Chen, Yue Wu, Huili Bai, Huandong Liu, Xiaosong Li
Medicine.2021; 100(6): e24458. CrossRef
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma
Eyun Song, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong, Won Gu Kim
Cancers.2021; 13(22): 5846. CrossRef
Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
Young Kee Shong
International Journal of Thyroidology.2021; 14(2): 98. CrossRef
Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma
Yan Dong, Dan Wang, Yisheng Luo, Ling Chen, Huili Bai, Yifan Shen, Yangli Zhang, Xueping Chen, Xinliang Su, Jinqiu Zhao, Huandong Liu, Jungao Lu, Zuoyi Yao, Yajing Zhao, Changlong He, Xiaosong Li
Oncology Letters.2021;[Epub] CrossRef
Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea
Eyun Song, Mijin Kim, Eui Young Kim, Bo Hyun Kim, Dong Yeob Shin, Ho-Cheol Kang, Byeong-Cheol Ahn, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Dong Jun Lim
Thyroid.2020; 30(5): 732. CrossRef
Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation
Yeon-Hee Han, Hwan-Jeong Jeong, Myung-Hee Sohn, Sun Y. Lee, Seok T. Lim
The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2020;[Epub] CrossRef
Metabolic Syndrome and the Risk of Thyroid Cancer: A Nationwide Population-Based Cohort Study
Joo-Hyun Park, Moonyoung Choi, Jung-Hun Kim, Jaemin Kim, Kyungdo Han, Bongsung Kim, Do-Hoon Kim, Yong-Gyu Park
Thyroid.2020; 30(10): 1496. CrossRef
Serum Adiponectin and Progranulin Level in Patients with Benign Thyroid Nodule or Papillary Thyroid Cancer
Hyemi Kwon, Se Eun Park, Ji-Sup Yun, Cheol-Young Park
Endocrinology and Metabolism.2020; 35(2): 396. CrossRef
The role of Slit2 as a tumor suppressor in thyroid cancer
Min Ji Jeon, Seonhee Lim, Mi-hyeon You, Yangsoon Park, Dong Eun Song, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim
Molecular and Cellular Endocrinology.2019; 483: 87. CrossRef
Metabolic Obesity Phenotypes and Thyroid Cancer Risk: A Cohort Study
Hyemi Kwon, Yoosoo Chang, Ara Cho, Jiin Ahn, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Hocheol Shin, Seungho Ryu, Eun-Jung Rhee
Thyroid.2019; 29(3): 349. CrossRef
Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Clinical Endocrinology.2019; 91(3): 449. CrossRef
Myxedema coma precipitated by diabetic ketoacidosis after total thyroidectomy: a case report
Jin Joo Kim, Eun Young Kim
Journal of Medical Case Reports.2019;[Epub] CrossRef
Comprehensive analysis for diagnosis of preoperative non-invasive follicular thyroid neoplasm with papillary-like nuclear features
Hye Seung Lee, Jae-Wook Lee, Ji Hyun Park, Wan-Seop Kim, Hye Seung Han, Seung Eun Lee, Paula Soares
PLOS ONE.2019; 14(7): e0218046. CrossRef
Rutin Scavenges Reactive Oxygen Species, Inactivates 5′-Adenosine Monophosphate-Activated Protein Kinase, and Increases Sodium–Iodide Symporter Expression in Thyroid PCCL3 Cells
Carlos Frederico Lima Gonçalves, Mariana Lopes de Freitas, Rodrigo Soares Fortunato, Leandro Miranda-Alves, Denise P. Carvalho, Andrea Claudia Freitas Ferreira
Thyroid.2018; 28(2): 265. CrossRef
Prevalence ofBRAFV600EMutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in aBRAFV600EPrevalent Area
Hyereen Kim, Bo Hyun Kim, Young Keum Kim, Jeong Mi Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Jong Ho Kim, Yun Kyung Jeon, Sang Soo Kim, Byung Joo Lee, Yong Ki Kim, In Joo Kim
Journal of Korean Medical Science.2018;[Epub] CrossRef
Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer
Neeta J. Erinjeri, Norman G. Nicolson, Christine Deyholos, Reju Korah, Tobias Carling
Journal of the American College of Surgeons.2018; 226(6): 950. CrossRef
Efficacy and Affecting Factors of 131I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
Chen Wang, Hongcui Diao, Ping Ren, Xufu Wang, Yangang Wang, Wenjuan Zhao
Frontiers in Oncology.2018;[Epub] CrossRef
Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Eyun Song, Min Ji Jeon, Hye-Seon Oh, Minkyu Han, Yu-Mi Lee, Tae Yong Kim, Ki-Wook Chung, Won Bae Kim, Young Kee Shong, Dong Eun Song, Won Gu Kim
European Journal of Endocrinology.2018; 179(3): 135. CrossRef
SPC24 is critical for anaplastic thyroid cancer progression
Huabin Yin, Tong Meng, Lei Zhou, Haiyan Chen, Dianwen Song
Oncotarget.2017; 8(13): 21884. CrossRef
Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis
Renfei Wang, Yueqian Zhang, Jian Tan, Guizhi Zhang, Ruiguo Zhang, Wei Zheng, Yajing He
Medicine.2017; 96(19): e6809. CrossRef
Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication
Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jae Hoon Chung, Seong Mi Moon, Byung Woo Jhun, Hyun Lee, Won-Jung Koh, Sun Wook Kim, Dongmei Li
PLOS ONE.2017; 12(1): e0169775. CrossRef
DelayedTSHrecovery after dose adjustment duringTSH‐suppressive levothyroxine therapy of thyroid cancer
Hye In Kim, Tae Hyuk Kim, Hosu Kim, Young Nam Kim, Hye Won Jang, Jung‐Han Kim, Kyu Yeon Hur, Jae Hoon Chung, Sun Wook Kim
Clinical Endocrinology.2017; 87(3): 286. CrossRef
Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease
Yun Mi Choi, Won Gu Kim, Tae Yong Kim, Sung Jin Bae, Hong-Kyu Kim, Eun Kyung Jang, Min Ji Jeon, Ji Min Han, Young Kee Shong, Won Bae Kim
The Korean Journal of Internal Medicine.2017; 32(1): 102. CrossRef
Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
Mijin Kim, Young Nam Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Hyeon Seon Ahn, Sin-Ho Jung, Sun Wook Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Tae Hyuk Kim, Tae Yong Kim
Clinical Endocrinology.2017; 86(3): 438. CrossRef
Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung
Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(1): 49. CrossRef
Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations
Tae Hyuk Kim, Chang-Seok Ki, Hye Seung Kim, Kyunga Kim, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Young Lyun Oh, Soo Yeon Hahn, Jung Hee Shin, Hye Won Jang, Sun Wook Kim, Jae Hoon Chung
The Journal of Clinical Endocrinology & Metabolism.2017; 102(5): 1757. CrossRef
Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer
Mijin Kim, Won Gu Kim, Hye-Seon Oh, Suyeon Park, Hyemi Kwon, Dong Eun Song, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Tae-Yon Sung, Min Ji Jeon
Thyroid.2017; 27(9): 1149. CrossRef
Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma
Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Sang Min Lee, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(7): 915. CrossRef
Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas
Hyemi Kwon, Min Ji Jeon, Jong Ho Yoon, Suck Joon Hong, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
Journal of Surgical Oncology.2017; 116(6): 746. CrossRef
Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
Douglas Van Nostrand
Journal of Nuclear Medicine.2017; 58(5): 697. CrossRef
Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy
Xingchen Shang, Xia Zhong, Xingsong Tian
Tumor Biology.2016; 37(8): 11163. CrossRef
Recent Updates on the Management of Medullary Thyroid Carcinoma
Bo Hyun Kim, In Joo Kim
Endocrinology and Metabolism.2016; 31(3): 392. CrossRef
Intraoperative Near‐infrared Imaging for Parathyroid Gland Identification by Auto‐fluorescence: A Feasibility Study
Frederic De Leeuw, Ingrid Breuskin, Muriel Abbaci, Odile Casiraghi, Haïtham Mirghani, Aïcha Ben Lakhdar, Corinne Laplace‐Builhé, Dana Hartl
World Journal of Surgery.2016; 40(9): 2131. CrossRef
Papillary thyroid carcinoma: different clinical behavior among pT3 tumors
Maria Joana Santos, Maria João Bugalho
Endocrine.2016; 53(3): 754. CrossRef
Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Journal of Surgical Oncology.2016; 113(2): 152. CrossRef
Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography
BIN LONG, MENGDI YANG, ZHIWEN YANG, HEQING YI, LINFA LI
Oncology Letters.2016; 11(2): 965. CrossRef
Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma
CUN-ZHI LU, SU-SHENG CAO, WEI WANG, JUN LIU, NING FU, FENG LU
Oncology Letters.2016; 11(4): 2420. CrossRef
Coexistence of papillary thyroid microcarcinoma and mucosa-associated lymphoid tissue lymphoma in a context of Hashimoto's thyroiditis
Saul Levy-Blitchtein, Stefany Plasencia-Rebata, Domingo Morales Luna, Juana del Valle Mendoza
Asian Pacific Journal of Tropical Medicine.2016; 9(8): 812. CrossRef
Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know
Mohammad Javed Ali
Ophthalmic Plastic & Reconstructive Surgery.2016; 32(4): 243. CrossRef
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma
Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(1): 100. CrossRef
Dietary evaluation of a low-iodine diet in Korean thyroid cancer patients preparing for radioactive iodine therapy in an iodine-rich region
Dal Lae Ju, Young Joo Park, Hee-Young Paik, Min-Ji Kim, Seonyeong Park, Kyong Yeun Jung, Tae Hyuk Kim, Hun Sung Choi, Yoon Ju Song
Nutrition Research and Practice.2016; 10(2): 167. CrossRef
Features Predictive of Distant Metastasis in Papillary Thyroid Microcarcinomas
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Tae Yong Kim, Young Kee Shong, Dong Eun Song, Won Bae Kim
Thyroid.2016; 26(1): 161. CrossRef
Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
Min Ji Jeon, Won Gu Kim, Seonhee Lim, Hyun-Jeung Choi, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Molecular and Cellular Endocrinology.2016; 419: 113. CrossRef
Differentiated Thyroid Cancer in Asians
Bo Hyun Kim
Endocrinology and Metabolism.2016; 31(1): 62. CrossRef
Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria
Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jin-Sook Ryu, Ji Min Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Konradin Metze
PLOS ONE.2015; 10(7): e0133625. CrossRef
The Impact of Low Adherence to the Low-iodine Diet on the Efficacy of the Radioactive Iodine Ablation Therapy
Dal Lae Ju, Young Joo Park, Hee-Young Paik, YoonJu Song
Clinical Nutrition Research.2015; 4(4): 267. CrossRef
High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma
Bo Hyun Kim, Seong-Jang Kim, Keunyoung Kim, Heeyoung Kim, So Jung Kim, Won Jin Kim, Yun Kyung Jeon, Sang Soo Kim, Yong Ki Kim, In Joo Kim
Annals of Nuclear Medicine.2015; 29(8): 721. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Changes in the Pulmonary Function Test after Radioactive Iodine Treatment in Patients with Pulmonary Metastases of Differentiated Thyroid Cancer
Eun Kyung Jang, Won Gu Kim, Ho-Cheol Kim, Jin-Won Huh, Hyemi Kwon, Yun Mi Choi, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Jin-Sook Ryu, Won Bae Kim, Karen M. Tordjman
PLOS ONE.2015; 10(4): e0125114. CrossRef
Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma
Tae Yon Sung, Mijin Kim, Tae Yong Kim, Won Gu Kim, Yangsoon Park, Dong Eun Song, Su-Yeon Park, Hyemi Kwon, Yun Mi Choi, Eun Kyung Jang, Min Ji Jeon, Young Kee Shong, Suck Joon Hong, Won Bae Kim
Thyroid.2015; 25(9): 1020. CrossRef
Thyroglobulin Level in Fine-Needle Aspirates for Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma: Two Different Cutoff Values According to Serum Thyroglobulin Level
Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2015; 25(4): 410. CrossRef
A Closer Look at Papillary Thyroid Carcinoma
Won Bae Kim
Endocrinology and Metabolism.2015; 30(1): 1. CrossRef
Protecting the normal in order to better kill the cancer
Bingya Liu, Lewis Ezeogu, Lucas Zellmer, Baofa Yu, Ningzhi Xu, Dezhong Joshua Liao
Cancer Medicine.2015; 4(9): 1394. CrossRef
Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470. CrossRef

Case Reports

Long-Term Survival of a Patient with Pulmonary Artery Intimal Sarcoma after Sequential Metastasectomies of the Thyroid and Adrenal Glands: Yun Mi Choi, Eun Kyung Jang, Seong Hee Ahn, Min Ji Jeon, Ji Min Han, Seong Chul Kim, Duck Jong Han, Gyungyup Gong, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2013;28(1):46-49. Published online March 25, 2013; DOI: https://doi.org/10.3803/EnM.2013.28.1.46

6,069 View
29 Download
9 Crossref

Abstract PDF PubReader

Cancer metastases to the thyroid or adrenal gland are uncommon. Furthermore, cases showing long-term survival after surgical resection of those metastatic tumors are rare. We report a case of pulmonary artery intimal sarcoma with metastases to the thyroid and adrenal glands sequentially that was successfully treated with sequential metastasectomies. A 62-year-old woman presented with a 4-week history of dyspnea on exertion and facial edema in November 1999. Echocardiography and chest computed tomography (CT) revealed an embolism-like mass in the pulmonary trunk. Pulmonary artery endarterectomy with pulmonary valve replacement was performed, and histopathology revealed pulmonary artery intimal sarcoma. A thyroid nodule was found by chest CT in November 2001 (2 years after initial surgery). During follow-up, this lesion showed no change, but we decided to obtain fine needle aspiration cytology (FNAC) in August 2004 (4.7 years after initial surgery). FNAC revealed atypical spindle cells suggestive of metastatic intimal sarcoma. She underwent total thyroidectomy. During follow-up, a right adrenal gland mass was detected by chest CT in March 2006 (6.3 years after initial surgery), and adrenalectomy was done, which also revealed metastatic sarcoma. She has been followed up without any evidence of recurrent disease until May 2012 (12.5 years after initial surgery).

Citations

Citations to this article as recorded by

Reoperation of Pulmonary Artery Intimal Sarcoma for Recurrence After Pulmonary Artery Replacement
Kentaro Miyazaki, Isao Matsumoto, Satoshi Nishikawa, Takashi Wada, Tetsuya Takayama, Daisuke Saito, Shuhei Yoshida, Kenji Iino, Hirofumi Takemura
Annals of Thoracic Surgery Short Reports.2024; 2(3): 484. CrossRef
Pulmonary artery sarcoma: An important mimic of pulmonary embolism—Case reports and literature review
Colin Tuft, Krishan Maheepala, Ajantha Raguparan, Anas Naeem, Suhrid Lodh, Steven Lindstrom
Respirology Case Reports.2022;[Epub] CrossRef
Rare case of metastatic liposarcoma to the thyroid gland and a review of the literature of metastatic sarcomas to the thyroid
Monica H. Xing, Neil Mundi, Aparna Govindan, Azita Khorsandi, Margaret Brandwein‐Weber, Ammar Matloob, Bobby Liaw, Mark L. Urken
Head & Neck.2021;[Epub] CrossRef
Left pneumonectomy with pulmonary arterioplasty under cardiopulmonary bypass for pulmonary artery intimal sarcoma
Akihiko Kitahara, Yuki Shimizu, Tatsuya Goto, Seijiro Sato, Terumoto Koike, Masanori Tsuchida
The Journal of the Japanese Association for Chest Surgery.2018; 32(4): 492. CrossRef
Intimal sarcoma of the pulmonary artery with multiple lung metastases: Long-term survival case
Sonia García-Cabezas, Macarena Centeno-Haro, Simona Espejo-Pérez, Elvira Carmona-Asenjo, Alberto L Moreno-Vega, Rosa Ortega-Salas, Amalia Palacios-Eito
World Journal of Clinical Oncology.2017; 8(4): 366. CrossRef
Clinical Characteristics and Treatment Outcomes of Primary Pulmonary Artery Sarcoma in Korea
Yunkyoung Lee, Hyun Jung Kim, Heeyoung Yoon, Chang-Min Choi, Yeon-Mok Oh, Sang-Do Lee, Chae-Man Lim, Woo-Sung Kim, Younsuck Koh, Jae Seung Lee
Journal of Korean Medical Science.2016; 31(11): 1755. CrossRef
An Extraordinary Case of Mesenchymal Chondrosarcoma Metastasis in the Thyroid
Santiago Ortiz, Francisco Tortosa, Manuel Sobrinho Simões
Endocrine Pathology.2015; 26(1): 33. CrossRef
Presentation and management of pulmonary artery sarcoma
Han Hsi Wong, Ioannis Gounaris, Ann McCormack, Marius Berman, Dochka Davidson, Gail Horan, Joanna Pepke-Zaba, David Jenkins, Helena M Earl, Helen M Hatcher
Clinical Sarcoma Research.2015;[Epub] CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251. CrossRef

Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma.: Min Ji Jeon, Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2011;26(4):330-334. Published online December 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.4.330

41,671 View
38 Download
3 Crossref

Abstract PDF

Papillary thyroid carcinoma could be a rare cause of malignant pleural effusion. The development of malignant pleural effusion in patients with papillary thyroid cancer is an extremely adverse prognostic indicator. Here, we report four cases that showed development of malignant pleural effusion during the clinical course of the papillary thyroid carcinoma and consider the prognosis. In four patients, the median survival time after the development of malignant pleural effusion was only 17 months.

Citations

Citations to this article as recorded by

Pleural fluid due to papillary thyroid cancer
Tomohiro Tamura, Toshihiro Shiozawa, Hiroaki Satoh, Koichi Kurishima, Katsunori Kagohashi, Norio Takayashiki, Nobuyuki Hizawa
Oncology Letters.2019;[Epub] CrossRef
Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma
Chisato Tomoda, Yuna Ogimi, Fumi Saito, Chie Masaki, Junko Akaishi, Kenichi Matsuzu, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Hiroshi Shibuya, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Koichi Ito
Endocrine Journal.2016; 63(3): 257. CrossRef
A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report
Andrew Rosenstengel, Ee Mun Lim, Michael Millward, YC Gary Lee
Journal of Medical Case Reports.2013;[Epub] CrossRef

Original Articles

Comparison of Different Staging Systems for Predicting Recurrence of Papillary Thyroid Carcinoma.: Won Gu Kim, Eui Young Kim, Ji Hye Yim, Ji Min Han, Min Ji Jeon, Tae Yong Kim, Jin Sook Ryu, Gyungyub Gong, Suck Joon Hong, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2011;26(1):53-61. Published online March 1, 2011; DOI: https://doi.org/10.3803/EnM.2011.26.1.53

3,948 View
26 Download
10 Crossref

Abstract PDF

BACKGROUND
Various staging systems for thyroid cancer that focus on cancer specific death have been suggested, but this approach had a limitation due to the relatively long clinical course and very low rate of cancer death. This study was performed to evaluate the staging systems and to determine the most predictive staging system for predicting recurrence. METHODS: The patients who underwent first total or near total thyroidectomy due to papillary thyroid cancer (PTC) at Asan Medical Center between January 1995 and December 2001 were the subjects of this study. The commonly used 8 staging systems were applied to these subjects. Disease free survival (DFS) and the relative importance of each staging system were determined by the Kaplan-Meier method, the Cox-proportional hazards model and the proportion of variation in the survival time explained (PVE). RESULTS: A total of 952 patients (M = 117, F = 835) were enrolled and their mean age was 45 years. During a median of 10 years of follow-up, 146 (15.3%) of 952 patients had recurred tumor. The independent prognostic factors were male gender, tumor size, extrathyroidal invasion and cervical lymph node metastasis. Risk stratification according to the American thyroid association (ATA) guideline was the most predictive staging system for recurrence of PTC (PVE 88.6%). The staging systems from EORTC (PVE 79.5%), and MACIS (PVE 68.4%) had significant values for predicting recurrence of PTC. The stage of NTCTCS could not predict recurrence (PVE 4.5%, P = 0.11). CONCLUSION: Risk stratification according to the ATA was most predictive staging system for predicting recurrence of PTC. The MACIS and EORTC staging systems have good value for predicting recurrence of PTC.

Citations

Citations to this article as recorded by

Unmet Clinical Needs in the Treatment of Patients with Thyroid Cancer
Won Bae Kim, Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong
Endocrinology and Metabolism.2020; 35(1): 14. CrossRef
Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma
Mijin Kim, Minkyu Han, Min Ji Jeon, Won Gu Kim, In Joo Kim, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Clinical Endocrinology.2019; 91(3): 449. CrossRef
Clinical Value of Lymph Node Ratio Integration with the 8th Edition of the UICC TNM Classification and 2015 ATA Risk Stratification Systems for Recurrence Prediction in Papillary Thyroid Cancer
Jandee Lee, Seul Gi Lee, Kwangsoon Kim, Seung Hyuk Yim, Haengrang Ryu, Cho Rok Lee, Sang Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Young Suk Jo
Scientific Reports.2019;[Epub] CrossRef
Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma
Yoon‑Jong Ryu, Ji‑Young Choe, Kyoungyul Lee, Soon‑Hyun Ahn
Oncology Letters.2019;[Epub] CrossRef
Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy
Suyeon Park, Won Gu Kim, Eyun Song, Hye-Seon Oh, Mijin Kim, Hyemi Kwon, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Thyroid.2017; 27(4): 524. CrossRef
Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
Mijin Kim, Young Nam Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Hyeon Seon Ahn, Sin-Ho Jung, Sun Wook Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Tae Hyuk Kim, Tae Yong Kim
Clinical Endocrinology.2017; 86(3): 438. CrossRef
Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria
Min Ji Jeon, Won Gu Kim, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Jin-Sook Ryu, Ji Min Han, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Konradin Metze
PLOS ONE.2015; 10(7): e0133625. CrossRef
Recent Changes in the Clinical Outcome of Papillary Thyroid Carcinoma With Cervical Lymph Node Metastasis
Min Ji Jeon, Won Gu Kim, Yun Mi Choi, Hyemi Kwon, Dong Eun Song, Yu-Mi Lee, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Ki-Wook Chung, Won Bae Kim
The Journal of Clinical Endocrinology & Metabolism.2015; 100(9): 3470. CrossRef
Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma
Min Ji Jeon, Tae Yong Kim, Won Gu Kim, Ji Min Han, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Young Kee Shong, Won Bae Kim
Clinical Endocrinology.2014; 81(4): 593. CrossRef
Influences of Hashimoto's Thyroiditis as Prognostic Factor of Papillary Thyroid Carcinoma
Hyun Ju Park, Dong Kun Lee, Ji Won Seo, Myung Koo Kang, Heon Soo Park, Rock Bum Kim, Sung Hwan Suh, Mi Kyoung Park, Duk Kyu Kim, Jong Chul Hong
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2014; 57(5): 320. CrossRef

Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hurthle Cell Neoplasm and the Risk of Malignancy.: Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Gyungyup Gong, Suck Joon Hong, Won Bae Kim, Young Kee Shong; Endocrinol Metab. 2010;25(4):316-320. Published online December 1, 2010; DOI: https://doi.org/10.3803/EnM.2010.25.4.316

3,314 View
32 Download
5 Crossref

Abstract PDF

BACKGROUND
Follicular neoplasm (FN) or Hurthle cell neoplasm (HN) is a less well understood pitfall when evaluating thyroid nodule with fine-needle aspiration (FNA). This study aimed to determine the rates of malignancy and the predictive factors for malignancy in thyroid nodules with a cytological diagnosis of FN or HN. METHODS: The patients who were cytologically diagnosed as having FN or HN after FNA between 1995 and 2004 at Asan Medical Center were included in this study. We collected the pathology data until 2009 and we analyzed the clinical characteristics associated with malignancy. RESULTS: A total 478 patients were cytologically diagnosed as having FN or HN during the study period and 327 (68%) among them underwent thyroid surgery. Thyroid malignancy was confirmed in 157 (48%) of 327 patients. Malignancy was confirmed in 124 patients with FN (124/253, 49%). They were 48 papillary, 65 follicular, 7 Hurthle cell and 3 medullary carcinomas and 1 anaplastic carcinoma. The malignancy in the cases of HN (33/71, 44.6%) was 9 papillary, 4 follicular and 20 Hurthle cell carcinomas. The risk of malignancy was not associated with male gender, a larger tumor size (> 4 cm) or the diagnosis of HN. However, an age below 20 years (RR 3.6, P = 0.03) and above 60 years (RR 2.3, P = 0.04) was associated with an increased risk of malignancy. CONCLUSION: About half of the patients with FN or HN on FNA cytology were diagnosed as having thyroid cancer after surgery. The malignancy rate for the cytologic diagnosis of HN was similar to that for FN. Thyroid surgery should be recommended for this situation, and especially for patients younger than 20 years or older than 60 years.

Citations

Citations to this article as recorded by

Predictive Factors Increasing the Risk of Malignancy in Thyroid Follicular Neoplasia
Fatma Özarslan, Hüseyin Özgür Aytaç, İlker Murat Arer, M. Eda Ertörer, Emrah Koçer, Murathan Erkent, Hakan Yabanoğlu
Cukurova Anestezi ve Cerrahi Bilimler Dergisi.2025; 8(1): 85. CrossRef
Diagnostic Value of Preoperative Serum Thyroglobulin Measurement for the Diagnosis of Malignancy in Follicular or Hürthle Cell Neoplasms of the Thyroid Gland
Nam Kyu Kim, Seong Joo Kang, Weon Hyoung Lee, Go Eun Yeo, You Jin Han, Bu Kyung Kim, Su Kyoung Kwon, Yo-Han Park, Young Sik Choi
Kosin Medical Journal.2014; 29(1): 17. CrossRef
Fine Needle Aspiration Cytology of Thyroid Follicular Neoplasm: Cytohistologic Correlation and Accuracy
Changyoung Yoo, Hyun Joo Choi, Soyoung Im, Ji Han Jung, Kiouk Min, Chang Suk Kang, Young-Jin Suh
Korean Journal of Pathology.2013; 47(1): 61. CrossRef
Predictive Factors of Malignancy in Thyroid Nodules with a Cytological Diagnosis of Follicular Neoplasm
Seong Hyeon Lee, Jeong Su Baek, Joo Young Lee, Jung Ah Lim, Soo Youn Cho, Tae Hyun Lee, Yun Hyi Ku, Hong Il Kim, Min Joo Kim
Endocrine Pathology.2013; 24(4): 177. CrossRef
Postoperative Findings of the Cytological Diagnosis of Follicular Neoplasm or Hürthle Cell Neoplasm and Risk of Malignancy
Jung Uee Lee, Minho Shong
Endocrinology and Metabolism.2010; 25(4): 298. CrossRef

Review Article

Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer.: Ka Hee Yi, Young Joo Park, Sung Soo Koong, Jung Han Kim, Dong Gyu Na, Jin Sook Ryu, So Yeon Park, In Ae Park, Chung Hwan Baek, Young Kee Shong, Young Don Lee, Jaetae Lee, Jeong Hyun Lee, Jae Hoon Chung, Chan Kwon Jung, Seung Ho Choi, Bo Youn Cho; Endocrinol Metab. 2010;25(4):270-297. Published online December 1, 2010; DOI: https://doi.org/10.3803/EnM.2010.25.4.270

5,784 View
59 Download
37 Crossref

Abstract PDF

No abstract available.

Citations

Citations to this article as recorded by

Thyroid Cancer Incidence Among Korean Individuals: A Comparison of South Korea and the United States
Dohun Kim, Guan Li, Peter K. Moon, Yifei Ma, Soohyun Sim, Sung Y. Park, Minkyung Oh, Uchechukwu C. Megwalu
The Laryngoscope.2024; 134(9): 4156. CrossRef
Updates in the 2024 Korean Thyroid Association Clinical Practice Guidelines for Differentiated Thyroid Cancer: from Diagnosis to Initial Treatment
Eun Kyung Lee
International Journal of Thyroidology.2024; 17(2): 259. CrossRef
Imaging Recommendations for Diagnosis, Staging, and Management of Cancer of the Thyroid, Parathyroid, and Salivary Glands
Abhishek Mahajan, Shreya Shukla, Suman Kumar Ankathi, Anuradha Shukla, Richa Vaish, Shubham Suryavanshi, Ujjwal Agarwal, Vasundhara Patil, Arpita Sahu, Shubham Padashetty, Sarbani Ghosh Laskar, Vijay Patil, Vanita Noronha, Nandini Menon, Kumar Prabhash, A
Indian Journal of Medical and Paediatric Oncology.2023; 44(02): 159. CrossRef
Authors’ Reply: A Time Trend Analysis of 5000 Robotic Thyroidectomies via Bilateral Axillo‐Breast Approach
JungHak Kwak, Hyeong Won Yu, Jong‐hyuk Ahn, Su‐jin Kim, Young Jun Chai, June Young Choi, Kyu Eun Lee
World Journal of Surgery.2023; 47(8): 2086. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Optimization of the design parameters for a thyroid care nuclide monitoring diverging collimator using Monte Carlo simulation
Dong-Hee Han, Seung-Jae Lee, Jang-Oh Kim, Da-Eun Kwon, Kyung-Hwan Jung, Cheol-Ha Baek
Journal of the Korean Physical Society.2022; 81(7): 675. CrossRef
Active Surveillance for Papillary Thyroid Microcarcinoma in a Population with Restrictive Diagnostic Workup Strategies
Ivona Lončar, Sam P.J. van Dijk, Madelon J.H. Metman, Jia Feng Lin, Schelto Kruijff, Robin P. Peeters, Anton F. Engelsman, Tessa M. van Ginhoven
Thyroid.2021; 31(8): 1219. CrossRef
Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?
Chang‐Mo Oh, Jiwon Lim, Yuh Seog Jung, Yeol Kim, Kyu‐Won Jung, Seri Hong, Young‐Joo Won
Cancer Medicine.2021; 10(12): 4087. CrossRef
Efficacy of Differential Diagnosis of Thyroid Nodules by Shear Wave Elastography—the Stiffness Map
Myung Hi Yoo, Hye Jeong Kim, In Ho Choi, Suyeon Park, Sumi Yun, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh
Journal of the Endocrine Society.2021;[Epub] CrossRef
Spatial distribution and determinants of thyroid cancer incidence from 1999 to 2013 in Korea
Jieun Jang, Dae-Sung Yoo, Byung Chul Chun
Scientific Reports.2021;[Epub] CrossRef
Income differences in screening, incidence, postoperative complications, and mortality of thyroid cancer in South Korea: a national population-based time trend study
Hee-Yeon Kang, Ikhan Kim, Yeon-Yong Kim, Jinwook Bahk, Young-Ho Khang
BMC Cancer.2020;[Epub] CrossRef
Differential Diagnosis of Thyroid Follicular Neoplasm from Nodular Hyperplasia by Shear Wave Elastography
Myung Hi Yoo, Hye Jeong Kim, In Ho Choi, Ji-Oh Mok, Hyeong Kyu Park, Dong Won Byun, Kyoil Suh
Soonchunhyang Medical Science.2019; 25(1): 10. CrossRef
Diagnostic Performance of Shear Wave Elastography as Add-on Test in Thyroid Nodules: a Systematic Review and Meta-Analysis
Sun-young Park, Ji Yang Song, Min Jin Lee, Kyung Min Lee, Mi Hye Jeon, Ryeo Jin Ko, Seok-Hyun Kim, Bong Joo Kang
International Journal of Thyroidology.2018; 11(1): 31. CrossRef
Structural Equation Modeling on Health-related Quality of Life among Patients with Thyroid Cancer
Seon Young Lee, Hyun Kyung Kim
Korean Journal of Adult Nursing.2018; 30(2): 171. CrossRef
Prevalence and Annual Incidence of Thyroid Disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study
Hyemi Kwon, Jin-hyung Jung, Kyung-Do Han, Yong-Gyu Park, Jung-Hwan Cho, Da Young Lee, Ji Min Han, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2018; 33(2): 260. CrossRef
Ten Years of the Korean Thyroid Association: Achievement and Future
Young Joo Park, Young Shin Song, Ka Hee Yi
International Journal of Thyroidology.2018; 11(1): 1. CrossRef
Prediction of Contralateral Occult Malignant Nodule in Patients with Unilaterally Confined Papillary Thyroid Carcinomas
Sang Wook Jo, Ha Kyoung Park, Tae Kwun Ha
Journal of Endocrine Surgery.2018; 18(3): 191. CrossRef
Surgical Treatment Guidelines for Patients with Differentiated Thyroid Cancer: The Korean Association of Thyroid and Endocrine Surgeons (KATES) Guidelines Taskforce
Jin-Woo Park, Ki-Wook Chung, Ji-Sup Yun, Hyungju Kwon, Hoon Yub Kim, Kee Hyun Nam, Kyoung Sik Park, Min Ho Park, Ja Sung Bae, Hyun Jo Youn, Kyu Eun Lee, Chi Young Lim, Jin Hyang Jung, Jun-Ho Choe, Lee Su Kim, Su Jung Lee, Jung Han Yoon
Korean Journal of Endocrine Surgery.2017; 17(1): 1. CrossRef
Thyroid fine-needle aspiration biopsy positively correlates with increased diagnosis of thyroid cancer in South Korean patients
Yoon Jae Cho, Do Young Kim, Eun-Cheol Park, Kyu-Tae Han
BMC Cancer.2017;[Epub] CrossRef
Current trends of practical issues concerning micropapillary thyroid carcinoma
Yoon Se Lee, Byung-Joo Lee, Hyun Joon Hong, Kang-Dae Lee
Medicine.2017; 96(45): e8596. CrossRef
The Use of the Bethesda System for Reporting Thyroid Cytopathology in Korea: A Nationwide Multicenter Survey by the Korean Society of Endocrine Pathologists
Mimi Kim, Hyo Jin Park, Hye Sook Min, Hyeong Ju Kwon, Chan Kwon Jung, Seoung Wan Chae, Hyun Ju Yoo, Yoo Duk Choi, Mi Ja Lee, Jeong Ja Kwak, Dong Eun Song, Dong Hoon Kim, Hye Kyung Lee, Ji Yeon Kim, Sook Hee Hong, Jang Sihn Sohn, Hyun Seung Lee, So Yeon Pa
Journal of Pathology and Translational Medicine.2017; 51(4): 410. CrossRef
Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?
Min-Hee Kim, Jin-young Huh, Dong-jun Lim, Moo-Il Kang
Thyroid.2017; 27(7): 936. CrossRef
Surgical Treatment Guidelines for Patients with Differentiated Thyroid Cancer: The Korean Association of Thyroid and Endocrine Surgeons (KATES) Guidelines Taskforce
Jin-Woo Park, Ki-Wook Chung, Ji-Sup Yun, Hyungju Kwon, Hoon Yub Kim, Kee Hyun Nam, Kyoung Sik Park, Min Ho Park, Ja Sung Bae, Hyun Jo Youn, Kyu Eun Lee, Chi Young Lim, Jin Hyang Jung, Jun-Ho Choe, Lee Su Kim, Su Jung Lee, Jung Han Yoon
Korean Journal of Endocrine Surgery.2017; 17(1): 1. CrossRef
Incidental Detection of Struma Ovarii on the Whole Body Scan in a Differentiated Thyroid Cancer Patient
Hye-Seon Oh, Eyun Song, Dong Eun Song, Won Bae Kim
International Journal of Thyroidology.2016; 9(2): 180. CrossRef
The Experience of Receiving Radioactive Iodine Therapy among Thyroid Cancer Patients
Kyung Ok Kang, Hyun Kyung Kim, Ji Young Kim, Seok Tae Lim
Journal of East-West Nursing Research.2016; 22(2): 148. CrossRef
Comparison of two- and three-dimensional sonography for the prediction of the extrathyroidal extension of papillary thyroid carcinomas
Yang Seon Yi, Sang Soo Kim, Won Jin Kim, Min Jung Bae, Ji Hyun Kang, Bo Gwang Choi, Yun Kyung Jeon, Bo Hyun Kim, Byung Joo Lee, Soo Geun Wang, In Joo Kim, Yong Ki Kim
The Korean Journal of Internal Medicine.2016; 31(2): 313. CrossRef
Changing trends in the management of well-differentiated thyroid carcinoma in Korea
Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
Endocrine Journal.2016; 63(6): 515. CrossRef
Low Dose versus High Dose Radioiodine Therapy
Kyoung Sook Won
Journal of Korean Thyroid Association.2015; 8(1): 14. CrossRef
History of Korean Thyroid Association and Recent Debates on Diagnosis and Treatment of Thyroid Cancer in Korea
Kwang Woo Lee
Journal of Korean Thyroid Association.2015; 8(1): 36. CrossRef
Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibody
Kwanhoon Jo, Min-Hee Kim, Yejee Lim, So-Lyung Jung, Ja-Seong Bae, Chan-Kwon Jung, Moo-Il Kang, Bong-Yun Cha, Dong-Jun Lim
European Journal of Endocrinology.2015; 173(4): 489. CrossRef
Time Trends Analysis of Characteristics of Patients with Thyroid Cancer in a Single Medical Center
Hyung Seo Jung, Min Ji Jeon, Dong Eun Song, Suck Joon Hong, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Journal of Korean Thyroid Association.2014; 7(2): 159. CrossRef
Unfounded Reports on Thyroid Cancer
Jae Hoon Chung
Journal of Korean Medical Science.2014; 29(8): 1033. CrossRef
Regional Lymph Node Metastasis in Papillary Thyroid Cancer
Jae Hyun Park, Kang San Lee, Keum-Seok Bae, Seong Joon Kang
Journal of Korean Thyroid Association.2014; 7(2): 129. CrossRef
Methods and Clinical Efficacy of Dosimetry-Based Treatment in Radioiodine Therapy of Thyroid Cancer
Jin Chul Paeng, June-Key Chung
Journal of Korean Thyroid Association.2013; 6(1): 43. CrossRef
Two Cases of Non-Small Cell Lung Cancer Masquerading as Metastatic Papillary Thyroid Cancer
Ju Hee Lee, Se-Hoon Lee, Hye Sook Min, Ji-hoon Kim, Do Joon Park, Young Joo Park
Journal of Korean Thyroid Association.2012; 5(2): 157. CrossRef
Diagnostic Dilemma of a Follicular Lesions/Neoplasm in Thyroid Fine Needle Aspiration Cytology
Chan Kwon Jung
Journal of Korean Thyroid Association.2012; 5(2): 104. CrossRef
Updated guidelines for the diagnosis and management of thyroid nodules
Ka Hee Yi
Journal of the Korean Medical Association.2011; 54(6): 629. CrossRef

Original Article

Factors Influencing Peripheral Conversion of Thyroxine to Tri-Iodothyronine in Athyreotic Individuals during Levothyroxine Replacement.: Eui Young Kim, Won Gu Kim, Tae Yong Kim, Jong Ho Yoon, Suck Joon Hong, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2010;25(2):119-124. Published online June 1, 2010; DOI: https://doi.org/10.3803/EnM.2010.25.2.119

4,727 View
63 Download

Abstract PDF: BACKGROUND
Tri-iodothyronine (T3) is the main active hormone, and 20% of this is derived from the thyroid gland and 80% is from the peripheral tissue according to 5'-monodeiodination of thyroxine (T4). In the previous studies, normal T3 levels were achieved with traditional levothyroxine (LT4) therapy alone in athyreotic patients, but there has been no data about the factors influencing peripheral conversion of LT4. The aim of this study was to determine the factor(s) influencing peripheral conversion of LT4 to T3 in athyreotic patients during LT4 replacement. METHODS: The patients who underwent total-thyroidectomy for any cause, and mostly for thyroid cancers, at Asan Medical Center between 2000 and 2008 were enrolled. The free T4, T3 and thyroid stimulating hormone (TSH) levels and age, gender, weight, height, body mass index (BMI) and the T4 dose were measured. Only patients with normal ranges of free T4 and TSH were included in the analysis. RESULTS: A total of 143 patients were enrolled. The mean T3, free T4 and TSH levels were 143.7 ng/dL, 1.4 ng/dL and 1.6 microU/mL, respectively. The mean weight and BMI were 62.9 kg and 24.6 kg/m2, respectively. We divided them into two groups according to the serum T3 level and we compared the characteristics of the groups. There were no differences in age, the gender distribution, the T4 dose/weight and the BMI between the low T3 group (T3 < or = 122 ng/dL, n = 14) and the normal T3 group (T3 > 122 ng/dL, n = 129). In the low T3 group, the mean body weight was significantly lower than that of the normal T3 group (59.0 +/- 6.0 vs. 63.4 +/- 9.9, respectively, P = 0.025). CONCLUSION: Lean body mass seems to be an important factor for determining the peripheral conversion of T4 to T3 in human. This suggest that a combination of T3/T4 is better than T4 only when we treat the patients with hypothyroidism and who have a negligible amount of functioning thyroid tissue, if they have a low lean body mass.

First
Prev
Page of 2
Next
Last

Search